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Companion Website
With this book you are given free access to a companion resources site:
www.wiley.com/go/barold/cardiac
The website includes more than 300 images taken from this book
You are free to download these images and use them for your own presentations to
students∗
How to access the website:
Look under the label below to see your access code.
Go to www,wiley.com/go/barold/cardiac and enter the code when prompted.
∗Please note that these images are for your own use for study and instruction. If you are using these
images in a presentation, the reference to the book should always be displayed along with the image.
See website for full copyright information.
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viiPreface to the first edition
The impetus for writing this book came from our ob-
servations that many healthcare professionals and
young physicians working in emergency rooms, in-
tensive and coronary care units were unable to inter-
pret simple pacemaker electrocardiograms correctly.
Over the years we also heard many complaints from
beginners in the field of cardiac pacing that virtu-
ally all, if not all, the available books are too compli-
cated and almost impossible to understand. Indeed,
the ever-changing progress in electrical stimulation
makes cardiac pacing a moving target. Therefore we
decided to take up the challenge and write a book
for beginners equipped with only a rudimentary
knowledge of electrocardiography and no knowl-
edge of cardiac pacing whatsoever. Because many
individuals first see the pacemaker patient after im-
plantation, the book contains little about indications
for pacing and implantation techniques. The book
starts with basic concepts and progressively covers
more advanced aspects of cardiac pacing including
troubleshooting and follow-up.
As one picture is worth a thousand words, this
book tries to avoid unnecessary text and focuses on
visual learning. We undertook this project with the
premise that learning cardiac pacing should be en-
joyable. Cardiac pacing is a logical discipline and
should be fun and easy to learn with the carefully
crafted illustrations in this book. The artwork is sim-
ple for easy comprehension. Many of the plates are
self-explanatory and the text in the appendix only
intends to provide further details and a comprehen-
sive overview.
Many of the images used to create the illustrations
in this book are taken from CorelDraw and Corel
Mega Gallery clipart collections.
We are grateful to Charlie Hamlyn of Blackwell
Publishing and Tom Fryer of Sparks for their superb
work in the production of this book.
S. Serge Barold
Roland X. Stroobandt
Alfons F. Sinnaeve
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viii Preface to the second edition
The first edition of the book has been well received
all over the world and translated into Japanese, Chi-
nese and Polish. The same format has been retained
in the second edition because of its wide popular-
ity and the frequent positive feedback that it facili-
tates learning and understanding. Many new plates
were added. A few plates were upgraded and a few
were deleted when the message was no longer rel-
evant. We have reviewed the advances in cardiac
pacing over the last seven years and introduced an
important new presentation on cardiac resynchro-
nization, which is a rapidly growing field. The in-
corporation of many suggestions from readers has
also contributed to the increased size of the second
edition. For example, the latter now includes an ex-
panded text (including a large section on cardiac
resynchronization), a discussion of indications, and
a list of pertinent references. As before, we omitted
the technical details of pacemaker implantation and
lead extraction. We are grateful to Thomas V. Hart-
man, Kate Newell, and Cathryn Gates from Wiley-
Blackwell Publishing for their outstanding work in
the production of this book.
S. Serge Barold
Roland X. Stroobandt
Alfons F. Sinnaeve
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ixAbbreviations
A ampere
ACC American College of Cardiology
AEGM atrial electrogram
AEI atrial escape interval
AF atrial fibrillation
AFR atrial flutter response
Ah amperehour
AH atrial–His
AHA American Heart Association
AHR atrial high rate
AMS automatic mode switching
AP atrial paced event
APC atrial premature complex
AR atrial event sensed in the refractory
period
As amperesecond
AS atrial sensed event
AT atrial tachycardia
ATP antitachycardia pacing
ATR atrial tachycardia response
AV atrioventricular
AVE atrioventricular extension
AVI atrioventricular interval (also called
AV delay)
AVI-U atrioventricular interval, unblanked
BiV biventricular
BLR basic lower rate
BOL beginning-of-life
BP biventricular paced event
BP blood pressure
bpm beats per minute
BV biventricular
C coulomb
CAD coronary artery disease
CHF congestive heart failure
CO cardiac ouput
CRT cardiac resynchronization therapy
CRT-D cardiac resynchronization therapy
device and defibrillator
CS coronary sinus
CSNRT corrected sinus node recovery time
CT computed tomography
ECG electrocardiogram
EGM electrogram
ELT endless loop tachycardia
EMI electromagnetic interference
EOL end-of-life
EOS end-of-service
ER evoked response
ERI elective replacement indicator
ERT elective replacement time
ESCI escape interval
ESCR escape rate
FARI filtered atrial rate interval
FCC Federal Communications Commission
HCM hypertrophic cardiomyopathy
HF heart failure
HR heart rate
HRS Heart Rhythm Society
HRV heart-rate variability
HV His–ventricular
Hz hertz
I current (in amps, A)
IACD intraatrial conduction delay
ICD implantable cardioverter-defibrillator
IV interventricular
LA left atrium
LBBB left bundle branch block
LBT listen before talk
LRI lower rate interval
LRL lower rate limit
LV left ventricle
LVEF left ventricular ejection fraction
LVESV left ventricular end-systolic volume
LVOT left ventricular outflow tract
A microampere
mA milliampere
mEq milliequivalent
MI myocardial infarction
MICS Medical Implant Communications
System
MRI magnetic resonance imaging
ms millisecond
MSDR maximum sensor-driven rate
MTR maximum tracking rate
mV millivolt
MV minute volume
MVP managed ventricular pacing
NYHA New York Heart Association
OVI open ventricular interval
PAVB postatrial ventricular blanking period
pAVI AV interval after a paced event
PM pacemaker
PMT pacemaker-mediated tachycardia
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x
ppm pacing per minute
PR peripheral resistance
PVAB postventricular atrial blanking period
PVARP postventricular atrial refractory period
PVARP-U postventricular atrial refractory period,
unblanked
PVC premature ventricular complex
(= VPC)
PVE premature ventricular event
pVRP ventricular refractory period after
pacing
R resistance (in ohms, )
RA right atrium
RAM random-access memory
RBBB right bundle branch block
RF radiofrequency
RNRVAS repetitive non-reentrant VA
synchrony
ROM read-only memory
RR respiratory rate
RRT recommended replacement time
RV right ventricle
RVA right ventricular apex
RVOT right ventricular outflow tract
SAI spontaneous atrial interval
SAR spontaneous atrial rate
SAS synchronous atrial stimulation
sAVI AV interval after a sensed event
SDI sensor-driven interval
SDR sensor-driven rate
SND sinus node dysfunction
SV stroke volume
sVRP ventricular refractory period after
sensing
SVT supraventricular tachycardia
TARP total atrial refractory period
TCL tachycardia cycle length
TDI tissue Doppler imaging
TEE transesophageal echocardiography
TV tidal volume
U voltage (in volts, V)
URI upper rate interval
URL upper rate limit
V volt
VA ventriculoatrial
VB ventricular blanking period
VEGM ventricular electrogram
VF ventricular fibrillation
VHR ventricular high rate
VP ventricular paced event
VPC ventricular premature complex
VPI ventricular paced interval
VPR ventricular paced rate
VR ventricular event sensed in the
refractory period
VRP ventricular refractory period
VRP-U ventricular refractory period,
unblanked
VS ventricular sensed event
VSP ventricular safety pacing
VT ventricular tachycardia
WI Wenckebach interval
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357Cardiac pacing
Implantation
A pacemaker (also known as a pulse generator) is a
device that delivers electrical stimuli over leads with
electrodes in contact with the heart. The lithium-
iodine battery is sealed in a titanium can and pro-
vides electricity out of a chemical reaction. The
pacemaker is like a little computer. The epoxy con-
nector block on top of the pacemaker makes the
connection from lead to pacemaker. The lead is an
insulated wire. There are two types of leads: bipo-
lar, with the two electrodes embedded inside the
heart, and unipolar, where only one electrode is in-
side the heart, and the pacemaker can acts as the
other electrode. Both types are widely used. In both
types, the tip electrode is virtually always the neg-
ative pole or cathode. Virtually all pacemakers are
implanted transvenously under local anesthesia us-
ing either the cephalic vein exposed by cutdown or
percutaneous puncture of the subclavian vein. The
leads are passed to the right side of the heart un-
der x-ray vision (fluoroscopy). More recently, for the
treatment of heart failure, the left ventricle may be
paced by insertion of a lead into a tributary of the
coronary sinus, a venous structure on the epicardial
surface of the left ventricle. The pacemaker pocket
is fashioned over the pectoralis major muscle below
the collarbone. True epicardial leads require thoracic
surgery and are used only when there is no venous
access.
Basic function
The pacing lead functions as a “two-way street” for
the transmission of electricity to the heart for pac-
ing as well as for the sensing of spontaneous cardiac
electric activity from the heart to the pacemaker. The
operative techniques and intraoperative measure-
ments are straightforward compared to the technical
knowledge required to understand the electrophys-
iology of pacing and follow-up of patients for the
best use of the important programmable functions.
The function of an implanted pacemaker can be al-
tered by means of a programmer, which is a kind of a
dedicated desktop computer. A modern pacemaker
lasts 7–10 years. When the battery is depleted, the
entire pacemaker (excluding the leads) is replaced.
Power source
The lithium–iodine battery is the gold standard
of pacemaker power sources, and the only one
presently used in pacemakers. The battery has a
long shelf life and is hermetically sealed to pro-
tect the electronic components of the pacemaker. In
lithium–iodine batteries, lithium is the anode and io-
dine the cathode. When delivering electric current,
this battery progressively develops a slow rise in in-
ternal resistance that can be measured by telemetry.
The rising battery impedance causes a fairly linear
drop in cell voltage, translated by design into a grad-
ual decline in the pacing rate reflecting the status of
the battery. The battery retains a satisfactory volt-
age for 90% of its life. Battery capacity (expressed in
amperehours, Ah) is the quantity that expresses the
longevity of a lithium–iodine battery. A pacemaker
generally holds a capacity between 0.8 and 2.5 Ah.
The current drain from the battery (expressed in
A) is utilized to produce the stimulus and to feed
the various sensing, detection, and “housekeeping”
electronic circuits. The output voltage of a fresh
cell is 2.8 volts (V). The cell voltage at the elective
replacement point is 2.2–2.4 V. The pacemaker re-
placement time can be determined by measuring
the pacemaker rate upon application of a magnet or
the battery voltage and/or impedance by telemetry
with the programmer.
Reminder: The pacemaker (or pacing) stimulus is
also known as a spike, an artifact, or an output pulse.
Caveat: Do not confuse cathode with anode! The ter-
minology of the battery terminals appears differ-
ent from that of the load. For the battery the an-
ode is the negative electrode where electrons are
freed from lithium atoms and positive lithium ions
are produced. In the battery the cathode is the pos-
itive terminal where free electrons rebind with io-
dine to form negative iodide ions. At the load, the
cathode is the negative terminal and the anode is
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the positive one. The connection of battery to cir-
cuit is simple: positive-to-positive and negative-to-
negative. Remember that the anode of the battery
or load is where the electrons leave. The cathode
of both battery and load is where the electrons en-
ter. It is as simple as that! These are the universal
definitions found in all good books about electricity
and/or electronics. It is not true that the anode and
cathode of the battery are reversed by convention.
The only convention is that the electric current flows
from positive to negative.
Rate or interval?
The pacemaker, design engineers, and the medical
staff all “think” in terms of intervals rather than rate.
We should do away with rate when defining timing
cycles. Rate is a relatively simple designation during
continuous pacing or continuous inhibition but it is
of little value and confusing if pacing and sensing
alternate. Yet, for ease of programming, manufactur-
ers have expressed parameters in terms of rate rather
than interval. Programmed rates may also be useful
when communicating with the patient or anyone
with little knowledge of pacing. The abbreviation
bpm refers to beats per minute of the intrinsic heart
rate and ppm refers to the paced rate. However, these
abbreviations are often used interchangeably.
Caveat: Peculiar rhythms are created by ECG
machines and Holter recorders functioning at an
incorrect speed. In a Holter recording, intermittent
slowing of the recording will cause a pseudotachy-
cardia. The diagnosis is evident when the QRS and
T waves are too narrow when compared to those
recorded at normal speed. Conversely, a faster speed
will cause pseudobradycardia, with excessively long
AV delays or PR intervals as well as QRS complexes.
Single chamber pacemakers
VOO mode
A VOO pacemaker generates stimuli with no rela-
tionship to the spontaneous rhythm. The VOO mode
is labeled “fixed-rate” or asynchronous. The com-
petitive stimuli will capture the ventricle only when
they fall outside the absolute refractory period of the
ventricle that follows spontaneous beats. The VOO
mode is now obsolete, and it is used only for testing
purposes by applying a magnet over the pace-
maker. Ventricular fibrillation induced by a com-
petitive pacemaker stimulus falling in the ventric-
ular vulnerable period (the R-on-T phenomenon)
is very rare outside of circumstances such as my-
ocardial ischemia or infarction, electrolyte abnor-
malities, or autonomic imbalance. Indeed, transtele-
phonic transmission of the electrocardiogram with
a magnet over a pacemaker is quite safe.
VVI mode
A VVI pacemaker senses the intracardiac ventricu-
lar depolarization or electrogram which is recorded
by measuring the potential (voltage) difference be-
tween the two electrodes (anode and cathode) used
for pacing. A VVI pacemaker has an internal clock
or lower rate timing cycle that begins with a paced
(VP) or sensed ventricular event (VS). The initial
portion of the cycle (after VP or VS) consists of the
ventricular refractory period (VRP, usually 200–350
ms), during which the pacemaker cannot sense any
signals. More specifically, any signal during the re-
fractory period cannot initiate a new lower rate in-
terval (LRI). Beyond the VRP, a sensed ventricular
event inhibits the pacemaker and resets the LRI, so
that the timing clock returns to baseline. A new pac-
ing cycle is reinitiated, and if no event is sensed the
timing cycle ends with the release of a ventricular
stimulus according to the LRI. The sensing func-
tion prevents the competition between pacemaker
and intrinsic rhythm seen with VOO pacing. Hence
the old term “demand pacemaker” for a VVI pace-
maker, to describe the delivery of a stimulus when
the spontaneous rate is less than the lower rate of
the pacemaker.
Caveats:
1. When a patient presents with an ECG showing no
pacemaker stimuli, the pacing function should be
tested by the application of a pacemaker magnet,
which converts any pacemaker to the fixed-rate
or asynchronous mode (VVI to VOO). One should
refrain from performing carotid sinus massage (a
vagal reflex producing sinus node slowing and
AV block) in this situation, because it may cause
prolonged bradycardia resulting in the delivery
of pacemaker stimuli that may or may not be
capable of capture. It is safer to first establish ef-
fective pacing with magnet application.
2. The stimulus-to-stimulus interval (automatic
interval) is usually equal to the escape interval,
which is measured electronically from the time of
intracardiac sensing to the succeeding stimulus.
In practice, the escape interval is measured from
the onset of the sensed QRS complex in the
surface ECG. The escape interval measured in
this way must necessarily be longer than the
electronic escape interval, because intracardiac
sensing takes place a finite time after the onset
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of the surface ECG. Thus, if the QRS complex
is wide and intracardiac sensing occurs 90 ms
from the beginning of the surface ECG, the
measured escape interval (with calipers) will be
90 ms longer than the programmed automatic
interval.
Hysteresis
In hysteresis the electronic escape interval is longer
than the automatic interval. Its purpose is to
maintain sinus rhythm and atrioventricular (AV)
synchrony for as long as possible at a spontaneous
rate lower (e.g. 50 bpm) than the automatic rate
of the pacemaker (e.g. 70 ppm). Thus when the
spontaneous rate drops below 50 bpm, the pace-
maker will take over at 70 ppm. It will continue to
pace at 70 ppm until the spontaneous rate exceeds
the automatic rate, i.e., when the spontaneous
QRS complex occurs within the 857 ms automatic
interval.
If the search hysteresis feature is enabled, the pace-
maker will periodically reduce the lower pacing rate
for a few cycles by a programmable value in order
to reveal potential intrinsic activity below the pro-
grammed lower rate or sensor rate. Hysteresis will
remain active when intrinsic activity is sensed dur-
ing the search period. If there is no intrinsic activity
during the search, pacing resumes at the lower rate,
or the sensor-indicated rate.
Caveat: Do not misinterpet hysteresis for over-
sensing with pauses.
Symbolic representation of pacemaker
events and basic measurements
AS (P) = atrial sensed event
AP (A) = atrial paced event
VS (R) = ventricular sensed event
VP (V) = ventricular paced event
AR = atrial event sensed in the pacemaker
refractory period
VR = ventricular event sensed in the
ventricular refractory period.
Some devices depict a ventricular premature com-
plex as a VPC or PVC. The refractory period is de-
fined below. The intervals between events are mea-
sured by electronic calipers.
Timing cycles are expressed in milliseconds (ms):
One second = 1000 milliseconds
The 60,000 rule is useful in converting rate to inter-
vals:
60,000/heart rate = interval in milliseconds
60,000/interval in milliseconds = heart rate
A pacemaker rate of 70 ppm gives an interval of
857 ms
bpm = beats per minute, which refers to the rate of
a spontaneous rhythm. ppm = pulses per minute,
which refers to the rate of a pacemaker. These des-
ignations are often used interchangeably.
Other single chamber pacemakers
A VVT pacemaker releases a ventricular stimulus
immediately upon sensing, which is the opposite
of inhibition with the VVI mode. The VVT mode
requires three timing intervals: LRI and VRP, like
the VVI mode, but additionally an upper rate in-
terval (URI) to limit the maximum paced ven-
tricular rate in response to ventricular sensing of
rapidly occurring potentials. Upon sensing a QRS
complex the pacemaker immediately discharges a
stimulus (within the QRS) in the absolute refrac-
tory period of the ventricular myocardium. The
VVT mode ensures stimulation rather than inhibi-
tion whenever the pacemaker senses signals other
than the QRS complex. The triggered VVT mode
is now rarely used as a primary pacing mode, but
it was useful in the early days when VVI pace-
makers were highly susceptible to external inter-
ference and the VVT mode was used to prevent
inhibition.
An AAI pacemaker is identical to the VVI mode
except that it paces and senses in the atrium. It re-
quires a higher sensitivity because the atrial elec-
trogram is smaller than the ventricular one. The
pacemaker refractory period (during which the
LRI cannot be initiated) should be longer than 400
ms to prevent sensing of the conducted QRS com-
plex as a far-field event in the atrial electrogram.
Sensing of the far-field QRS complex by an AAI
pacemaker (especially a more sensitive unipolar
system) will cause slowing of the pacing rate be-
cause the sensed event (though not originating
from the atrium itself) resets the LRI. An AAI
pacemaker may be considered in patients with
sick sinus syndrome with normal AV conduction.
The subsequent development of AV block in care-
fully selected patients is less than 2% per year.
The advantages of AAI pacing are related to the
preservation of normal ventricular depolarization
and cost-effectiveness. This is in contrast to modes
with pacing-induced ventricular depolarization,
which tend to produce long-term LV dysfunction
related to the cumulative duration of RV pacing.
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Reminders:
1. Many ventricular premature complexes are not
sensed by the atrial lead as far-field signals in the
AAI mode.
2. The AOO and AAT modes work in the atrium
and are functionally similar to their ventricular
counterparts.
Basic electricity
Electrons flow from the negative terminal to the pos-
itive terminal of an electric circuit. In the early days,
the concept of electron flow was not fully under-
stood so scientists randomly decided that current in
a conductor flowed from the positive terminal to the
negative terminal. It is still convention (and confus-
ing to some) today to show current flowing in this
direction (i.e., opposite to electron flow).
Current is the amount of charge (electrons or other
charged particles) that flows through an electric cir-
cuit within a unit of time. Its unit is the ampere (A).
The flow of water is a good analogy for electricity.
Water flows through a pipe because of water pres-
sure. Voltage is the potential difference that controls
the flow of electrons through an electric circuit. Cur-
rent flows from a site of high potential to a low one.
The basic unit of electric potential difference (volt-
age) is the volt (V). The electrons in a pacemaker
circuit come from the battery. Thus, voltage is the
force behind the electrons and current is a measure
of how many electrons are flowing per unit of time.
Resistance or impedance is a measure of the oppo-
sition to the flow of electrons. Resistance limits the
current that flows through a circuit for a particular
applied voltage. The unit of resistance is the ohm ().
Current (I), voltage (V) and resistance (R) are re-
lated by Ohm’s law:
V = I × R
According to Ohm’s law an increase in the pressure
(voltage) must cause an increase in the flow (cur-
rent) if the resistance remains the same. Increasing
the resistance while keeping the voltage the same
decreases the current (flow).
The battery supplies the voltage that creates the
flow (current) in a circuit with a given load or re-
sistance. The battery capacity denotes how long the
battery will last while providing a current of 1 am-
pere. It is measured in ampere hours (Ah). So a bat-
tery with a capacity of 1000 mAh (1 Ah) would last
for one hour in a one-amp circuit (1000 mAh is 1A
for 1 hour). A lithium-iodine battery with a capacity
of 2 Ah in a pacemaker circuit with a current drain
of 25 A (= 0.000025A) will last for 2 Ah/0.000 025
A = 80,000 hours or approximately 3333 days = ap-
proximately 9 years.
Chronic pacing threshold and
safety margin
The pacing threshold is the minimum “electrical ac-
tivity” that causes consistent pacing outside the my-
ocardial refractory period of the heart. In practice
the pacing threshold is determined in terms of volts
(V) and pulse duration. All effort should be made at
the time of implantation to obtain a pacing thresh-
old as low as possible, because its initial value may
ultimately determine the threshold at maturity and
hence the voltage and pulse duration required for
safe long-term pacing. Local steroid elution attenu-
ates the increase of pacing threshold during lead
maturation and maintains low pacing thresholds
during follow-up. Steroid elution made the implan-
tation of high-efficiency pacing leads with a small
surface of 1.2 mm2 feasible. Steroid-eluting leads are
associated with remarkably low pacing threshold by
virtue of their effect on the electrode–myocardial in-
terface and tissue reaction. About eight weeks af-
ter implantation in most cases, the pacing threshold
has stabilized and attained its chronic value. Then,
the output voltage and pulse duration of the pace-
maker should be programmed to maintain consis-
tent long-term capture with an adequate margin of
safety and maximal conservation of battery capacity.
The capture threshold can vary during the course of
a normal day and according to metabolic and phar-
macological factors. Consequently it is important to
provide protection for threshold fluctuations by a
safety margin in terms of the pacemaker output.
In practice, the safety margin is determined in
terms of volts, not pulse duration. The general rec-
ommendation is a voltage safety margin of 2 (or
100%). The output voltage of the pacemaker should
be double the chronic voltage threshold at the same
pulse duration. Voltage safety margin = output volt-
age/threshold voltage = 2 : 1 at an identical pulse
duration. This value is acceptable in pacemakers
without automatic adjustment of the output. How-
ever, the concept of a 2 : 1 safety margin has been
challenged in view of data gathered by systems
capable of automatic determination of the pacing
threshold and adjustment of the output pulse. This
experience has shown that a safety margin of 2 : 1
may not be sufficient in the occasional patient. In-
deed, some physicians program a larger safety mar-
gin in pacemaker-dependent patients.
The relationship of voltage and pulse duration at
threshold and at any time afterwards is not linear,
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and is represented by the strength–duration curve. A
shorter pulse duration requires a higher voltage to
attain the pacing threshold. The strength–duration
curve is steep with a short pulse duration, and be-
comes essentially flat at a pulse duration greater than
2 ms, a point which is called the rheobase. The curve
shifts to the right as the chronic pacing threshold be-
comes established. Although the terms rheobase and
chronaxie are used to describe the strength–duration
curve, they are rarely used in the routine follow-up
of pacemaker patients.
Important reminders:
1. At a fixed voltage, increasing the pulse duration
from 0.1 to 0.2 ms may not necessarily yield a
voltage safety margin of 2, or 100%, despite the
steepness of the strength–duration curve (on the
left) for short pulse durations.
2. At a fixed voltage, tripling the pulse duration (not
starting beyond 0.2 ms) will provide an adequate
voltage safety margin based on the configuration
of the strength–duration curve. Thus, a thres-
hold of 2.5 V at 0.2 ms permits a programmed
“chronic” output of 2.5 V at 0.6 ms, for a voltage
safety margin of 2.
3. When the pulse duration is ≥ 0.3 ms, tripling the
pulse duration while keeping the voltage con-
stant may not provide a voltage safety margin of
2 because of the less steep and eventually straight
configuration of the strength–duration curve (on
the right) at longer pulse durations.
4. The relatively flat configuration of the strength–
duration curve from 0.5 to 1.5 ms indicates that an
increase in pulse duration in this range (keeping
the voltage constant) will certainly not provide a
voltage safety margin of 2.
5. Try to pace at a voltage lower than the tradi-
tional output of 5 V for greater efficiency and
less wasted battery output.
The pacing threshold is lowest during a short
period called the supernormal phase which corre-
sponds with the second half of the T wave. Con-
sistent ventricular capture during this period and
failure at other times, suggests that the pacemaker
output is near threshold.
Let us consider some examples:
(a) Threshold 2.5 V at 0.1 ms: program 2.5 V at
0.3 ms.
(b) Threshold 2.5 V at 0.2 ms: program 2.5 V at
0.6 ms.
(c) Threshold 2.5 V at 0.3 ms: program 5 V at 0.3 ms.
(d) Threshold 0.5 V at 0.2 ms. This is a very low
pacing threshold. The pacemaker can be pro-
grammed at 0.5 V at 0.6 ms, but many would
prefer going to 1 V at 0.4 or 0.5 ms, a set-
ting that would still provide substantial bat-
tery conservation.
(e) Threshold 5 V at 0.3 ms. Increasing the pulse du-
ration when the voltage is fixed at 5 V may not
provide an adequate voltage margin. Increase
the voltage output above 5 V if available in the
pacemaker. If not, watch the patient carefully for
bradycardia and asystole and decide whether
to reposition the lead or implant a high-output
pulse generator providing a 10 V output.
Reminder: The pacing thresholds are less than 2.5 V
at 0.5 ms pulse duration in more than 95% of patients
with steroid-eluting leads. Patients with such leads
rarely have a significant pacing threshold increase
compared to those with non-steroid leads. Conse-
quently it does not make sense to leave the out-
put (voltage and pulse duration) at nominal values.
Appropriate programming of the pacemaker output
can increase battery longevity. Furthermore, as the
voltage of the lithium-iodine battery is 2.8 V, pac-
ing is more efficient when performed close to that
voltage.
Caveats:
1. Always test the pacing threshold on deep respira-
tion and coughing to detect an unstable electrode.
2. In the presence of left bundle branch block (LBBB)
with a QRS complex resembling a paced ventric-
ular beat, pseudocapture will be seen when the
rate of the pacemaker stimulus is very close to
that of the spontaneous rhythm and the stimulus
falls just before the spontaneous QRS complex.
This may resemble capture with latency (delayed
interval from stimulus to ventricular activation).
Long rhythm strips are needed for the diagno-
sis, which will be obvious when the ventricular
stimulus moves away from the QRS complex.
3. Beware of isoelectric paced QRS complexes that
can mimic lack of capture. Look for the T wave,
because the presence of repolarization means that
depolarization must have occurred.
Automatic determination of the
pacing threshold
Some pacemakers have algorithms that periodically
and automatically measure the ventricular capture
threshold. The pacemaker recognizes the presence
of capture, provides a stronger backup pulse if
there is loss of capture, and then adjusts the output
automatically at a given value over the pacing
threshold. Such periodic threshold measurements
are memorized by the device, and the threshold
graph during the preceding follow-up period can
be retrieved by interrogation of the pacemaker.
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Capture verification has increased patient safety,
and it probably increases battery longevity.
Some programmers are also designed to perform
a pacing threshold test automatically at the time of
follow-up, and a printout of the procedure can be
filed in the pacemaker chart.
Sensing
A pacemaker senses the potential difference be-
tween the two electrodes (anode and cathode) used
for pacing. A bipolar system senses the potential
difference between the two electrodes in the heart
and requires recording of the bipolar electrogram to
determine the characteristics of the signal available
for sensing. The final bipolar electrogram depends
on the electrograms registered at the two sites and
the travel time of depolarization between the two
electrodes. The bipolar electrogram can be easily
recorded at the time of implantation with an ECG
machine (leads applied to the two legs), by connect-
ing the tip and proximal electrodes of the pacing lead
to the free or loose right-arm and left-arm electrodes
and recording lead I (which provides the potential
difference between the two arms and therefore the
potential difference between the two intracardiac
electrodes).
For a unipolar system (one electrode in the heart
and the other on the pacemaker can), the unipolar
electrogram from the tip electrode closely resembles
the available voltage for sensing, because the con-
tribution from the unipolar plate is usually negligi-
ble. The unipolar electrogram can be easily recorded
by connecting the unipolar V lead of the ECG to
the tip electrode, with the other ECG electrodes on
the limbs in the usual fashion. The amplitude of the
electrogram (in the setting of an adequate slew rate)
must exceed the sensitivity of the pacemaker for
reliable sensing. The ventricular signal often mea-
sures 6–15 mV, a range that exceeds the commonly
programmed ventricular sensitivity of 2–3 mV. Oc-
casionally a pacemaker senses the supraventricular
QRS complex normally, but does not detect some
ventricular extrasystoles because their electrogram
(originating from a different site) is smaller, a situa-
tion not always correctible by reprogramming ven-
tricular sensitivity. This is an accepted limitation of
the sensing function of pacemakers. The atrial signal
is smaller, and should ideally exceed 2 mV.
A signal with a gradual slope (low slew rate) is
more difficult to sense than one with a sharp up-
stroke (high slew rate). If the signal amplitude is
large enough, the slew rate will always be suffi-
cient and need not be measured. Determination of
the slew rate is most useful when a signal is low
or borderline (3–5 mV in the ventricle). On a long-
term basis, the amplitude of the signal diminishes
slightly but the slew rate may diminish further.
These changes are usually of no clinical importance
for sensing except in the case of smaller signals.
The sensing circuit contains a bandpass filter that
transmits some electrical frequencies more freely
than others. A pacemaker filter is designed to pass
all the signals of interest and attenuate unwanted
signals such as T waves or external interference. A
typical bandpass filter favors the passage of signals
with a frequency of 20–80 Hz in order to sense the
wide range of QRS complexes, and attenuates sig-
nals outside this range.
Caveat: The escape interval in a VVI pacemaker is
measured from the onset of the surface QRS com-
plex. In pacemakers with identical automatic and
electronic escape intervals, the measured escape in-
terval must of necessity be longer than the automatic
interval by a value ranging from a few milliseconds
to almost the entire duration of the QRS complex
(with “late” sensing), depending on the temporal
relationship of the intracardiac electrogram and the
surface ECG. Do not confuse this with hysteresis.
Sensitivity
Programmability of sensitivity is important because
the ideal electrode for sensing does not exist. Sensi-
tivity is a measure of the minimal potential differ-
ence required between the terminals of a pacemaker
to suppress its output. Looking above a wall is a
good analogy of the numeral representation of sensi-
tivity. The higher the wall, the less one will see above
it. The lower the wall, the more one will see above it.
The higher the numerical value of sensitivity, the less
sensitive the pacemaker becomes. Thus, a setting of
6 mV can only sense a signal of 6 mV or greater
and cannot sense signals smaller than 6 mV. On the
other hand, a “higher” sensitivity of 1 mV will allow
sensing of all signals of 1 mV or larger. The sensing
threshold is determined by programming the pacing
rate lower than the intrinsic rate while the sensitiv-
ity is gradually reduced (larger numerical value in
mV) until failure to sense is observed. The sensing
threshold is the largest possible numeric sensitivity
value associated with regular sensing. As a rule, sen-
sitivity should be programmed at a numerical value
at least half the threshold value: e.g., from a sensing
threshold of 8 mV one can program a sensitivity of
4 mV. Oversensing requires a decrease in sensitivity
(increase in the numerical value). Most program-
mers now permit a fully automatic assessment of
the signal amplitude at the time of follow-up. These
measurements are taken from the sense amplifier,
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and represent the signal amplitude after it has been
processed.
Caveats:
1. Always test appropriate sensing, especially atrial
sensing, with deep respiration, to unmask signif-
icant fluctuations of the signal with respiration.
2. The absolute amplitude of the signal measured
from the electrogram is only a rough approxi-
mation of the signal utilized for sensing. This is
because the sensing circuit filters and processes
the signal for sensing.
Polarity: unipolar versus bipolar
pacing and sensing
New lead technology and design have eliminated
the previous advantage of unipolar leads. In prac-
tice, the long-term performance of unipolar and
bipolar systems is similar. Bipolar leads, by virtue of
their greater signal-to-noise ratio (promoting greater
protection against extraneous interference), allow
the use of higher sensitivities. A high sensitivity
is especially useful for atrial sensing, an important
requirement of contemporary dual chamber pace-
makers with the capability of diagnosing supraven-
tricular tachyarrhythmias. This diagnosis permits a
change in the pacing mode automatically to avoid
rapid ventricular pacing. Bipolar leads are also asso-
ciated with less crosstalk in dual chamber pacemak-
ers (ventricular sensing of the atrial stimulus). Bipo-
lar leads are less sensitive than unipolar systems to
external interference (myopotentials etc.). The con-
figuration of many pacemakers is programmable to
either the unipolar or the bipolar mode (provided
they have bipolar leads) to correct certain pacemaker
problems. In some devices, when the circuit detects
a high impedance (resistance) from a fracture in one
of the electrodes, the pacemaker can automatically
change from the bipolar to the unipolar mode of
pacing using the intact electrode.
Reminders:
1. The tip electrode is almost always the cathode,
because the cathodal pacing threshold is lower.
In a bipolar system the proximal (ring) electrode
is the anode, while in a unipolar system the pace-
maker can is the anode.
2. Contemporary pacemakers allow programming
of unipolar or bipolar function in a variety of
ways in individual channels: pacing only, sensing
only, or both. A bipolar lead can be unipolarized
by using either the tip or the ring electrode as
the only intracardiac electrode for sensing and/or
pacing.
Ventricular fusion and
pseudofusion beats
Ventricular fusion beats occur when the ventricles
are depolarized simultaneously by spontaneous
and pacemaker-induced activity. A ventricular fu-
sion beat can exhibit various configurations de-
pending on the relative contributions of the two
foci involved in ventricular activation. A ventric-
ular fusion beat is often narrower than a pure ven-
tricular paced beat. Fusion therefore occurs in the
heart itself.
Ventricular pseudofusion beats consist of the su-
perimposition of an ineffectual ventricular stimu-
lus on a surface QRS complex originating from a
single focus, and they represent a normal manifes-
tation of VVI pacing. A VVI pacemaker obviously
does not sense the surface QRS complex. Rather,
it senses the intracardiac ventricular electrogram
registered between the two pacing electrodes. A
substantial portion of the surface QRS complex can
be inscribed before the intracardiac electrogram
generates the required voltage (according to the
programmed sensitivity) to inhibit the ventricu-
lar channel of a VVI pacemaker. Thus a VVI pace-
maker can deliver a ventricular stimulus within
the spontaneous QRS complex before the device
has the opportunity to sense the “delayed” elec-
trogram generated in the right ventricle as the
depolarization reaches the recording site(s). The
stimulus thus falls in the absolute refractory pe-
riod of the ventricular myocardium. The stimulus
does not depolarize any portion of the ventricles,
and true fusion does not occur. The “fusion” oc-
curs on the ECG recording and not in the heart
itself as in ventricular fusion. True sensing failure
must always be excluded with long ECG record-
ings. Pacemaker stimuli falling beyond the sur-
face ECG always indicate undersensing. A pseu-
dopseudofusion beat (discussed later) is a variant
of a pseudofusion beat seen in patients with dual
chamber pacemakers.
Operational characteristics of a
simple DDD pacemaker
Ventricular channel
As in a standard VVI pacemaker, the ventricular
channel of a DDD pacemaker requires two basic tim-
ing intervals: the lower rate interval (corresponding
to the programmed lower rate) and the ventricular
refractory period.
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The lower rate interval (LRI) of a DDD pacemaker
is the longest interval between consecutive ven-
tricular stimuli without an intervening sensed P
wave, or from a sensed ventricular event to the
succeeding ventricular stimulus without an inter-
vening sensed P wave.
The ventricular refractory period (VRP) is tradi-
tionally defined as the period during which the
pacemaker is insensitive to incoming signals. The
function of the ventricular refractory period in a
DDD pacemaker is similar to that in a VVI pace-
maker. Yet many pacemakers can now actually
sense within part of the refractory period to per-
form pacemaker functions (and influence certain
timing intervals) other than resetting the lower
rate interval. The pacemaker VRP now focuses
only on the lower rate interval, which cannot be
reset or reinitiated by a ventricular signal falling
within the refractory interval. The VRP starts with
either a sensed or a paced ventricular event, and
is usually equal after pacing and sensing. The
lower rate (interval) of many DDD pacemakers is
ventricular-based in that it is initiated by a paced
or sensed ventricular event. Atrial-based lower
rate timing is more complex, and is discussed later.
DDD pacing or VVI pacing with an
atrial channel
Now the pacemaker acquires an atrioventricular in-
terval and an upper rate interval.
The AV interval (AVI) is the electronic analog of the
PR interval and is designed to maintain AV syn-
chrony between the atria and the ventricles. The
AV interval starts from the atrial stimulus and ex-
tends to the following ventricular stimulus, or it
starts from the point when the P wave is sensed
and also terminates with the release of the ventric-
ular stimulus. Atrial tracking is a term used to de-
scribe the response of a dual chamber pacemaker
to a sensed atrial event which leads to the emis-
sion of a ventricular output pulse. Let us assume
for now that the AV delay in our simple DDD
pacemaker after atrial sensing is equal to that af-
ter atrial pacing, though they may be different in
more complex pacemakers.
The upper rate interval (URI) is the speed limit to
control the response of the ventricular channel to
sensed atrial activity. For example, if the upper
rate interval is 500 ms (upper rate = 120 ppm),
a P wave occurring earlier than 500 ms from the
previous atrial event (atrial rate faster than 120
ppm) will not be followed by a ventricular stim-
ulus. Such an arrangement allows atrial sensing
with 1 : 1 AV synchrony between the lower rate
and the upper rate. The upper rate interval of any
DDD pacemaker is a ventricular interval, and it is
defined as the shortest interval between two con-
secutive ventricular stimuli or from a sensed ven-
tricular event to the succeeding ventricular stim-
ulus while maintaining 1 : 1 AV synchrony with
sensed atrial events. In a simple DDD pacemaker
the upper rate interval is intimately related to the
electronic refractory period of the atrial channel,
as discussed later.
Derived timing intervals
The four basic timing intervals of a simple DDD
pacemaker, as already explained, consist of lower
rate interval (LRI), ventricular refractory period
(VRP), AV interval (AVI), and upper rate interval
(URI). Additional timing intervals can be derived
from these four basic intervals. Let us assume that
the lower rate of our simple DDD pacemaker is
ventricular-based. The atrial escape interval (AEI)
is the LRI minus the AVI. This is sometimes called
the VA interval. The atrial escape interval starts
with either a ventricular paced or a sensed event,
and terminates with the release of the atrial stim-
ulus. Although derived from two other intervals,
the atrial escape interval is crucial in the analysis
of DDD pacemaker function because it represents
the interval the pacemaker uses to determine when
the next atrial stimulus should occur after a sensed
or paced ventricular event. In our DDD pacemaker
with ventricular-based lower rate timing, the atrial
escape interval always remains constant after pro-
gramming the lower rate interval and AV delay.
At this point our simple DDD pacemaker has four
basic intervals and one derived one. As the DDD
pacemaker grows in complexity, we shall see how
a basic upper rate interval is best equated with in
terms of the total atrial refractory period (TARP). The
latter had been considered initially a fundamental
interval for the sake of simplicity in the construction
of a simple DDD pacemaker. It is actually a derived
interval as discussed later.
Influence of events in one chamber upon
the other
The operation of the two channels of a DDD pace-
maker are intimately linked, and an event detected
by one channel generally influences the function of
the other.
Atrial channel. As in the normal heart, an atrial
event must always be followed by a ventricular
event after some delay. A sensed atrial event al-
ters pacemaker function in two ways: (a) it triggers
a ventricular stimulus (after a delay equal to the
AVI) provided the ventricular channel senses no
signal during the AVI; (b) it inhibits the release of
the atrial stimulus that would have occurred at the
completion of the atrial escape interval. In other
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words, it aborts the atrial escape interval, which
therefore does not time out in its entirety. This is
self-evident, because the atrial cycle starts with a
sensed P wave and there is no need for atrial stim-
ulation immediately after a spontaneous atrial
event. Therefore the atrial channel functions si-
multaneously in the triggered mode (to deliver
the ventricular stimulus for AV synchrony) and
in the inhibited mode to prevent competitive re-
lease of an atrial stimulus after sensing a P wave.
The function of the atrial channel can thus be de-
picted by “TI” in the third position of the standard
pacemaker code. Because the ventricular channel
functions only in the inhibited mode, a DDD pace-
maker can be coded as a DDTI/I device, which
would be more awkward but more correct than
the traditional DDD designation.
Ventricular channel. A sensed ventricular event out-
side the AV delay, such as a ventricular extrasys-
tole (or premature ventricular complex) will in-
hibit the atrial and ventricular channels. The atrial
escape interval in progress is immediately termi-
nated, and release of the atrial stimulus is inhib-
ited. The sensed ventricular event also inhibits the
ventricular channel and initiates a new atrial es-
cape interval. Thus both the atrial and ventricu-
lar channels are inhibited simultaneously. When
a ventricular event is sensed within the AV de-
lay there is no need for the pacemaker to release
a ventricular stimulus at the completion of the
AV delay because spontaneous ventricular activ-
ity is already in progress. Therefore the pacemaker
aborts the AV delay by virtue of the sensed ven-
tricular event. The AV delay is thus abbreviated.
The sensed ventricular event immediately starts a
new atrial escape interval.
Atrial refractory period
It is axiomatic that the atrial channel of a DDD pace-
maker must be refractory during the AV delay to pre-
vent initiation of a new AV delay before completion
of an AV delay already in progress.
The postventricular atrial refractory period
(PVARP) begins immediately after the emission
of a ventricular event and is the same after a ven-
tricular stimulus or a sensed ventricular signal.
An atrial signal falling within the PVARP cannot
initiate a programmed AV interval. The PVARP
is designed to prevent the atrial channel from
sensing the ventricular stimulus, the far-field QRS
complex (a voltage that can be seen by the atrial
channel), very premature atrial ectopic beats, and
retrograde P waves. In the normal heart, an iso-
lated ventricular event may occasionally be fol-
lowed by a retrograde P wave because of retro-
grade ventriculoatrial (VA) conduction (the AV
junction being a two-way street). Although this
is a physiological phenomenon, it may be hemo-
dynamically unfavorable if it becomes sustained.
The PVARP should be programmed to a duration
longer than the retrograde VA conduction time, to
prevent the atrial channel from sensing retrograde
P waves.
The total atrial refractory period (TARP) is the sum
of the AVI and the PVARP. The duration of the
TARP always defines the shortest upper rate inter-
val or the fastest paced ventricular rate. The AVI,
PVARP, and URI are interrelated in a simple DDD
pacemaker without a separately programmable
URI. In such a system, the URI is controlled solely
by the duration of the TARP according to the for-
mula: upper rate (ppm) = 60,000/TARP (ms). So
far, in the simple DDD pacemaker, the TARP is the
upper rate interval, and it is constructed by means
of a few timing cycles.
Sensing in the refractory period: true or false?
The first part of any refractory period consists of a
blanking period during which the pacemaker can-
not sense at all. The second part of the refractory pe-
riod permits sensing, and each detected event is of-
ten represented symbolically by a “refractory sense
marker.” In the atrium refractory sensed events can-
not initiate an AV delay, and in the ventricle they
cannot start an atrial escape interval or lower rate
interval. In one designation, AR and VR depict an
atrial refractory sensed event and ventricular refrac-
tory sensed event respectively. The rapid and irreg-
ular atrial rates in atrial fibrillation, if sensed by the
atrial channel, will inscribe many AR events within
the AV delay beyond the initial blanking period (ini-
tiated by atrial sensing or pacing) and multiple AR
events in the PVARP beyond the initial postventric-
ular atrial blanking period initiated by ventricular
pacing or sensing.
Upper rate interval versus PVARP
Now that the function of the PVARP is clear, it makes
sense to consider the PVARP itself as a basic inter-
val controlling the upper rate. In this way the up-
per rate interval can be demoted to a derived in-
terval. This manipulation converts the upper rate
interval of our evolving DDD pacemaker or the
TARP (AVI + PVARP) to a derived function.
The six intervals of a simple DDD
pacemaker
According to the above concepts, we now have a
DDD pacemaker working with four basic intervals
(LRI, VRP, AVI, and PVARP) and two derived
intervals (AEI, and TARP = URI). Such a pacemaker
can function quite well provided the atrial stimulus
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does not interfere with the function of the ventric-
ular channel. If it does, the disturbance is called
AV crosstalk, because the atrial stimulus, if sensed
by the ventricular channel, can cause ventricular
inhibition.
The fifth basic timing interval
Prevention of crosstalk is mandatory, and it re-
quires the addition of a brief ventricular blanking
period beginning coincidentally with the release
of the atrial stimulus. This is known as the posta-
trial ventricular blanking period (PAVB). No signal
can be detected during this blanking period. The
ventricular channel then “opens” after this short
blanking period so that ventricular sensing (with
reset of the atrial escape interval and lower rate in-
terval) can occur during the remainder of the AV
delay. Obviously a long postatrial ventricular blank-
ing period will predispose to ventricular undersens-
ing. The addition of this important blanking interval
yields a DDD pacemaker with five basic cycles and
two derived cycles. This format was the basis of the
first-generation DDD pacemakers that were clini-
cally used and accepted. Even a sophisticated con-
temporary DDD pacemaker reduced to having only
these seven intervals would function satisfactorily if
appropriately programmed. The addition of further
timing intervals represents refinements rather than
essential elements of DDD pacing.
Do we need more than seven timing
intervals in our evolving DDD pacemaker?
Further refinements of DDD pacemaker function
have introduced two other timing intervals:
(a) Ventricular safety pacing (VSP) to complement
the blanking period in dealing with crosstalk.
This function does not prevent crosstalk but
merely offsets its consequences.
(b) Upper rate interval programmable indepen-
dently of the TARP for a smoother upper rate
response than the rather abrupt slowing pro-
vided by the TARP when it is the only interval
controlling the upper rate (interval).
Refractory periods
In a DDD pacemaker, how does an event in one
channel affect the refractory period of the other?
Four possible events may be considered: AS, AP, VS,
and VP.
(a) VS and VP both initiate the VRP and PVARP,
starting simultaneously.
(b) AP initiates the AV delay and an atrial refrac-
tory period extending through the entire dura-
tion of the AV delay. The AV delay is therefore
the first part of the TARP, the second part being
the PVARP. Release of AP initiates an important
interval (postatrial ventricular blanking period)
to prevent crosstalk, which is a pacemaker dis-
turbance where the ventricular channel senses
the atrial stimulus (discussed later).
(c) AS generates an atrial refractory period in the
AV delay like AP, but it is not associated with a
ventricular blanking because AS cannot induce
crosstalk (discussed later).
The faces of DDD pacing
A DDD pacemaker with ventricular-based lower
rate timing capable of dealing with four events (AS,
AP, VS, VP) can behave in one of four ways, judged
by the examination of a single cycle starting with VS
and the way the cycle terminates:
1. DVI: VS–AP–VP
2. AAI: QRS–AP–QRS
3. VDD: VS–AS–VP
4. Totally inhibited “mode” without stimuli
In the inhibited situation the RR interval (VS–VS)
is shorter than the lower rate interval, and the PR
interval is shorter than the programmed AV delay.
Inhibition does not always mean that the pacemaker
senses both the atrial and ventricular signals. In-
deed, in the presence of atrial undersensing, the
ECG may show inhibition if the pacemaker (actu-
ally working in the DVI mode) emits no stimuli be-
cause the RR interval is shorter than the atrial escape
interval.
Ventricular pseudopseudofusion beats
Remember that in a DDD pacemaker a sensed ven-
tricular event inhibits both the atrial and ventric-
ular channels. A ventricular pseudofusion beat oc-
curs when a ventricular stimulus falls within the
spontaneous QRS before the intracardiac ventricu-
lar electrogram has developed sufficient amplitude
to be sensed. In the same way, an atrial stimulus
can fall within the surface QRS complex before the
intracardiac ventricular electrogram has developed
sufficient amplitude to be sensed. In this situation,
when an atrial stimulus deforms the QRS complex,
the arrangement is called a pseudopseudofusion ven-
tricular beat, to underscore that the process involves
two chambers instead of just one, as in the case of
pseudofusion beats.
Caveat: In the presence of normal atrial and ventric-
ular sensing, a pacemaker stimulus falling within
the QRS complex may be atrial (pseudopseudofu-
sion) or ventricular (pseudofusion). In a device with
a ventricular-based lower rate, the stimulus is atrial
if it terminates the atrial escape interval, which is
always constant. In a device with an atrial-based
lower rate system (where atrial events control the
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lower rate), the stimulus is atrial if it terminates an
interatrial interval equal to the lower rate interval.
Crosstalk and crosstalk intervals
In patients without an underlying cardiac rhythm,
inhibition of the ventricular channel by crosstalk can
be catastrophic. The postatrial ventricular blanking
period (PAVB) starts with the atrial stimulus and
is usually programmable from about 10 to 60 ms.
Note again that no blanking period is in effect after
atrial sensing. Some pacemakers are designed with
an additional safety mechanism to counteract the
inhibitory effect of crosstalk should the postatrial
ventricular blanking period be unsuccessful. This
special “safety period” is really a crosstalk detec-
tion window, and it is often described in pacemaker
specifications as starting from the atrial stimulus. In
fact, it cannot be functional until the brief postatrial
ventricular blanking period has timed out. Never-
theless, the AV delay is often described as having
two parts. The first part is the ventricular safety pac-
ing (VSP) window, which extends from the onset of
the AV delay for a duration of 100–110 ms. During
the VSP interval, a sensed ventricular signal does
not inhibit the DDD pacemaker. Rather, it immedi-
ately triggers a ventricular stimulus delivered pre-
maturely only at the completion of the VSP interval,
producing a characteristic abbreviation of the paced
AV interval (AP–VP). If a QRS complex is sensed
within the VSP window, it will also trigger an early
ventricular stimulus. However, this triggered ven-
tricular stimulus falls harmlessly within the QRS
complex in the absolute period of the ventricular
myocardium. In the second part of the AV delay be-
yond the VSP interval, a sensed ventricular signal
inhibits the pacemaker in the usual fashion.
Manifestations of crosstalk
1. In pacemakers with a VSP interval, crosstalk will
cause shortening of the paced AV delay (AP–VP).
In a device with ventricular-based lower rate tim-
ing, the pacing rate will increase because the sum
of the constant atrial escape interval and the ab-
breviated AV delay becomes less than the lower
rate interval. In a device with atrial-based lower
rate timing, the pacing interval remains constant
as it is controlled by the interval between two
consecutive atrial stimuli, which is always equal
to the programmed lower rate interval.
2. In pacemakers without a VSP interval, the ECG
will show: (a) prolongation of the interval be-
tween the atrial stimulus and the succeeding con-
ducted QRS complex to a value greater than the
programmed AV delay; (b) ventricular asystole, if
there is no AV conduction; (c) an atrial pacing rate
interval shorter than the lower rate interval (atrial
pacing rate faster than the lower rate), because
the interval between two consecutive atrial stim-
uli becomes equal to the sum of the atrial escape
interval (AEI) and the short postatrial ventricular
blanking period (PAVB) because sensing of the
atrial stimulus can only occur after the blanking
period has timed out.
3. Crosstalk tachycardia. In pacemakers with VSP
and ventricular-based lower rate timing, a lower
rate of 80 ppm (LRI = 750 ms) yields an atrial
escape interval of 450 ms if the AV delay = 300 ms.
During continual crosstalk with an abbreviated
paced AV delay (AP–VP) of 100 ms, the pacing
interval becomes 450 + 100 = 550 ms, correspon-
ding to a rate of 109 ppm.
Caveat: VSP can be puzzling in the ECG without
markers. When the atrial stimulus falls within a QRS
complex and is invisible on the surface ECG, a single
visible ventricular stimulus will fall beyond the QRS
complex. This must not be interpreted as ventricular
undersensing. To make the diagnosis, go back to the
previous ventricular event and with calipers move
to the end of the atrial escape interval when the atrial
stimulus should have occurred. Then add the VSP
interval, and its end should coincide with the late
stimulus in question, thereby proving it is ventricu-
lar and establishing normal pacemaker function. If
VSP has not occurred and the QRS complex fell in
the postatrial ventricular blanking period, add the
AV delay to the atrial escape interval (measured as
indicated) rather than the VSP interval.
Reminders:
1. The frequent occurrence of VSP involving sponta-
neous QRS complexes should immediately raise
the possibility of atrial undersensing.
2. The opposite of AV crosstalk is ventriculoatrial
(VA) crosstalk, where the atrial channel senses
ventricular activity. VA crosstalk is important
in pacemakers with automatic mode switching
(discussed later).
3. In pacemakers with atrial-based lower rate ti-
ming, during AV crosstalk the atrial pacing rate
will remain constant in duration to conform to
the atrial-based lower rate and the AEI will vary
to accommodate the constancy of the atrial pa-
cing rate.
Increasing complexity: our
simple DDD pacemaker grows to
nine intervals
Many pacemakers have nine timing intervals, five
related to the ventricular channel and four to the
atrial channel. A ventricular paced or sensed event
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initiates: (a) lower rate interval (LRI), (b) upper rate
interval (URI; independent of TARP), (c) PVARP, (d)
ventricular refractory period (VRP), and (e) atrial es-
cape interval (AEI). An atrial paced or sensed event
initiates: (a) AV interval (AVI) and (b) TARP (derived
as the sum of AVI and PVARP). An atrial paced event
initiates (a) postatrial ventricular blanking period
(PAVB) and (b) VSP interval.
A pacemaker with the capability of programming
a longer URI independently of the TARP provides
two levels of upper rate response. The first level
defines the onset of the Wenckebach upper rate re-
sponse and occurs when the P–P interval is shorter
than the upper rate interval but longer than the
TARP. The second level uses the TARP itself to define
the onset of block when the P–P interval becomes
shorter than the TARP.
Upper rate response of
DDD pacemakers
The maximum paced ventricular rate of a DDD pace-
maker can be defined either by the duration of the
TARP or by a separate timing circuit controlling the
ventricular channel. In general, upper rate limitation
by only the TARP (as in our early DDD pacemaker)
is less suitable because it produces a sudden fixed-
ratio block such as 2 : 1 or 3 : 1 block. In contrast, a
smoother response occurs with a Wenckebach upper
rate response, which requires a separate URI timing
interval that must be longer than the TARP.
Fixed-ratio block
In this system the upper rate becomes a function of
only the TARP (AVI + PVARP). As the atrial rate
increases, any P wave falling within the PVARP is
unsensed and, in effect, blocked. The AV delay al-
ways remains constant. If the programmed upper
rate is 120 ppm (TARP = 500 ms) and the lower
rate is 60 ppm, a 2 : 1 response will occur when the
atrial rate reaches 140 ppm. One P wave is blocked
(or unsensed) and the other initiates an AV delay
and triggers a ventricular response. The situation is
not as simple mathematically when the lower rate
is 70 ppm, because the ventricular rate cannot fall
below the lower rate. An upper rate response us-
ing fixed-ratio block may be inappropriate in young
or physically active individuals, because the sudden
reduction in the ventricular rate with activity may
be poorly tolerated.
Wenckebach upper rate response
The Wenckebach upper rate response requires a sep-
arately programmable upper rate interval (URI). The
purpose of the Wenckebach response is to avoid a
sudden reduction of the paced ventricular rate (as
occurs in fixed-ratio block) and to maintain some de-
gree of AV synchrony at faster rates. The URI must
be longer than the TARP. During the Wenckebach
upper rate response, the pacemaker will synchro-
nize its ventricular stimulus to sensed atrial activ-
ity. The pacemaker cannot violate its URI. There-
fore, upon atrial sensing, the pacemaker has to wait
until the URI has timed out before it can release a
ventricular stimulus. For this reason the AV delay
(initiated by atrial sensing) must be extended to de-
liver the ventricular stimulus at the completion of
the URI. The sensed AV delay gradually lengthens
throughout the Wenckebach sequence, but the ven-
tricular rate remains constant at the programmed
upper rate. Mathematically the AV delay must pro-
gressively lengthen in the Wenckebach progression
simply because the URI cannot be violated and the
atrial rate interval or P–P interval is shorter than the
URI but longer than the TARP. Eventually a P wave
will fall in the PVARP, where it will not be followed
by a ventricular stimulus, and a pause will occur.
In other words, the Wenckebach response maintains
the constant URI at the expense of extension of the
AV delay (AS–VP).
1. The maximum prolongation of the AV interval
represents the difference between the URI and
the TARP.
2. With progressive shortening of the P–P interval,
the Wenckebach upper rate response eventually
switches to 2 : 1 fixed-ratio block, which occurs
when the P–P interval becomes shorter than the
TARP.
3. There are only two ventricular paced intervals
during a Wenckebach upper rate sequence: (a)
repeated ventricular pacing at the upper rate in-
terval; (b) a longer interval (pause) between two
successive ventricular beats following the unde-
tected P wave in the PVARP. The pause may ter-
minate with AS or AP, and the ventricular event
may be VS or VP, according to circumstances.
Some patients feel the pause at the end of a
Wenckebach sequence as an uncomfortable sen-
sation. The pause may be abbreviated or even
eliminated with appropriate programming of the
sensor function of a DDDR pacemaker. This pro-
cess has been called sensor-driven rate-smoothing.
4. Let us consider two clinical examples:
(a) A DDD pacemaker is programmed as fol-
lows: upper rate = 100 ppm (URI = 600 ms),
AV delay = 150 ms, PVARP = 250 ms. The
TARP will be 250 + 150 = 400 ms. The pace-
maker will therefore respond to an atrial rate
faster than 100 bpm by exhibiting Wencke-
bach sequences, with the longest prolonga-
tion of the AV interval being 200 ms (URI mi-
nus TARP). Thus the AV delay will vary from
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its programmed value of 150 ms to a maxi-
mum of 350 ms. Fixed-ratio block will occur
when the P–P interval is shorter than the
TARP (400 ms), or at an atrial rate of 150 bpm.
(b) When the same DDD pacemaker is pro-
grammed with AV delay = 200 ms, PVARP
= 250 ms, upper rate = 125 ppm (URI = 480
ms), it would be difficult to produce an actual
Wenckebach upper rate response. The maxi-
mum prolongation of the AV interval would
be 30 ms (URI minus TARP) and its maximum
duration 230 ms. In this case, the pacemaker
will respond with a Wenckebach sequence at
an atrial rate of 125 bpm, but less than 133
ppm. When the atrial rate exceeds 133 bpm,
fixed-ratio block will occur (P–P shorter than
TARP of 450 ms).
Remember the three important variables:
URI, TARP, and the P–P interval
(atrial rate)
1. URI ≤ TARP:
 No Wenckebach response is possible.
2. URI > TARP:
 P–P interval > URI. When the P–P interval is
longer than the URI, the pacemaker maintains
1 : 1 AV synchrony.
 P–P interval < URI. When the P–P interval be-
comes shorter than the URI but longer than
the TARP (i.e., URI > P–P > TARP), the pace-
maker responds with a Wenckebach upper rate
response.
 P–P interval < TARP. When the P–P interval is
shorter than the TARP, the pacemaker can only
respond with a fixed-ratio form of upper rate
limitation.
Duration of the AV interval and
programmability of the upper rate
The sensed AV interval (sAVI) initiated by AS
(AS–VP), and not the one initiated by AP (pAVI),
determines the point where fixed-ratio block occurs,
i.e., when P–P interval is less than TARP or (AS–VP)
+ PVARP. In many pacemakers the sAVI (AS–VP)
can be programmed to a shorter value than the pAVI
(AP–VP) interval, thereby shortening the TARP dur-
ing atrial sensing. Furthermore the sAVI (AS–VP)
can decrease further with exercise according to the
sensed atrial rate and/or sensor activity. This short-
ening on exercise mimics the physiological response
of the PR interval and provides hemodynamic bene-
fit and a more advantageous shorter TARP. (In some
pacemakers the TARP can also shorten further on ex-
ercise because of an adaptive PVARP that shortens
on exercise based on designed algorithms.) There-
fore a shorter TARP allows programming (sepa-
rately) of a shorter URI, to permit a Wenckebach
upper rate response to occur at faster atrial rate.
Lower rate timing of dual chamber
pacemakers
Traditional DDD pacemakers are designed with
ventricular-based lower rate timing. In this system a
ventricular paced (VP) or ventricular sensed (VS)
event initiates the lower rate interval (LRI) and
the atrial escape interval. The atrial escape inter-
val always remains constant. The LRI is the longest
VP–VP or VS–VP interval without intervening atrial
and ventricular sensed events. In atrial-based lower
rate timing, the LRI is initiated and therefore con-
trolled by atrial sensed or paced (AS or AP) events
rather than ventricular events. The LRI becomes the
longest AP–AP or AS–AP interval. The atrial escape
interval becomes variable and adapts its duration to
maintain a constant AP–AP or AS–AP interval equal
to the LRI. The duration of the atrial escape interval
can be calculated as the LRI minus the AV interval
immediately preceding the atrial escape interval in
question. In an atrial-based lower rate system, ven-
tricular premature complexes initiate either the basic
atrial escape interval (as if it were ventricular-based)
or a complete LRI according to design.
Caveat: In hysteresis the escape interval after sensing
is longer than the pacemaker automatic interval.
Phantom programming
This describes unintended, inadvertent, or mysteri-
ous reprogramming of a pacemaker. It may be due to
reprogramming by an operator who made no record
of it in the patient’s chart. It may also be caused
by electromagnetic interference unbeknown to the
patient.
Programmability of lower rate
Patients with coronary artery disease and angina
pectoris tend to have their pacemaker programmed
to a low rate to avoid the precipitation of angina
(chest pain). This may be true for VVI pacing but
not for VDD, DDD, rate-adaptive DDD (DDDR),
and rate-adaptive VVI (VVIR) pacing, which such
patients tolerate well because their heart responds
more efficiently on exercise. However, the upper rate
should be programmed cautiously. Patients with
sick sinus syndrome and atrial tachyarrhythmias
may benefit from overdrive suppression by increas-
ing the pacing rate to 80 bpm, which may eliminate
or reduce atrial tachyarrhythmias (Table 1).
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Rate Increase (a) To optimize cardiac output; (b) to overdrive or terminate
tachyarrhythmias; (c) to adapt to pediatric needs; (d) to test AV
conduction in AAI pacemakers; (e) to confirm atrial capture using
the AAI mode by observing a concomitant increase in the
ventricular rate; (f) rate-drop response for the treatment of
vasovagal syncope – an abrupt fall in the spontaneous rate causes
pacing at a higher rate (than the low basic pacing rate) for a given
duration; (g) to prevent polymorphic ventricular tachycardia after
ablation of the AV junction for refractory supraventricular
tachyarrhythmias
Decrease (a) To assess underlying rhythm and dependency status; (b) to
adjust the rate below the angina threshold; (c) to allow the
emergence of sinus rhythm and preservation of atrial transport; (d)
to test sensing function; (e) sleep mode to provide a lower rate
during the expected sleep time. Some devices use an activity sensor
to drop the rate automatically with inactivity
Output Increase To adapt to pacing threshold
Decrease (a) To test pacing threshold; (b) to program pacemaker according to
chronic threshold to enhance battery longevity; (c) to reduce
extracardiac stimulation (voltage rather than pulse duration) of
pectoral muscles or diaphragm; (d) to assess underlying rhythm
and dependency status
Sensitivity Increase To sense low amplitude P or QRS electrograms
Decrease (a) To test sensing threshold; (b) to prevent T wave or afterpotential
sensing by ventricular channel; (c) to avoid sensing extracardiac
signals such as myopotentials
Refractory
period
Increase (a) Atrial: to minimize sensing of the far-field QRS during AAI
pacing; (b) ventricular: to minimize T wave or afterpotential sensing
by the ventricular channel
Decrease (a) To maximize QRS sensing; (b) to detect early ventricular
premature beats
Hysteresis To delay onset of ventricular pacing and to preserve atrial transport
function in the VVI mode
Polarity Conversion to
unipolar mode
(a) To amplify the signal for sensing when the bipolar electrogram is
too small; (b) to compensate temporarily for a defect in the other
electrode
Conversion to
bipolar mode
(a) To decrease electromagnetic or myopotential interference; (b) to
evaluate oversensing; (c) to eliminate extracardiac anodal
stimulation
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AV interval (AVI) Increase or
decrease to
optimize LV
function
(a) Differential: to permit a longer interval after an atrial paced
event than a sensed atrial event; (b) rate-adaptive: to shorten the AV
delay with an increase in heart rate
Postventricular
atrial refractory
period (PVARP)
Increase To prevent sensing of retrograde P waves
PVARP extension
after a VPC
On/off To prevent sensing of retrograde P wave after a VPC
Postventricular
atrial blanking
period (PVAB)
Increase To prevent VA crosstalk
Postatrial
ventricular
blanking period
(PAVB)
Increase To prevent AV crosstalk
Ventricular safety
pacing (VSP)
On/off To guarantee ventricular stimulation in the presence of crosstalk
Separately
programmable
upper rate
URI > TARP To provide a smoother (Wenckebach) upper rate response and
avoid abrupt slowing of the ventricular rate when URI = TARP
Endless loop tachycardia
Endless loop tachycardia (ELT) sometimes called
pacemaker-mediated tachycardia, is a well-known
complication of DDD, DDDR, and VDD pacing. It
represents a form of ventriculoatrial (VA) synchrony,
or the reverse of AV synchrony. Any circumstance
that causes AV dissociation (separation of the P wave
from the paced or spontaneous QRS complex) can
initiate ELT, but only in patients with retrograde
VA conduction. The most common initiating mecha-
nism is a ventricular premature complex (VPC) with
retrograde VA conduction (Table 2).
When the atrial channel senses a retrograde P
wave, a ventricular stimulus is issued at the com-
pletion of the AV delay, which may have to be
extended to conform to the URI. The pacemaker
provides the anterograde loop of a process similar
to the reentrant mechanism of many spontaneous
tachyarrhythmias. VA conduction following ventric-
ular pacing provides the retrograde limb of the reen-
trant loop. The atrial channel of the pacemaker again
senses the retrograde P wave, and the process per-
petuates itself. The cycle length of ELT is often equal
to the URI, but it can be longer than the URI if ret-
rograde VA conduction is delayed. The tachycardia
is called a balanced ELT when its rate is slower than
the programmed upper rate. The true programmed
AV delay will be seen in ELT when the rate is slower
than the programmed upper rate because the AVI is
not extended. When the ELT is at the upper rate, the
AV delay is extended to conform to the URI.
Diagnosis and prevention of endless
loop tachycardia
The presence of retrograde VA conduction and its
duration must always be determined (Table 3).
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endless loop tachycardia (ELT).
1. Ventricular extrasystoles (most common
cause)
2. Subthreshold atrial stimulation
3. Atrial extrasystole with prolongation of AV
delay to conform to programmed upper rate
interval > total atrial refractory period
4. Application and withdrawal of the magnet
5. Decrease in atrial sensitivity: undersensing
of anterograde P waves with preserved
sensing of retrograde P waves
6. Myopotential sensing, usually by the atrial
channel
7. Programmer electromagnetic interference,
sensed by the atrial channel only
8. Excessively long AV delay
9. Programming the VDD mode when the
sinus rate is slower than the programmed
lower rate
10. Treadmill exercise (rarely) and increase in
sinus rate with Wenckebach upper rate
response and AV delay extension
11. Sensing of a far-field signal by the atrial
lead, usually the far-field R wave
The maneuvers to initiate ELT are repeated un-
til appropriate programming of the pacemaker
prevents induction of tachycardia. In general the
PVARP should be programmed at least 50 ms longer
than the VA conduction time. A PVARP of 300 ms
offers protection against ELT in most patients with
retrograde conduction (Table 4).
Reminder: Application of the magnet over the pace-
maker immediately terminates ELT in virtually
100% of the cases, because it eliminates sensing.
Table 3. Situations where retrograde
VA conduction can be evaluated.
1. Programming to VVI mode
2. Programming the atrial output to
sub-threshold level in the DDD mode
3. Application and withdrawal of the magnet
4. Holter monitoring
5. Treadmill exercise (rarely)
Table 4. Programmability for the
prevention of endless loop
tachycardia.
1. Program PVARP
2. Automatic PVARP extension after VPC
3. Adaptive PVARP
4. Programmable sensitivity: 60–75 % of
anterograde P waves are at least 0.5 mV
larger than retrograde P waves
5. Shortening of the AV delay
6. Programming to a non-tracking mode such
as DDI is no longer acceptable
Caveats:
1. The rate of ELT is not always at the programmed
upper rate. In the DDI mode an endless loop with
repetitive retrograde VA conduction will occur at
the lower rate, and no tachycardia is possible.
2. Programming a long PVARP will limit the upper
rate. This may be important in vigorous or young
patients.
ELT should be considered a complication of the
past, because it is almost always prevented by pro-
gramming the PVARP to contain the retrograde P
waves. Problems arise when the VA conduction time
is very long and a long PVARP restricts programma-
bility of the upper rate. In such cases, pacemakers
utilize special automatic tachycardia-terminating al-
gorithms.
Repetitive non-reentrant VA
synchrony: the cousin of endless
loop tachycardia
ELT is a form of repetitive VA synchrony, and
as mentioned it is a reentrant or circus-movement
tachycardia. Repetitive VA synchrony can occur in
the VVI or VVIR with continual retrograde VA con-
duction, where it may cause hemodynamic impair-
ment and the pacemaker syndrome. Repetitive VA
synchrony can also occur in the DDD or DDDR
mode when a paced ventricular beat causes retro-
grade VA conduction but the retrograde P wave is
unsensed (unlike ELT) because it falls within the
PVARP. Under certain circumstances, this form of
VA synchrony can become self-perpetuating, when
the pacemaker continually delivers an ineffectual
atrial stimulus (despite being well above the pac-
ing threshold under normal circumstances) in the
atrial myocardial refractory period generated by the
preceding retrograde P wave. The potential
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reentrant circuit does not close as in ELT, and
this arrhythmia is often labeled as being non-
reentrant. Both ELT and repetitive non-reentrant
VA synchrony depend on VA conduction, and they
are physiologically similar, sharing similar initiat-
ing and terminating mechanisms. Repetitive non-
reentrant VA synchrony depends on a short atrial
escape interval (relatively fast lower rate and/or a
long AV delay) and a relatively long VA conduction
time. Thus it is more likely to occur during sensor-
driven faster pacing rates. The process may there-
fore occur when programming a very long AV de-
lay to promote AV conduction and normal ventric-
ular activation. Occasionally, during ELT, magnet
application over the pacemaker can cause a locked
arrangement similar to repetitive non-reentrant VA
synchrony (with preservation of VA conduction), so
that removal of the magnet reinitiates ELT.
Types of dual chamber pacemakers
Simpler pacing modes can be easily derived from
the DDD mode by the removal of certain intervals
and equalizing others. All retain a fundamental LRI,
ventricular refractory period, and AV delay initiated
by atrial pacing, except for the DOO mode, which
has only an AV delay and LRI.
DVI mode
The DVI mode may be considered as the DDD mode
with the PVARP lasting through the entire duration
of the atrial escape interval. As the AV delay is al-
ways refractory in a DDD pacemaker, the TARP, in
effect, lasts through the entire LRI. No URI can ex-
ist because atrial sensing is impossible. Therefore the
LRI, TARP, and URI are all equal. Crosstalk intervals
are retained. The DVI mode is rarely used, and it is
obsolete as a primary pacing mode. The term “com-
mitted,” and variants thereof, are therefore obsolete
descriptions of the DVI mode.
DDI mode
The DDI mode may be considered as the DDD mode
with equal URI and LRI. This concept facilitates
understanding of complex rhythms generated by
this mode, although this conceptualization is not
recommended by some experts. Nevertheless, it
is easy to remember and apply. Remember the
DDTI/I designation for the DDD mode. The DDI
mode is simply created by removing the “T” from
the atrial channel. Thus atrial sensing occurs but no
“T” function is possible. In other words, a sensed
P wave cannot trigger a ventricular stimulus, and
a programmed AV interval cannot occur after atrial
sensing. The programmed AV delay can only exist as
the AP–VP interval. This means that atrial tracking
cannot occur. The DDI mode will therefore always
exhibit a constant ventricular paced rate equal to
the LRI. There is no URI (as URI = LRI). A PVARP
is retained because atrial sensing occurs. Crosstalk
intervals are retained. In the early days of DDD
pacing, the DDI mode was useful in patients with
AV block and paroxysmal atrial tachyarrhythmias
because it prevented rapid ventricular pacing dur-
ing tachycardia. The use of the primary continuous
DDI mode for this problem has been superseded
by automatic mode switching of a DDD pacemaker
to the DDI mode upon the detection of an atrial
tachyarrhythmia, and reversion to the DDD mode
automatically upon termination of tachycardia.
During DDI pacing with atrial fibrillation and
AV block, many AR markers (atrial refractory sense
events) will be seen in the atrial refractory period (in
the AV delay and the PVARP) and AS markers out-
side the atrial refractory period. AS cannot start an
AV delay. The AR markers provide diagnostic repre-
sentation of the underlying arrhythmia and insight
as to how the pacemaker activates the automatic
mode-switching function.
VDD mode
The original atrial synchronous pacemaker was the
VAT system without ventricular sensing. Then ven-
tricular sensing was added (VAT + VVI = VDD). The
VDD mode functions like the DDD mode except that
the atrial output is turned off. The required timing
intervals include LRI, URI, AVI, and PVARP. The
omitted atrial stimulus begins an implied AV delay,
during which, according to traditional design, the
atrial channel is refractory. In the absence of atrial
activity, the VDD mode will continue to pace effec-
tively in the VVI mode (at the LRI of its DDD parent)
because the VDD keeps all the basic cycles of the
DDD mode despite the missing atrial output. This
is an important disadvantage of the VDD mode, be-
cause VVI pacing during sinus bradycardia may be
poorly tolerated, and may cause the pacemaker syn-
drome. No crosstalk intervals are required, because
there is no atrial stimulation in the VDD mode.
Reminder: One can easily derive the function and
timing cycles of all dual chamber pacemakers start-
ing with a thorough knowledge of the timing cycles
of DDD pacemakers.
Caveat: There are two types of response to the sensed
P wave in the VDD mode according to design: (1)
A P wave falling in the implied AV delay is not
sensed, and the LRI remains constant. (2) In some
pacemakers a P wave in the implied AV interval
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can be sensed, and can actually reinitiate an entirely
new AV delay so that the VS–VP or VP–VP interval
becomes longer than the programmed (ventricular-
based) LRI. This produces a form of hysteresis with
the maximum extension of the LRI being equal to
the AS–VP interval.
Overdrive suppression and the
underlying rhythm
Continuous pacing may suppress the underlying
spontaneous rhythm, a phenomenon called overdrive
suppression. Thus the sudden interruption of pacing
may cause prolonged asystole because it takes time
for a dormant rhythm to “wake up.” The underlying
rhythm is determined by programming to the VVI
and gradually reducing the rate, sometimes as low as
30 ppm. Often a slow rhythm “warms up” and will
emerge. Most patients tolerate such a slow rate of
pacing. A patient who has a poor underlying rhythm
is often labeled as being “pacemaker-dependent.”
This is a vague term which has never been clearly
defined. One meaning refers to the occurrence of
severe or life-threatening symptoms with failure to
pace, as may occur with lead dysfunction, battery
failure, or electromagnetic interference. Pacemaker
dependency may be tested by totally and abruptly
inhibiting the pacemaker, but this may dangerous.
The emergence of a slow rhythm during gradual re-
duction of the pacemaker rate to 30 ppm does not
mean that the patient is not pacemaker-dependent.
The presence of pacemaker dependency should be
displayed prominently on the cover of the pace-
maker chart, together with the list of medications
the patient is taking.
Caveat: Always have two programmers on hand in
case one malfunctions during induced severe brady-
cardia or asystole.
Pacemaker hemodynamics
The early pacemakers had little in the way of elec-
tronics, and no hemodynamic refinement. VVI pa-
cing was basically non-physiologic and ignored the
atrium. Pacemaker syndrome was relatively com-
mon. The advent of DDD pacing was hailed as the
universal pacing mode. However, patients with sick
sinus syndrome and poor atrial chronotropic func-
tion complained of fatigue and inability to perform
exercise to a level they thought reasonable because
the heart rate did not increase on exercise. The sub-
sequent development of rate-adaptive pacemakers
(with artificial sensors in addition to the natural P-
wave sensor) permitted a pacemaker to respond by
increasing its rate like the normal heart on effort.
These pacemakers improved effort tolerance in pa-
tients with bradycardia at rest or with activity. Many
older patients have little ability to increase their car-
diac output by increasing left ventricular contractil-
ity and therefore stroke volume (volume of blood
ejected per heart beat), so that an increase in heart
rate is their only way to increase cardiac output on
effort. The cardiac output may increase by as much
as 300% on exercise by rate increase alone. Unfortu-
nately the settings on rate-adaptive pacemakers are
often left on factory settings unless the patient be-
comes symptomatic or the physician has a particular
interest in the technology.
AV synchrony
The atrial contribution provides about 15–30% of the
cardiac output (volume of blood in liters ejected by
the heart per minute) at rest in individuals with nor-
mal LV systolic function. Although the atrial contri-
bution plays little or no role in exercise, when heart
rate is basically the only determinant of cardiac out-
put, AV synchrony at rest is vital to prevent pace-
maker syndrome and atrial tachyarrhythmias. The
loss of AV synchrony can be especially detrimental
in patients with LV diastolic dysfunction, where the
systolic function can be normal but the ventricle is
stiff and non-compliant, as in hypertrophy from hy-
pertension. Furthermore, patients with heart failure
often do not tolerate loss of AV synchrony.
Reminder: Loss of or inappropriate AV synchrony is
the cause of pacemaker syndrome. The optimal AV
delay for the individual patient cannot be predicted,
but it can be evaluated echocardiographically.
Ventricular activation sequence
While the AV delay and rate responsiveness are
essential components of pacemakers, the role of
the ventricular activation sequence is presently be-
coming recognized. In patients with sick sinus syn-
drome and normal AV conduction, AAI or AAIR
pacing (associated with a small risk of AV block even
in highly selected patients) provides the best hemo-
dynamics because it preserves normal ventricular
activation. Long-term RV pacing, which by neces-
sity causes abnormal LV activation (similar to left
bundle branch block), may cause long-term dete-
rioration of LV function or precipitate congestive
heart failure in patients with poor LV function. This
disturbance seems to be based on the cumula-
tive duration of right ventricular pacing. For this
reason, the AV delay should be programmed to
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promote AV conduction if possible, so that the ad-
vantage of normal ventricular depolarization offsets
the depressant effect of pacing on the LV. Patients
with relatively normal AV conduction who require
minimal or backup pacing could be paced with a
slow lower rate such as 40–50 ppm to allow a spon-
taneous rhythm most of the time, with the hope of
preventing long-term deterioration of LV function.
Patients with a long PR interval (≥ 280 ms) require
ventricular pacing for optimal hemodynamic bene-
fit. The shorter (and optimized) AV delay produces
an immediate hemodynamic benefit but the nega-
tive impact of abnormal pacing-induced LV depo-
larization may become a long-term problem. Thus,
DDD or DDDR pacing should be weighed against
the long-term detrimental risks involved with con-
tinual RV pacing. For this reason, biventricular pac-
ing may be a better option.
Biventricular pacemakers (see Cardiac resynchro-
nization, below) are used to treat congestive heart
failure in patients with poor LV function and left
bundle branch block. The latter produces an in-
efficient left ventricular contramarked first-degree
AV blockcation because of abnormal ventricular de-
polarization and contraction. Biventricular pacing
produces “resynchronization” by promoting a more
physiologic pattern of depolarization and a more
efficient LV contraction.
Caveat: Programming a long AV delay to promote
normal AV conduction may increase the risk of end-
less loop tachycardia and repetitive non-reentrant
VA synchrony by promoting retrograde VA conduc-
tion.
Rate-adaptive pacemakers
A sensor monitors the need for a faster pacing rate
according to activity and works independently of
intrinsic atrial activity. A VVI pacemaker with rate-
adaptive function is coded as a VVIR pacemaker. A
DDDR pacemaker is thus a DDD device with rate-
adaptive function or rate modulation. However, the
VDDR mode is a misnomer because such a mode
operates in the VDD mode except when it is sensor-
driven, when the pacing mode becomes VVIR. Ta-
ble 5 shows the characteristics of pacemakers with
and without the “R” designation for rate-adaptive
function.
Five basic parameters can be programmed in
sensor-driven pacemakers: sensor threshold, lower
rate, upper sensor rate, upper tracking (or atrial-
driven) rate, and sensor slope. Unfortunately many
pacemakers are left at their nominal settings (out
of the box), which may not be optimal for some
patients.
Table 5. Characteristics of commonly used pacing modes.
Characteristics VVI VVIR AAI AAIR DDD DDI DDDR DDIR
Simplicity +++ +++ ++ ++ + + — —
AV synchrony — — + + + + a + + a
Potential for pacemaker
syndrome
+ + — — — — — —
Normal LV activation — — + + —b —b —b —b
Propensity to ELT — — — — + + c + + c
Tracking of SVT — — — — + — + —
Contraindicated in AV block — — + + — — — —
Increase of pacing rate in atrial
chronotropic incompetence
— + — + —d — + +
Cost — + — + ++ ++ +++ +++
a In the DDI mode if normal sinus rhythm is faster than the programmed rate, and in the DDIR mode if
normal sinus rhythm is faster than the sensor-driven rate, AV dissociation with hemodynamic
disadvantage is frequent in patients with AV block.
bUnless AV delay is prolonged to allow for normal anterograde conduction.
cEndless loop without tachycardia at the lower rate or at the sensor-driven rate.
dVentricular pacing rate does not increase if the sinus rate does not increase on exercise.
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The sensor threshold is the minimum degree of
sensor activation to initiate an increase in heart rate.
In other words, it sets the lowest level of sensor acti-
vation that will be counted and used for rate control.
Threshold settings may be numeric or descriptive.
Sedentary patients may require a more sensitive set-
ting. The sensor slope determines the rate of change
of the heart rate in response to sensor activation.
Increasing the slope will result in an increased pac-
ing rate for the same amount of activity. The nor-
mal sinus node produces a linear increase in the
heart rate during exercise. However, the slope can
be variable, and it depends on the degree of condi-
tioning. Some manufacturers have designed pace-
makers with an auto-responsive slope and thresh-
old. The pacemaker learns the appropriate settings
based on the patient’s activity. These automatic sys-
tems are not perfect, but are better than empiric or
no programming of the rate-adaptive response.
The pause in the Wenckebach upper rate response
can be attenuated or even eliminated by appropriate
programming of a DDDR pacemaker. This process
is called sensor-driven rate smoothing.
The sensor in DDDR pacemakers can also influ-
ence intervals other than the LRI. These include:
1. The AV delay, which shortens on exercise to
mimic physiologic shortening of the PR interval.
2. The PVARP. Shortening of the PVARP on exercise,
coupled with adaptive shortening of the AV inter-
val, produces substantial shortening of the total
atrial refractory period. This allows program-
ming of a faster upper rate. An adaptive PVARP
allows programming of a relatively long PVARP
at rest when endless loop tachycardia is likely
to occur. Initiation of endless loop tachycardia is
quite unusual on exercise with fast atrial-driven
ventricular pacing, so that a shorter PVARP is
safe.
Programming the pacemaker
An easy way to program the sensor-driven response
is to have the patient walk up and down the hallway
and adjust the parameters accordingly. Avoid over-
programming the threshold response, which will
produce an excessively fast pacing rate poorly toler-
ated by patients.
Caveat: After the implantation of a pacemaker, fluid
in the pacemaker pocket may dampen vibrations
and the response of activity rate-adaptive pace-
makers. If these devices are programmed too early,
there may be an excessive rate response several
weeks later, after the absorption of fluid. It would
appear wise to leave the rate-adaptive function of
activity-driven devices turned off for a time after
implantation, to prevent constantly changing pac-
ing rates when the patient turns in bed, etc. Such
fluctuations may cause confusion for the personnel
monitoring the patient.
The pacemaker stimulus
Contemporary digital ECG recorders distort the
pacemaker stimulus, so it may become larger and
show striking changes in amplitude and polarity.
Digital recorders can also miss some of the pace-
maker stimuli because of sampling characteristics.
Diagnostic evaluation of the pacemaker stimulus is
only possible with analog machines. Many inkjet
recorders and ECG machines with a stylet writer are
analog recorders. With such recorders, the direction
and amplitude of the pacemaker stimulus may yield
valuable information about lead displacement or de-
fects. A bipolar lead with an insulation defect may
pace normally but exhibit a very large stimulus arti-
fact on the electrocardiogram (unipolar–bipolar phe-
nomenon), in contrast to the tiny deflections with an
intact bipolar lead.
Caveats
1. Static interference may generate deflections mi-
micking pacemaker stimuli. Careful scrutiny of
the deflections often suggests they are not pace-
maker stimuli. When in doubt, measure the tim-
ing cycles to and from the deflection in question
and establish the lack of relationship to pace-
maker function.
2. The interval from the stimulus to the onset of car-
diac depolarization is called latency. The normal
value for the RV is 40 ms or less. If there is a rel-
atively long isoelectric (zero) interval from stim-
ulus to QRS or P wave, the commonest cause is
isoelectric depolarization in the ECG lead in ques-
tion. Confirmation requires the recording of se-
veral ECG leads simultaneously to demonstrate
the true onset of cardiac depolarization. Hyper-
kalemia is a common cause of increased latency.
Other causes of latency include serious metabolic
disorders, right ventricular infarction, and termi-
nal situations.
Magnet mode
The magnet mode refers to the response of a pace-
maker when a magnet is applied over it. The magnet
closes the special reed-switch within the pulse gen-
erator, which eliminates sensing. The device then
paces at the asynchronous mode at a rate specific to
the manufacturer. The magnet rate is designed to re-
flect the degree of battery depletion. The behavior
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and rate of the magnet mode varies according
to manufacturer. The magnet mode can be pro-
grammed “off’ in some pacemakers.
Normal QRS patterns during right
ventricular pacing
Pacing from the right ventricle (RV), regardless of
site, virtually always produces a left bundle branch
block (LBBB) pattern in the precordial leads (de-
fined as the absence of a positive complex in lead
V1 recorded in the fourth or fifth intercostal space).
Pacing from the RV apex produces negative paced
QRS complexes in the inferior leads (II, III, and aVF),
because depolarization begins in the inferior part of
the heart and travels superiorly away from the infe-
rior leads. The mean paced QRS frontal-plane axis is
always superior, usually in the left or less commonly
in the right superior quadrant.
Pacing from the right ventricular
outflow tract
Primary lead placement in the right ventricular out-
flow tract (RVOT) or septum, or lead displacement
from the RV apex towards the RVOT initially shifts
the frontal-plane paced QRS axis to the left inferior
quadrant, a site considered normal for spontaneous
QRS complexes. The inferior leads become positive.
Then the axis shifts to the right inferior quadrant as
the stimulation site moves more superiorly towards
the pulmonary valve. With the backdrop of dom-
inant R waves in the inferior leads, RVOT pacing
may generate qR, QR, or Qr complexes in leads I
and aVL. Occasionally, with slight displacement of
the pacing lead from the RV apex to the RV outflow
tract, leads I and aVL may register a qR complex in
conjunction with the typical negative complexes of
RV apical stimulation in the inferior leads. This qR
pattern in leads I and aVL must not be interpreted
as a sign of myocardial infarction.
qR and Qr complexes in inferior and
precordial leads
RV pacing from any site never produces qR com-
plexes in V5 and V6 in the absence of myocardial
infarction or ventricular fusion with a spontaneous
conducted QRS complex. A qR or Qr (but not a
QS deflection) complex in the precordial or inferior
leads is always abnormal during RV pacing from any
site in the absence of ventricular fusion. In contrast,
a q wave is common in the lateral leads (I, aVL, V5,
and V6) during uncomplicated biventricular pacing
(using the RV apex), and should not be interpreted
as representing myocardial infarction or RVOT dis-
placement of an RV apical lead. Uncomplicated RV
apical pacing may (rarely) display a qR complex in
lead I (but not aVL).
Dominant R wave of the paced QRS
complex in lead V1 during conventional
RV apical pacing
A dominant R wave in V1 during RV pacing has been
called a “right bundle branch block” (RBBB) pattern
of depolarization, but this terminology is potentially
misleading because this pattern may not be related
to RV activation delay. In our experience a domi-
nant R wave of a paced ventricular beat in the right
precordial leads (V1 and V2 recorded in the fourth
intercostal spaces) occurs in approximately 8–10% of
patients with uncomplicated RV apical pacing. The
position of precordial leads V1 and V2 should be
checked, because a dominant R wave can be some-
times recorded at the level of the third or second
intercostal space during uncomplicated RV apical
pacing. The pacing lead is almost certainly in the RV
(apex or distal septal site) if leads V1 and V2 show
a negative QRS complex when recorded one space
lower (fifth intercostal space). However, a dominant
R wave may not be always eliminated at the level
of the fifth interspace if RV pacing originates from
the midseptal region. Furthermore, in the normal
situation with the ventricular lead in the RV, the
“RBBB” pattern from pacing RV sites results in a
vector change from positive to negative by lead V3
in the precordial sequence. Therefore a tall R wave
in V3 and V4 signifies that a pacemaker lead is most
probably not in the RV, after excluding ventricular
fusion from spontaneous AV conduction. However,
left ventricular (LV) pacing generating a positive
complex in lead V1 may not necessarily be accom-
panied by a positive complex in leads V2 and V3.
The ECG pattern with a truly posterior RV lead has
not been systematically investigated as a potential
cause of a tall R wave in V1 during RV pacing.
We have never seen a so-called “RBBB” pattern
in lead V1 during uncomplicated RV outflow tract
pacing, and it has never been reported so far. Right
axis deviation of the ventricular paced beats in the
frontal plane with a deep S wave in leads I and aVL
does not constitute an RBBB pattern without looking
at lead V1.
Significance of a small r wave in lead V1
during uncomplicated RV pacing
A small early r wave (sometimes wide) may oc-
casionally occur in lead V1 during uncomplicated
RV apical or outflow pacing. There is no evidence
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that this r wave represents a conduction abnormal-
ity at the RV exit site. Furthermore, an initial r wave
during biventricular pacing does not predict initial
LV activation.
Paced QRS duration during conventional
right ventricular pacing
A long paced QRS duration is a significant indepen-
dent predictor of heart-failure hospitalization in pa-
tients with sinus node dysfunction and AV block.
On this basis, serial determinations of the paced
QRS duration may be clinically useful to evaluate
LV function and the risk of developing heart failure.
Left ventricular endocardial pacing
Passage of a pacing lead into the LV rather than the
RV occurs usually via an atrial septal defect (patent
foramen ovale), or less commonly via the subcla-
vian artery. The diagnosis of a malpositioned en-
docardial LV lead will be missed in a single-lead
ECG. The problem may be compounded if the ra-
diographic malposition of the lead is not obvious, or
if insufficient projections are taken. A 12-lead paced
ECG will show an RBBB pattern of paced ventric-
ular depolarization with QRS positivity commonly
preserved in the right precordial leads, or at least in
V1. The positive QRS complexes are unaltered when
leads V1 and V2 are recorded one intercostal space
lower. During LV pacing the frontal-plane axis of
paced beats can indicate the site of LV pacing, but as
a rule with an RBBB configuration the frontal-plane
axis cannot differentiate precisely an endocardial LV
site from one in the coronary venous system. The di-
agnosis of an endocardial LV lead is easy with trans-
esophageal echocardiography (TEE). In the usual
situation, it will show the lead crossing the atrial
septum then passing through the mitral valve into
the LV.
An endocardial LV lead is a potential source of
cerebral emboli. Most patients with neurologic man-
ifestations do not exhibit echocardiographic evi-
dence of thrombus on the pacing lead. In symp-
tomatic patients, removal of the lead after a period
of anticoagulation should be considered. A chronic
LV lead in asymptomatic or frail elderly patients is
sometimes best treated with long-term anticoagu-
lant therapy.
A Medline search from the years 2000–2010
revealed a substantial number of reports document-
ing inadvertent endocardial LV lead placement
(pacing and ICD leads). The true incidence of this
problem is unknown, but the Medline data suggest
that there are probably many unreported cases. It
is disturbing that this serious but avoidable compli-
cation (avoided simply by looking at a 12-lead ECG
at the time of implantation) is still being recognized
at late follow-up, by which time lead extraction can
be problematic.
Manifestations of myocardial
infarction in the paced rhythm
Anterior myocardial infarction
Stimulus-qR pattern
Because the QRS complex during RV pacing resem-
bles (except for the initial forces) that of spontaneous
left bundle branch block (LBBB), many of the crite-
ria for the diagnosis of myocardial infarction (MI)
in LBBB also apply to MI during RV pacing. During
RV pacing, as in LBBB, an extensive anteroseptal MI
close to the stimulating electrode will alter the initial
QRS vector, with forces pointing to the right because
of unopposed RV activation. This causes (initial) q
waves in leads I, aVL, V5, and V6, producing an St-
qR pattern. The abnormal q wave is usually 30 ms
or more, but a narrower one is also diagnostic. The
sensitivity of the St-qR pattern varies from 10% to
50% according to the way data are analyzed. The
specificity is virtually 100% (Table 6).
Late notching of the ascending S wave
(Cabrera’s sign)
As in LBBB, during RV pacing an extensive anterior
MI may produce notching of the ascending limb
of the S wave in the precordial leads, usually V3
and V4 (Cabrera’s sign) ≥ 30 ms and present in two
leads. Slight slurring (with a rapid upward deflec-
tion: dV/dt or slope) of the ascending limb of the S
wave does not constitute a Cabrera’s sign. Cabrera’s
sign may occur together with the St-qR pattern in
anterior MI. The sensitivity varies from 25% to 50%
according to the size of the MI, but the specificity is
close to 100% if notching is properly defined.
Inferior myocardial infarction
The paced QRS complex is often unrevealing. Dur-
ing RV pacing in inferior MI, diagnostic Qr, QR, or
qR complexes provide a sensitivity of 15% and speci-
ficity of 100%. Cabrera’s sign in both leads III and
aVF is very specific but even less sensitive than its
counterpart in anterior MI.
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379Table 6. Difficulties in the diagnosis of myocardial infarction during ventricular
pacing.
1. Large unipolar stimuli may obscure initial forces, cause a pseudo Q wave and false ST segment current
of injury
2. Fusion beats may cause a pseudoinfarction pattern (qR/Qr complex or notching of the upstroke of the
S wave)
3. QRS abnormalities have low sensitivity (many false negatives) but high specificity (few false positives).
These include qR or Qr patterns and Cabrera’s sign in the appropriate leads
4. Retrograde P waves may simulate Cabrera’s sign
5. Diagnosis of acute MI
 Signs in QRS complex are not useful for the diagnosis of acute MI
 Looking at the underlying rhythm: cardiac memory. Repolarization ST–T wave abnormalities
(mostly T-wave inversion) in the spontaneous rhythm may be secondary to RV pacing per se, and
not related to ischemia or non-Q-wave MI
 Differentiation of MI versus ischemia may be impossible
 Differentiation of acute MI versus old or indeterminate-age MI may be impossible if old MI is
associated with prominent chronic T-wave changes, usually indicative of an acute process
 ST segment abnormalities may help the diagnosis of acute myocardial infarction during ventricular
pacing. ST elevation ≥ 5 mm in predominantly negative paced QRS complexes is the best marker. ST
depression ≥ 1 mm in V1, V2, and V3 and ST elevation ≥ 1 mm in leads with a concordant (same
direction) QRS deflection. So-called primary T-wave abnormalities where the T wave is in the same
direction as the QRS complex are not diagnostically useful during RV pacing
Diagnosis of acute myocardial infarction
during right ventricular pacing
The diagnosis of myocardial ischemia or infarc-
tion should be based on the new development of
ST elevation, because leads V1–V3 sometimes show
marked ST elevation during ventricular pacing in
the absence of myocardial ischemia or infarction.
One study reported the value of ST segment abnor-
malities in the diagnosis of acute MI during ventric-
ular pacing and their high specificity. ST elevation
≥ 5 mm in predominantly negative QRS complexes
is the best marker, with a sensitivity of 53% and
specificity of 88%, and this was the only criterion
of statistical significance in their study. Other less
important ST changes with high specificity include
ST depression ≥ 1 mm in V1, V2, and V3 (sensitiv-
ity 29%, specificity 82%), and ST elevation ≥ 1 mm
in leads with a concordant QRS polarity. ST depres-
sion concordant with the QRS complex may occur
in leads V3–V6 during uncomplicated RV pacing.
Diagnosis of myocardial ischemia during
right ventricular pacing
Marked discordant ST elevation (> 5 mm) during RV
pacing, a marker for the diagnosis of acute MI, could
also be used for the diagnosis of severe reversible
transmural myocardial ischemia. ST depression in
leads V1 and V2 is rarely normal; it should be consi-
dered abnormal and indicative of anterior or inferior
MI or ischemia. So-called primary T-wave abnor-
malities (discordant) are not diagnostically useful
during RV pacing if they are not accompanied by
primary ST abnormalities.
Cardiac memory
Cardiac memory refers to T-wave abnormalities
manifested on resumption of a normal ventricular
activation pattern after a period of abnormal
ventricular activation, such as ventricular-pacing
transient LBBB, ventricular arrhythmias, or
Wolf–Parkinson–White syndrome. Pacing-induced
T-wave inversion is usually localized to precordial
and inferior leads. The direction of the T wave
of the memory effect in sinus rhythm is typically
in the same direction as the QRS vector of the
abnormal impulse. The marked repolarization ab-
normalities reach a steady state in a week with RV
endocardial pacing at physiologic rates. Memory-
related repolarization abnormalities persist when
normal depolarization is restored, and they resolve
completely in a month. The changes and their
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duration are associated with complex biochemical
abnormalities, and they are proportional to the
amount of delivered ventricular pacing.
One report indicated that cardiac memory in-
duced by RV pacing results in a distinctive T-vector
pattern that allows discrimination from ischemic
precordial T-wave inversions regardless of the coro-
nary artery involved. T-wave axis, polarity, and am-
plitude on a 12-lead ECG during sinus rhythm were
compared between cardiac-memory and ischemic
patients. The combination of (1) positive T wave in
aVL, (2) positive or isoelectric T wave in lead I, and
(3) maximal precordial T wave inversion > T wave
inversion in lead III was 92% sensitive and 100%
specific for cardiac memory, discriminating it from
ischemic precordial T-wave inversion regardless of
the coronary artery involved.
Pacemaker alternans
Pacemaker QRS alternans is characterized by alter-
nate changes in paced QRS morphology. The causes
include respiratory fluctuation, pericardial effusion,
mechanical pulsus alternans leading to electrical al-
ternans from varying depolarization, and true al-
ternating intraventricular alternans from the pacing
site. Alternans can only be diagnosed after ventric-
ular bigeminy or alternate fusion beats are ruled out
by changing the pacing rate. True alternans repre-
sents a form of exit block (persisting over a range of
rates) seen only in severe myocardial disease under
circumstances that also cause latency and second-
degree Wenckebach exit block from the pacing site.
Complications of pacemakers
Two major groups of complications are associ-
ated with pacemaker implantation: (a) non-electrical
complications, including acute complications at the
time of implantation such as pneumothorax and
complications of lead placement and pocket forma-
tion, and (b) electrical complications and arrhyth-
mias.
Non-electrical complications
Table 7 lists the principal non-electrical/arrhythmic
complications.
Complications due to venous access
The risks of a complication related to subclavian
vein puncture technique depend on operator skill
and the difficulty of the subclavian puncture due
to the patient’s anatomy. The use of the cephalic
cut-down technique almost eliminates these com-
plications. The use of the axillary vein is safer than
subclavian puncture. The incidence of pneumotho-
rax is virtually zero with the cephalic or axillary vein
approach.
Pneumothorax from subclavian puncture is uncom-
mon but may occasionally occur in patients with
emphysema or anatomic abnormalities. Pneu-
mothorax may be asymptomatic and noted on
routine follow-up chest x-ray, or it may be asso-
ciated with pleuritic pain, respiratory distress, or
hypotension. A pneumothorax that involves less
than 10% of the pleural space is mostly benign
and resolves without intervention. A pneumo-
thorax > 10% or a tension pneumothorax requires
the immediate placement of a chest tube.
Hemoptysis may occur if the lung is punctured,
and it may be associated with a pneumothorax.
Hemoptysis is usually self-limiting.
Hemothorax is a rare complication of subclavian
puncture. It can be caused by laceration of the
subclavian artery or by inadvertently introduc-
ing a large dilator or sheath into the artery. It is
not caused by trauma to the lungs. In the absence
of pneumothorax, bleeding is usually controlled
by lung pressure. However, if the ipsilateral lung
is also collapsed, blood may escape freely into
the pleural space (hemopneumothorax), and this
may result in substantial hemorrhage-associated
hypotension and hemodynamic compromise ne-
cessitating draining.
Air embolism is a rare complication of subclavian
vein puncture and mostly occurs when the lead is
advanced through the introducer sheath, because
of the development of physiologic negative pres-
sure. This complication can be avoided by using
the deep Trendelenburg position during advance-
ment of the introducer sheath or leads, by pinch-
ing the sheath when the trocar is withdrawn, or by
using sheaths with a hemostatic valve. The diag-
nosis of air embolism is obvious on fluoroscopy.
Patients are mostly tolerant of this complication.
However, respiratory distress, hypotension, and
arterial oxygen desaturation may occur with a
large embolus. Therapy consists of 100% O2 with
inotropic support. Usually no therapy is required,
as the air is eventually absorbed into the lungs.
Venous thrombosis or occlusion of the subclavian
and innominate veins is common but frequently
asymptomatic. Acute symptomatic thrombosis is
relatively uncommon and may cause unilateral
arm swelling, usually several weeks after implan-
tation. Superior vena cava syndrome (from occlu-
sion) is more serious but rare, and causes facial
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Venous access Pneumothorax, subcutaneous emphysema
Hemothorax
Air embolism
Brachial plexus injury
Thoracic duct injury
Trauma to the subclavian artery with occasional AV fistula (subclavian or innominate
vein)
Aortic perforation by atrial lead
Injury to internal mammary artery
Hematoma
Pacemaker
pocket
Infection, septicemia, etc. Conservative therapy is often unsuccessful and removal of
the entire system may be required
Hematoma/seroma
Erosion
Pacemaker migration
Twiddler’s syndrome
Muscle stimulation from a flipped but normally functioning unipolar or extravascular
insulation defect
Chronic pain, including subcuticular malposition of the pulse generator
Intravascular Subclavian or innominate vein thrombosis
Thrombosis of superior vena cava
Coronary sinus dissection or perforation during implantation of a left ventricular lead
Large right atrial thrombus
Endocarditis with vegetations
Manifest pulmonary embolism (rare)
Cardiac perforation
Cardiac tamponade
Entanglement of lead in the tricuspid valve and ruptured chordae
Tricuspid insufficiency
Pericardial rub
Post-pericardiotomy syndrome
Severe mitral insufficiency and heart failure from abnormal depolarization of the
papillary muscles
Late reduction of left ventricular function from dyssynchrony with the development of
heart failure
Lead problems Displacement
Malposition in the coronary venous system
Endocardial left ventricular malposition across a patent foramen ovale or via
subclavian arterial puncture (or via atrial or ventricular septum defect). Lead may then
cause mitral valve perforation
Right ventricular perforation or lead perforation of the interventricular septum
Right atrial perforation with risk of lung penetration and right-sided pneumothorax
and/or pneumopericardium
Diaphragmatic pacing: left side with or without right ventricular perforation and right
side by phrenic nerve stimulation by atrial pacing
Intercostal muscle stimulation due to perforation
Post-pericardiotomy syndrome (pericarditis, etc.) with or without lead perforation
Intracardiac rupture of lead during attempt to remove old or broken lead
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edema and cyanosis as well as collateral veins on
the thorax. Symptomatic thrombosis manifested
by arm swelling can be treated conservatively
with arm elevation, with heparin followed by oral
anticoagulation, or more aggressively with throm-
bolytic drugs. Superior vena cava syndrome re-
quires vascular consultation for possible surgi-
cal correction. The subclavian vein is occluded in
about 30% of chronic cases.
Pulmonary embolism occurs rarely, but the inci-
dence may be underestimated as it is usually un-
recognized. The presence of a symptomatic pul-
monary embolism (potentially life-threatening) in
a patient with a device should raise the suspicion
of a source from a pacing or ICD lead.
Brachial plexus injury may occur from the needle
stick in the brachial plexus located close to the sub-
clavian/axillary vein. This complication should
be suspected postoperatively if the patient com-
plains of pain or paresthesias of the upper extrem-
ity. There is usually complete recovery, but neural
injury may result in permanent muscle atrophy
and impairment of shoulder motion.
Lead-related complications
Lead malposition may occur during transvenous
lead placement. In patients with atrial septal de-
fect or a large patent foramen ovale, the ventric-
ular lead may be advanced inadvertently into the
left ventricle. This complication occurs because
fluoroscopy is often limited to the AP projection
during the procedure and LV placement may re-
semble RV placement. An LV lead should be sus-
pected when the tip of the lead is posterior on
fluoroscopy and ventricular pacing gives rise to
an RBBB pattern in the ECG.
Lead dislodgment usually occurs in the first days
after implantation, and may occur up to
three months after initial implantation. RV lead
dislodgment occurs in about 1% of cases, but atrial
lead dislodgment is more common. Lead displace-
ment may be due to improper initial lead position-
ing, poor lead fixation, or excessive arm–shoulder
motions soon after surgery. Dislodgment of the
lead may cause loss of capture and undersensing.
The diagnosis is confirmed by device interroga-
tion showing changes in the sensing and pacing
thresholds compared to implantation data, and a
chest x-ray in the case of macro-displacement. Im-
mediate lead repositioning is mandatory.
Lead damage may occur during implantation. An
insulation break may occur due to inadvertent
placement of a suture around the lead without a
protective sleeve, a too-tight suture on the sleeve,
or an accidental cut during surgery.
Pocket-related complications
A pocket seroma is due to fluid accumulation and
is usually benign when not accompanied by signs
of inflammation. It is observed more commonly
after pulse generator change when the new pulse
generator is smaller than the previous one. Aspi-
ration should be discouraged because of the risk
of introducing infection by contamination.
Pocket hematoma is relatively common. A
hematoma is usually managed conservatively un-
less it expands in size and becomes tense and
painful, whereupon evacuation becomes neces-
sary, with reoperation to identify and control
the site of bleeding. Pocket aspiration should be
avoided. The risk of postoperative bleeding is
higher with heparin than with warfarin.
Erosion is characterized by deterioration of tissue
over an implanted pulse generator or movement
of a lead toward or through the skin. Risk fac-
tors include a too-small pocket with tension on
the overlying tissue, and a too-superficial or lat-
eral implantation of the pulse generator in thin
adults or children. When erosion is recognized at
an early stage, signaled by redness and thinning of
the skin, elective re-operation can be considered to
relocate the pulse generator to a submuscular site.
If any portion of the pulse generator or lead com-
pletely erodes through the skin, the site should be
considered infected.
Infection occurs in about 1–2% of primary implan-
tations, but is more common after device replace-
ment. The mortality is very high if the leads
and the pulse generator are not removed. The
manifestations range from local reactions (red-
ness, tenderness, swelling, abscess around the
device) to uncommon life-threatening systemic
sepsis with positive blood cultures. Early infec-
tions are usually caused by Staphylococcus aureus.
Late infections are commonly caused by Staphy-
lococcus epidermidis, are more indolent, and may
present months or years after implantation, some-
times with only pain at the pacemaker site. Ve-
getations may occur in the right atrium, right ven-
tricle, and tricuspid valve. Vegetations are best
visualized by transesophageal echocardiography.
The presence of infection mandates complete lead
and device removal followed by antibiotics. Par-
tial removal is associated with a high recurrence
rate.
Perforation
Cardiac perforation is a rare but potentially seri-
ous and often unrecognized complication of pace-
maker lead implantation. It may occur at the time of
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implantation and cause hypotension from cardiac
tamponade. Perforation usually does not lead to
tamponade if the lead is withdrawn and reposi-
tioned, because the perforation is often self-sealing.
The reported incidence of symptomatic perfora-
tion after implantation is about 1%. The true inci-
dence of perforation is not well known because it
may be subclinical and asymptomatic. Indeed, CT
scans in patients with uncomplicated pacing show
a 5% incidence of right ventricular perforation and
10% in the case of atrial leads. Risk factors include
female sex, increasing age, and the use of stiff stylets.
Administration of oral steroid within 7 days preced-
ing lead implantation predisposes to perforation.
After implantation, right ventricular perforation
of the free wall may be recognized by pericardial
pain, abdominal pain, dyspnea, syncope, friction
rub, sinus tachycardia, increasing ventricular pacing
threshold, poor sensing, diaphragmatic stimulation,
intercostal muscle stimulation, pericardial effusion,
and left hemothorax. Rarely, perforation occurs into
the left ventricle through the ventricular septum.
The ECG may show a right bundle branch pattern
if the lead paces the left ventricle usually from the
pericardial space. The chest x-ray may show the lead
beyond the cardiac shadow. An echocardiogram and
CT scan should be performed to document lead posi-
tion. Transesophageal echocardiography is superior
to transthoracic echocardiography in delineating the
entire course of a pacing lead. The CT scan is partic-
ularly helpful when echocardiography is equivocal.
Multidetector computed tomography is emerging as
the imaging modality of choice in diagnosing atrial
and ventricular lead perforation. The development
of small-diameter active fixation pacing and im-
plantable cardioverter-defibrillator (ICD) leads may
be associated with increased risk for delayed right
ventricular perforation. Subacute right ventricular
perforation (several days or weeks after seemingly
uncomplicated implantation and occasionally much
later) is a rare but serious complication of lead im-
plantation. The clinical presentation has changed,
so that perforation currently occurs usually up to
60 days after implantation and rarely a few months
later. The late presentation may create an important
diagnostic problem, and the situation may become
catastrophic if unrecognized.
These complications may lead to death if they
are not recognized early. In most patients, the leads
can safely be removed in the operating room under
fluoroscopic guidance and continuous electrogram
(EGM) monitoring to confirm the diagnosis, with
surgical backup support and together with TEE.
Simple withdrawal of the lead is successful in 80%
of cases. A stable asymptomatic perforation can
be left alone if pacing and sensing are satisfactory.
If parameters are unsatisfactory, a stable asymp-
tomatic perforated lead can be left in place and a
new lead implanted.
The unipolar EGM may show an upright com-
plex that looks like a standard precordial lead over
the lateral chest. When the lead is gradually with-
drawn, some ventricular ectopy may occur as the
lead passes through the ventricular wall. Then, obvi-
ous ST elevation (current of injury) occurs. This dis-
appears when endocardial contact is lost. The intra-
cavitary EGM often shows a deep S wave followed
by gradual reduction of its amplitude, and P waves
eventually appear as the lead is further withdrawn.
Recording of an adequate unipolar ventricular
electrogram from the proximal RV electrode but an
atypical one from the distal electrode should raise
the suspicion of lead perforation, as does the pres-
ence of ST elevation from the proximal electrode and
its absence from the distal electrode.
Right atrial leads may perforate both pericardium
and pleura, resulting in right-sided pneumothorax,
pneumopericardium, and rarely aortic laceration.
Recurrent postcardiac injury syndrome in the ab-
sence of perforation should be considered in patients
who, after pacemaker lead insertion, develop peri-
cardial and pleural effusion associated with markers
of inflammation.
Electrical complications
Accessory muscle stimulation
Accessory muscle stimulation may occur at several
sites:
1. Contraction of the diaphragm. Left diaphrag-
matic stimulation by pacemaker stimuli may oc-
cur during traditional pacing with and without
lead perforation of the RV. Perforation must al-
ways be excluded when diaphragmatic pacing
is observed. Late appearance of diaphragmatic
pacing suggests an insulation defect of the pa-
cing lead. Left ventricular pacing from a coronary
vein (in the absence of perforation) is an impor-
tant and troublesome cause of left diaphragmatic
pacing during biventricular pacing for the treat-
ment of heart failure. Contraction of the right di-
aphragm is related to a malpositioned right atrial
electrode.
2. Left intercostal muscle stimulation is invariably
due to ventricular lead perforation.
3. Deltopectoral muscle stimulation (twitching)
may be due to: (a) an extravascular lead insu-
lation leak – in the case of a bipolar pacemaker,
this always indicates an insulation problem; (b)
a unipolar pacemaker that has flipped over in a
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large pocket so that the anode faces the skeletal
muscle; (c) a normally functioning unipolar pace-
maker without any other problems – this is now
rare with better pacemaker design but can occur
at high voltage outputs.
Decreasing the output voltage with preservation
of an adequate safety margin often minimizes or
eliminates accessory muscle stimulation. Decreasing
the pulse duration alone is usually ineffective.
Generator-related complications
Normal functioning of a pacing system depends on
proper connection between the leads and the gener-
ator. Care should be exercised to avoid misconnec-
tion of the leads. A loose setscrew usually causes
oversensing due to the generation of spurious sig-
nals, intermittent failure to pace, or increased pacing
threshold and lead impedance.
Abnormalities involving pacemaker
stimuli
Tables 8 and 9 list the causes of loss of capture by
visible stimuli and the causes of absent stimuli.
Undersersensing
Table 10 lists the causes of undersensing.
Reminder: Occasionally undersensing with a small
bipolar signal can be corrected by programming to
unipolar sensing. Do not expect an appropriately
programmed pacemaker to sense all kinds of VPCs,
because they are associated with a variety of electro-
grams, some of which may not be sensed because of
a low amplitude and/or slow slew rate. Attempting
to increase sensitivity to sense all VPCs may cause
oversensing.
Oversensing
Oversensing is not uncommon. Table 11 outlines the
important causes of oversensing.
Afterpotential
The cathodal pacemaker stimulus charges the
electrode–tissue interface to a large voltage (polar-
ization voltage) which is subsequently dissipated
over a relatively long time to electrical neutrality.
The decay of the afterpotential (of lower amplitude,
opposite polarity but longer duration than the out-
put stimulus) creates a voltage that changes with
time, and thus it can be sensed (like a changing spon-
taneous intracardiac signal) by a pacemaker com-
ing out of its refractory period, when it will reset
the lower rate interval. Sensing of the afterpoten-
tial should be suspected when the interval between
two consecutive pacemaker stimuli lengthens to a
Table 8. Loss of capture by visible pacemaker stimuli.
1. Normal situation: stimuli in myocardial refractory period
2. Electrode–tissue interface
 Early displacement or unstable position of pacing leads (commonest cause). Microdislodgment (a
diagnosis of exclusion) causes a marked rise in capture threshold but displacement is not apparent
on a chest x-ray
 Elevated pacing threshold without obvious lead displacement (exit block): acute or chronic reaction
at the electrode–tissue interface
 Subcutaneous emphysema (see Table 7)
 Twiddler’s syndrome causing late displacement
 Myocardial infarction or ischemia, hypoxia
 Hypothyroidism
 Elevation of pacing threshold after defibrillation or cardioversion. This is usually transient, for a few
minutes or less
 Electrolyte abnormalities, usually hyperkalemia, severe acidosis
 Drug effect: flecainide and propafenone can elevate the pacing threshold with therapeutic doses
3. Electrode: fracture, short circuit, or insulation break
4. Pulse generator
 Normal pacemaker with incorrect programming of parameters
 Pacemaker failure from exhaustion or component failure
 Iatrogenic causes: component failure after defibrillation, electrocautery, or therapeutic radiation
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1. Normal situation: total inhibition of pacemaker when the intrinsic rate is faster than the preset
pacemaker rate
2. Hysteresis with normal pacemaker function: escape interval after ventricular sensing is longer than
the automatic interval during pacing
3. Pseudomalfunction: overlooking tiny bipolar stimuli in the ECG
4. Normal pulse generator with poor anodal contact:
 Subcutaneous emphysema with air preventing contact of the anode of a unipolar pacemaker with
the tissues. This occurs soon after subclavian vein puncture
 Air entrapment in the pacemaker pocket preventing contact of the anode (on the can) of a unipolar
pacemaker with the tissues. This may occur after battery replacement when a new and smaller
pacemaker is inserted in a large pacemaker pocket
5. Lead problem: fracture, loose connection, or set-screw problem on the pacemaker itself
6. Abnormal pulse generator:
 Total battery depletion
 Component failure
 Sticky reed-switch (magnet application produces no effect)
7. Extreme electromagnetic interference.
8. Oversensing of signals originating from outside or inside the pulse generator
9. Filter settings of ECG recorder masking pacing stimuli
10. Saturation of ECG amplifier
Table 10. Causes of undersensing.
Normal situations Ventricular premature complexes with a small electrogram different from those
of sensed conducted beats
Beats falling inside blanking or refractory periods
Oversensing can cause undersensing because an oversensed signal generates a
refractory period into which a succeeding physiologic signal cannot be sensed
Note: Ventricular pseudofusion beats should not be mistaken for undersensing
Abnormal situations Poor lead position with low-amplitude electrogram
Lead dislodgment: low amplitude electrogram
Lead malfunction: insulation defect or partial fracture
Hyperkalemia, severe metabolic disturbance, and toxic effects of antiarrhythmic
drugs
Transient undersensing after cardioversion or defibrillation
Chronic fibrosis and scarring around the electrode
Signal attenuation with the passage of time
Development of new bundle branch block
Myocardial infarction near the electrode
Electronic component failure (rare)
Jammed magnetic reed-switch (rare)
Interference with reversion to the noise-reversion asynchronous rate
Attenuation of adequate cardiac signal upon entry in the pacing system
Mismatch between input and source impedance (e.g., combination of
large-surface-area electrode with low-input-impedance pulse generator (rare
with contemporary pacemakers)
P1: SFK/UKS P2: SFK
part-II BLBK303-Barold May 17, 2010 10:39 Trim: 276mm×219mm Printer Name: Yet to Come
386 Table 11. Causes of oversensing
intracorporeal voltages.
Ventricular T wave
oversensing Afterpotential
P wave (rare)
Crosstalk: sensing of atrial
stimulus
Myopotentials
False signals
Triboelectric signals (static) in
unipolar devices
Atrial
oversensing
Far-field R wave (VA
crosstalk)
Myopotentials
False signals
Ventricular T wave (rare)
Triboelectric signals (static) in
unipolar devices
value approximately equal to the sum of the lower
rate interval and the pacemaker refractory period.
This form of oversensing is now rare, and it is eas-
ily controlled by prolonging the refractory period or
decreasing the output or sensitivity.
False signals (voltage transients)
Abrupt changes in the resistance within a pacing sys-
tem can produce large voltage changes between the
poles used for pacing. Such signals are called false
signals. False signals are almost always invisible on
the surface ECG, so their presence must be assumed
until they are revealed by a telemetered ventricular
electrogram. Such “make–break” signals may occur
with intermittent derangement of a pacemaker cir-
cuit from loose connections, wire fracture with oth-
erwise well-apposed ends, insulation defect, short
circuits, poorly designed active fixation leads, or the
interaction of two leads in the heart (one active, the
other inactive) lying side by side touching each other
intermittently. Oversensing of false signals from a
defective lead can cause erratic pacemaker behavior
with pauses of varying duration. False signals often
occur at random and can be demonstrated in the
telemetered ventricular electrogram, often as large
and irregular voltage deflections.
Remember that oversensing can be associated
with undersensing, because the ventricular refrac-
tory period generated by a sensed false signal may
contain a spontaneous QRS complex. This mixture
of disturbances and the constantly changing pauses
often create a chaotic pattern of pacing which is
characteristic of a lead problem and must not be
misinterpreted as pacemaker component failure.
The characteristic pattern of false signals usually
permits the exclusion of P-wave oversensing
(rare), T-wave oversensing, and/or afterpotential
oversensing, which can be identified by more
regular manifestations. The telemetered ventricular
electrogram can be diagnostic when oversensing
of false signals (potentially serious) mimics T-wave
sensing (less serious, as it causes only bradycardia).
Reminder: If false signals causing oversensing are
suspected, move the pacemaker around in its pocket
and evaluate the effect of deep respiration, arm
movement, and changes in position to unmask an
extravascular lead problem such an intermittent
fracture. The lead impedance can be normal if the
fracture is intermittent.
Myopotentials
Myopotentials represent electrical activity origi-
nating from skeletal muscles. A unipolar ventric-
ular pacemaker may sense such myopotentials and
cause ventricular inhibition. In a DDD pacemaker
myopotentials sensed only by the atrial channel can
be tracked, and they cause an increase in the ventri-
cular pacing rate. Various maneuvers can bring out
this interference during follow-up evaluation. This
disturbance can often be controlled by a reduction
in sensitivity, or programming to the bipolar mode
if feasible.
Caveat: Lack of ventricular pacing during provoca-
tive maneuvers for myopotential oversensing may
be due to myopotential inhibition (oversensing), but
may sometimes be caused by an intermittent lead
fracture which has become manifest during the test-
ing procedure
Pacemaker response to oversensing
interference
Pacemakers can be inhibited by low-frequency in-
terference, which is uncommon. Pacemakers are
designed to respond to rapidly occurring (high-
frequency) extraneous signals by reverting tem-
porarily to the protective asynchronous mode
(interference mode), functioning usually at the pro-
grammed lower rate. A signal sensed in the un-
blanked portion of the ventricular refractory pe-
riod (VRP) or in a part thereof (specifically called
the noise sampling period) reinitiates a new VRP
or noise sampling period respectively. This process
repeats itself with each detected signal so that the
“overlapping” effect of these special timing cycles
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Normal function Application of the magnet
Inaccurate speed of ECG machine
Apparent malfunction in special situations such as hysteresis, sleep rate
Reversion to interference rate in response to electromagnetic interference if the
noise-reversion rate differs from the programmed lower rate
Abnormal function Battery depletion with slowing of the rate
Runaway pacemaker
Component failure
Permanent or temporary change in mode after electrocautery, therapeutic
radiation, or defibrillation
Phantom reprogramming (done without documentation) or misprogramming
Oversensing (e.g., T-wave sensing)
Crosstalk resulting in ventricular safety pacing causing an increase in the pacing
rate
prevents the initiation of a lower rate interval be-
cause the entire pacemaker cycle consists of VRP or
noise sampling periods. This repeated reinitiation
or overlapping effect assures the delivery of a pace-
maker stimulus at the interference rate. The pace-
maker returns to its normal operating mode when
noise is no longer detected.
Changes in pacemaker rate
Changes in pacemaker rate (Table 12) can be puz-
zling. The diagnosis should be relatively simple
knowing the programmed parameters.
Lead malfunction
The lead is the weakest link in the pacing system.
The manifestations of lead malfunction can be var-
ied, and may be obvious or so subtle as to defy de-
tection. Tables 13 and 14 list the manifestations of
lead fracture and insulation defect.
Difficulties with atrial pacing and sensing
The diagnosis of atrial problems requires a tho-
rough knowledge of pacemaker timing intervals,
Table 13. Manifestations of lead fracture.
 No stimuli because of an open circuit (markers may show normal emission of stimulus)
 Stimuli without capture
 Oversensing of false signals: the false signals are invisible on the ECG but can be demonstrated by
telemetry of event markers and electrograms. Some devices record and count non-physiologic V–V
intervals (< 140 ms) for storage in the pacemaker memory: a large number of abnormally short V–V
intervals (reflecting false signals) is highly suggestive of lead dysfunction
 Oversensing can cause undersensing; occasionally the sensed signal itself can be attenuated
 Telemetry showing an abnormally high lead impedance, but the value can be normal if the fracture is
intermittent or there is a concomitant insulation break; failure to secure the set screw can also cause a
high impedance
 Maneuvers: if suspected, one should apply pressure along the course of the subcutaneous portion of
the lead, extend the arm on the side of the pacemaker, place the arm behind the back, and rotate the
shoulder backward to unmask a crush injury due to clavicle–first rib compression
 A fracture may or may not be detectable on an x-ray
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 Extracardiac muscle stimulation if the defect is extravascular (twitching)
 Pacing may be preserved but loss of capture can occur when a large current is shunted from the
electrodes; an insulation defect accelerates battery depletion
 Undersensing from signal attenuation
 Oversensing of false signals; oversensing can cause undersensing
 False signals are invisible on the ECG but telemetry with annotated markers can demonstrate false
signals on the electrogram (also programming in the AAT or VVT mode may be of help). A large
number of abnormally short V–V intervals (reflecting false signals) is highly suggestive of an insulation
defect or lead fracture.
 Unipolarization of a bipolar lead
 Telemetry shows an abnormally low lead impedance, but the value can be normal if the insulation
defect is intermittent
 The insulation is radiolucent, and abnormalities cannot be detected on an x-ray
especially when the ECG reveals only one stimulus,
atrial or ventricular. In this respect Table 15 outlines
the differential diagnosis of the presence of an atrial
stimulus but no ventricular stimulus during DDD
or DDDR pacing, and Table 16 deals with the pre-
sence of a ventricular stimulus but no atrial stimulus
during DDD or DDDR pacing.
Never neglect determination of atrial
capture in dual chamber pacemakers
The presence of atrial stimuli does not mean atrial
capture. Unsuspected atrial fibrillation is a common
cause of lack of atrial capture. Telemetered AP mar-
kers simply reflect release of AP, and cannot indicate
successful atrial capture (Table 17).
Apparent atrial undersensing in dual
chamber pacing (functional atrial
undersensing)
True atrial undersensing is an important cause of
prolongation of the interval from AS to VS beyond
the programmed AV interval. Barring true atrial un-
dersensing from a low-voltage atrial electrogram,
other causes include the following:
1. Ventricular oversensing during the AV interval.
2. Long or extended PVARP. An atrial electrogram
or P wave (with an adequate signal for sensing)
may be forced into an excessively long PVARP
sometimes due to automatic extension initiated
by a pacemaker-defined VPC. If the patient’s PR
interval is quite long and the spontaneous rate
is relatively fast, there is a greater likelihood that
Table 15. Presence of an atrial stimulus but no ventricular stimulus during DDD or
DDDR pacing.
1. Atrial pacing followed by a conducted QRS complex before completion of the AV delay: apply the
magnet for diagnosis
2. Isoelectric or tiny ventricular stimuli: use double standardization of the ECG machine
3. Concealed ventricular stimuli within the QRS complex (pseudofusion): marker channel confirms
diagnosis
4. Disconnection of the ventricular circuit as in a lead fracture; this causes apparent AAI pacing:
reprogram to the VVI mode, whereupon no stimuli will be seen in the VVI and VOO (magnet) modes
5. Crosstalk in devices without ventricular safety pacing: application of the magnet confirms diagnosis
6. Oversensing during the AV delay: apply magnet; use telemetry to demonstrate the electrogram and
annotated markers
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DDDR pacing.
1. In some devices, magnet application causes VOO pacing
2. Disconnection of the atrial circuit: VVI pacing in the DDD mode and no stimulation the AAI and AOO
modes
3. Isoelectric or tiny atrial stimuli: use double standardization of the ECG machine
4. Concealed atrial stimuli within the QRS complex (pseudopseudofusion): use marker channel for
diagnosis
5. DDI mode when the atrial channel is continually inhibited: apply magnet for diagnosis
6. Apparent VVI pacing: the atrial stimulus (occasionally because of atrial undersensing) is coincident
with the onset of the spontaneous QRS complex with a left bundle branch block configuration
a P wave will fall closer to the preceding QRS
complex and therefore in the PVARP, which need
not be unduly long to cause “functional” atrial
undersensing.
3. Upper rate response (pre-empted Wenckebach
upper rate response). Prolongation of the AS–VS
interval may result from failure of delivery of the
ventricular stimulus if the URI has not timed out
by the time the AVI has terminated. In this situ-
ation the interval between two consecutive QRS
complexes must exceed the URI of the pulse gen-
erator.
4. Short but reinitiated PVARP. If the ventricular
channel senses a signal other than the QRS (e.g.,
T wave), the PVARP is reinitiated by the over-
sensed signal and the P wave may fall in this new
PVARP. In this situation, P-wave sensing may be
restored by decreasing the sensitivity of the ven-
tricular channel.
Table 17. How to test for atrial capture.
1. If the paced P wave is not discernible in the 12-lead ECG, record the ECG at double standardization to
bring out P waves and tiny bipolar stimuli. Faster paper speed may help
2. In the presence of relatively normal AV conduction, program the AAI or AOO mode. Use several
pacing rates to demonstrate the consistent relationship of the atrial stimulus to the succeeding
spontaneous conducted QRS complex
3. In patients with AV block, reduce the pacing gradually to 30 ppm. This is often well tolerated. Then use
the AAI or AOO at various fast rates to determine atrial capture by looking at the P-wave
configuration and rate which must correspond to the pacing rate
4. A paced P wave may be difficult to see if the AV delay is too short. A relatively late P wave can be
unmasked by prolonging the AV delay. A “late” P wave from the atrial stimulus usually indicates
interatrial conduction delay and the risk of delivering the P wave too late to provide appropriate AV
synchrony. In other words the atrial transport function provided by atrial pacing may be largely
wasted if the P wave is too close to the paced QRS complex. In severe cases the paced P wave occurs
inside the paced QRS complex. Such a patient requires careful programming of the AV delay under
echocardiographic control and evaluation for pacemaker syndrome
5. Shorten the AV delay. If the paced QRS morphology changes, it means that there was ventricular
fusion with the spontaneous QRS complex at the longer AV delay and therefore atrial capture giving
rise to AV conduction
6. In patients with relatively fast sinus rhythm, program the DVI mode, which provides competitive
atrial pacing beyond the atrial myocardial refractory period
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Reminder: What looks like atrial undersensing may
be functional in association with a atrial signal of
sufficient size to be sensed.
Automatic mode switching
In the past, paroxysmal atrial arrhythmias consti-
tuted a contraindication to dual chamber pacing.
Advances in pacemaker technology have now made
it possible to use dual chamber pacemakers safely in
this patient population. Dual chamber pacemakers
equipped with automatic mode switching (AMS)
can now protect the patient from rapid ventricular
pacing by automatically functioning in a non-atrial
tracking mode (VVI, VVIR, DDI, DDIR) during
supraventricular tachycardia (SVT). AMS requires
fundamental changes in the operation of pacemaker
timing cycles to maximize SVT detection above the
programmed upper rate. Although many of the
AMS algorithms from a variety of manufacturers
are device-specific, the actual timing cycles required
for SVT detection are basically independent of AMS
algorithm design. For appropriate SVT detection,
the atrial signal should be of sufficient amplitude
and the obligatory blanking periods (when the
sensing amplifier is temporarily disabled), should
be restricted to a small fraction of the pacing cycle.
Blanking periods cannot be eliminated, because
they prevent the oversensing of undesirable signals
that are inherent to all pacing systems.
Appropriate AMS depends on several parame-
ters:
(a) the programmed detection rate
(b) atrial sensing and the characteristics of the ar-
rhythmia
(c) the characteristics of the AMS algorithm
AMS failure may occur if the amplitude of the
atrial electrogram is intermittently or consistently
too small to be sensed, or if an atrial signal occurs
systematically during the atrial blanking period.
An AMS algorithm also provides important
data about SVT: onset, AMS response, and resyn-
chronization. Since AMS programs also provide
data on the time of onset and duration of AMS
episodes, AMS data may be considered a surrogate
marker of SVT recurrence. Stored electrograms
have enhanced the accuracy of AMS in detecting
SVT. The total duration of atrial fibrillation (AF)
is correctly represented by the total duration of
AMS, which can be considered a reliable measure
of total AF duration. Automatic mode switching
algorithms, which provide data on the time of
onset and duration of AMS episodes, allow a more
accurate determination of the proportion of time a
patient with AF is in AF, and have led to the concept
of “AF burden.” The extremely high sensitivity and
specificity of AMS for AF is clinically useful for
assessing the need for anticoagulation and/or the
necessity or efficacy of antiarrhythmic therapy.
The prevalence of recurrent AF, particularly
asymptomatic episodes, is easily underestimated.
Asymptomatic AF is far more common than symp-
tomatic AF. This has important implications for anti-
coagulation therapy. Furthermore, AMS events may
serve as a valuable tool for studying the natural
history and burden of SVT even in asymptomatic
patients.
Timing cycles related to automatic
mode switching
The unblanked portion of the AV interval (initiated
by a paced or sensed atrial event) was designed
to enhance sensing of AF during the AV interval
to facilitate AMS. A ventricular paced or sensed
event initiates the postventricular atrial refractory
period (PVARP), the first portion of which is the
postventricular atrial blanking period (PVAB). The
second part of the PVARP is unblanked (PVARP-U),
but sensing within it cannot initiate an AV delay.
The PVARP initiated by ventricular pacing is almost
always equal to the PVARP initiated by ventricu-
lar sensing. Far-field sensing of the R wave within
the PVARP can be corrected by programming lower
atrial sensitivity or the PVAB to a longer value. Pro-
grammability of the PVAB is a relatively new feature
of pacemakers. A long PVAB predisposes to atrial
undersensing of SVT, which is crucial for AMS ac-
tivation. Sensing of SVT for AMS function is there-
fore possible during the unblanked refractory pe-
riods (AVI-U and PVARP-U) as well as during the
cycle without atrial refractory periods, where atrial
sensing initiates an AV delay.
VA crosstalk
The atrial channel cannot sense a signal associ-
ated with the ventricular stimulus because the atrial
channel of all pacemakers is blinded or blanked by
the relatively long PVAB that starts coincidentally
with emission of the ventricular stimulus. Ventricu-
loatrial (VA) or reverse crosstalk refers to far-field
sensing that occurs when ventricular signals in the
atrial electrogram are sensed by the atrial channel
in the PVARP beyond the PVAB (sensing the paced
QRS complex) or in the unblanked terminal por-
tion of the AV delay (sensing the spontaneous QRS
complex). VA crosstalk occurs because the smaller
atrial electrograms during SVT require higher atrial
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sensitivity for sensing than the normal rhythm. VA
crosstalk can often be eliminated by reducing atrial
sensitivity, but this carries the risk of atrial under-
sensing during SVT, when atrial signals become
smaller. Far-field atrial sensing may be reduced by
the use of bipolar sensing and improved pulse ge-
nerator and lead technology.
Caveat: Detection of smaller signals during atrial
tachyarrhythmias requires a high atrial sensitivity,
which predisposes to VA crosstalk.
Testing for VA crosstalk
The propensity for VA crosstalk during the PVARP
should be tested during ventricular pacing. The
AS–VP interval is shortened to permit contin-
ual ventricular capture. The pacemaker is then
programmed to the highest atrial sensitivity and
the largest ventricular output (voltage and pulse
duration). These settings should be evaluated at
several pacing rates to at least 110–120 ppm, be-
cause faster ventricular pacing rates impair dissi-
pation of the afterpotential or polarization voltage
at the electrode–myocardial interface. Such param-
eters enhance the afterpotential and therefore gen-
erate a voltage superimposed on the tail end of the
paced QRS complex. The combined voltage from
these two sources may be sensed as a far-field sig-
nal by the atrial channel. VA crosstalk can be elimi-
nated by decreasing atrial sensitivity provided one
knows that the atrial signals during SVT can be
sensed at the lower sensitivity. In devices with a
programmable PVAB, the testing procedure if pos-
itive for VA crosstalk can be performed at various
durations of the PVAB until VA crosstalk is elimi-
nated. VA crosstalk within the AV interval is eval-
uated by programming a low lower rate and long
AVI, to promote spontaneous sinus rhythm and AV
conduction.
Mode switching algorithms
A “rate cut-off” criterion is commonly used to acti-
vate AMS, in the form of a sensed atrial rate excee-
ding a programmable value (for a defined period of
time or number of cycles). The atrial rate is continu-
ously monitored by increasing/decreasing counters
or by consecutive rapid atrial event counters. AMS
is activated when the count of the short atrial cy-
cles exceeds the programmed cut-off criterion. Many
Medtronic pacemakers activate AMS after detecting
4/7 atrial intervals shorter than the tachycardia de-
tection interval. In one system (Boston Scientific),
atrial events above the tachycardia detection rate in-
crement the detection counter, whereas events be-
low the tachycardia detection rate decrement the
counter. Atrial tachyarrhythmia is detected when
the counter reaches a fixed value. AMS then oc-
curs over a programmable time between 1 and 5
minutes. Another algorithm uses a “running aver-
age” rate as a criterion to move towards AMS (Early
Medtronic and current St. Jude devices). This me-
chanism (“mean, filtered, or matched atrial rate”) is
based on a moving value related to the duration of
the prevailing sensed atrial cycle. AMS will occur
when the “filtered” interval shortens to the tachy-
cardia detection interval. It is faster for the filtered
atrial interval to reach the tachycardia detection in-
terval when atrial tachycardia starts in the setting of
a higher resting sinus rate (shorter filtered atrial rate
interval) than from a sinus bradycardia.
Detection of atrial flutter by dual
chamber pacemakers
Patients with paroxysmal atrial flutter represent a
challenge for AMS algorithms. AMS failure may oc-
cur during atrial flutter when alternate flutter waves
coincide with the PVAB (lock-in phenomenon).
Some devices provide additional algorithms to un-
mask the presence of “blanked” atrial flutter so as to
activate AMS. In some designs, the duration of the
blanking periods prevents the pacemaker from de-
tecting atrial flutter, if the atrial cycle does not match
the sensing window of the atrial channel. In other
words, the duration of the PVAB imposes mathe-
matical limits on the detection of atrial flutter. If
AV interval + PVAB > atrial cycle length (P–P or
f–f interval), the pacemaker will exhibit 2 : 1 atrial
sensing of atrial flutter (2 : 1 lock-in). Sensing of al-
ternate atrial signals will occur if AVI + PVARP <
2 atrial cycles. Abbreviation of the PVAB may solve
the problem if far-field R-wave sensing does not oc-
cur. If PVAB is non-programmable, restoration of
1 : 1 atrial sensing would require programming of
the AV interval to very short durations such as 50
ms. Restoration of AMS function by shortening of
the AVI to circumvent a fixed PVAB produces unfa-
vorable hemodynamics for long-term pacing if the
AVI remains permanently short in the absence of
SVT.
The detection of atrial signals can be ameliorated
by reducing the blanked AV interval. Thus, a design
that allows substantial shortening of the AS–VP in-
terval only with increasing sensed atrial rates opti-
mizes sensing of atrial flutter, and yet preserves a
physiologic AV interval at rest and low levels of ex-
ercise. During SVT when (AS–VP interval) + PVAB
= 30 + 150 = 180 ms, this combination allows sen-
sing of atrial flutter with a cycle length up to 180 ms
(333 bpm). Another algorithm, specifically designed
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for atrial flutter, automatically extends the PVARP
for one cycle whenever the pacemaker detects an
atrial cycle length less than twice (AV interval +
PVAB) and the atrial rate is greater than half the
tachycardia detection rate (or the atrial interval is
less than twice the tachycardia detection interval).
AMS occurs if an atrial event is sensed within the
extended PVARP, thereby revealing the true atrial
cycle.
Caveat: Troubleshooting automatic mode switching
requires knowledge of the algorithm, blanking pe-
riods, atrial signal in sinus rhythm, and atrial sensi-
tivity.
Retriggerable atrial refractory period
Some pacemakers with a retriggerable or resettable
atrial refractory period revert to the DVI or DVIR
mode upon sensing a fast atrial rate. In such a sys-
tem, an atrial signal detected in the PVARP beyond
the initial PVAB does not start an AV interval but
reinitiates a new total atrial refractory period (TARP)
or the sum of AVI + PVARP. This process repeats it-
self, so that SVT faster than the programmed upper
rate (i.e., P–P interval < TARP) automatically con-
verts the atrial channel to the asynchronous mode
and the pacemaker to the DVI mode at the lower
rate, or the DVIR mode, according to design and
programmability.
Reminder: The concept of overlapping refractory pe-
riods is important in the ventricular channel of pace-
makers, to prevent continuous inhibition due to
rapidly recurring extraneous signals from interfer-
ence.
Minimizing right ventricular pacing
Many studies in the last decade have shown that
long-term RV apical pacing may produce substantial
LV dysfunction and heart failure. At this juncture
one cannot predict this risk in individual patients,
though certain factors such as LV dysfunction at the
time of implantation predispose to this complication
(Table 18).
1. Do not pace if it is not necessary
The majority of patients treated with pacemakers
for sick sinus syndrome, including those with di-
lated cardiomyopathy, reduced LV ejection fraction
(LVEF), and congestive heart failure, have a nor-
mal ventricular activation sequence manifested as
a QRS duration < 120 ms on the baseline electro-
cardiogram and therefore do not require continual
ventricular pacing. Furthermore, most have reliable
AV conduction that remains stable over time.
Avoidance of RV pacing is especially important in
ICD patients without sinus or AV nodal dysfunction,
where the VVI or DDI pacing mode (with a long
AV delay) at a rate of 40 ppm may be appropriate
for many patients equipped with ICDs incapable of
providing automatic minimal ventricular pacing.
2. Alternative-site ventricular pacing
This includes the RV septum and RV outflow tract.
Direct His bundle pacing may prevent the negative
effects of RV apical pacing. However, it is a complex
technique that cannot be achieved in all patients,
and it is associated with high pacing thresholds and
long implantation times. In contrast, paraHisian
pacing, which produces physiologic ventricular
activation similar to direct His bundle pacing, is
easier to perform and more reliable than direct
His bundle pacing. Preliminary data suggest that
paraHisian pacing is superior to RV apical pacing
in preserving LV function.
3. AAI and AAIR pacing
These pacing modes carry a small risk of AV block in
a few patients (1–2% per year). These pacing modes
are rarely used in the USA for fear of litigation. In
Europe, AAI and AAIR modes are considered viable
and acceptable in carefully screened patients with
sick sinus syndrome without bundle branch block
and delayed AV conduction.
4. Algorithms to minimize RV pacing
Much evidence has emerged recently about the
harmful effects of chronic RV pacing (mostly apical)
on LV function. Minimizing RV pacing may reduce
chronic changes in cellular structure, changes in LV
geometry that contribute to impaired hemodynamic
performance, mitral regurgitation, and increased left
atrial diameters, with the aim of reducing the risk of
atrial fibrillation, congestive heart failure, and death.
On this basis, strategies to minimize RV pacing have
become important, especially in patients with sick si-
nus syndrome, where continual RV pacing may not
be necessary.
(a) Long fixed AV delay
Using the DDDR (or DDIR) mode with a fixed long
AV delay (250–300 ms) in patients with normal AV
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Method Comments
Do not pace if it is not
necessary
Use the DDD(R) or DDI(R) mode with a long AV delay and slow lower rate
according to behavior of the spontaneous rhythm
Alternative-site pacing
away from the RV apex
1. RV septal and RVOT pacing
2. Direct His bundle and paraHisian pacing
3. Biventricular or monochamber ventricular pacing with LV lead: consider
this approach in selected patients with LVEF ≤ 35% (even in the absence
of HF) especially with mitral regurgitation and Cum%VP expected to be
high (e.g., complete AV block)
4. Bifocal RV pacing (2 RV sites): produces CRT of lesser magnitude than
biventricular pacing in CRT candidates but may be useful in selected
patients with poor LV function and narrow QRS complex. One of the
sites may be paraHisian
Programming maneuvers
(functional AAIR pacing)
1. Using the DDDR (or DDIR) mode with a fixed long AV delay (250–300
ms) in patients with normal AV conduction is of limited value
2. AV search hysteresis (autointrinsic conduction search, Search AV+) in
the DDDR mode
AAI and AAIR modes By definition, AAI(R) pacing eliminates the possibility of RV pacing but
carries a small risk of AV block
New pacing modes A special algorithm maintains AAI or AAIR pacing. Return to AAIR from
DDDR is achieved by periodic AV conduction checks. Occasional
second-degree AV block is often well tolerated in the AAIR mode. Marked
first-degree AV block may cause pacemaker syndrome. These new pacing
modes are effective in minimizing RV pacing but long-term results on LV
function are unknown. This pacing mode can reduce AF
conduction is of limited value in preventing RV pac-
ing. During AV block, pacing must occur with the
programmed long AV delay. A long atrial refractory
period may cause atrial undersensing and limits the
programmable upper rate. A long AV delay favors
endless loop tachycardia or repetitive non-reentrant
VA synchrony with functional loss of atrial capture
and pacemaker syndrome.
(b) Dynamic AV delay (AV search hysteresis,
autointrinsic conduction search, search AV+)
These algorithms in the DDDR mode promote spon-
taneous AV conduction by allowing the functional
AV delay to be longer than the programmed AV de-
lay as long as AV conduction remains intact. During
AV block, the AV delay is physiologically shorter
and more appropriate than with devices working
with a fixed long AV delay (e.g., 200 vs. 300 ms).
In this algorithm the device periodically extends the
AV (AP-V and AS-V) delay (gradually or suddenly)
to a programmable value to search for AV conduc-
tion. If a conducted ventricular event is sensed dur-
ing this extended AV delay, the pacemaker inhibits
the ventricular output and continues to function (in
the functional AAI or AAIR mode) with such an ex-
tended AV delay until no ventricular event is sensed.
If there is a single cycle with no intrinsic ventricular
event within the extended AV delay, the AV exten-
sion is cancelled and the pacemaker reverts to the
programmed (unextended) AV delay on the next cy-
cle. The pacemaker then waits until the next search
function (after a programmable time) is activated to
look for the return of spontaneous AV conduction.
This feature is particularly valuable in patients who
would otherwise be suitable for permanent AAI or
AAIR pacing.
(c) New pacing modes in which the algorithm
maintains AAI or AAIR pacing (automatic
mode switching DDDR → AAIR → DDDR)
The switch to AAIR from DDDR is achieved
by periodic AV conduction checks by the device
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monitoring for a conducted ventricular sensed
event. First- and second-degree AV block are tole-
rated in the AAIR mode up to a predetermined pro-
grammable limit. The permitted cycles of second-
degree AV block are short, but an occasional patient
may become symptomatic. Supraventricular tach-
yarrhythmias activate automatic mode switching to
the DDIR mode (AAIR → DDIR or DDDR → DDIR).
Pacemakers with automatic mode switching
DDDR → AAIR→ DDDR according to AV conduc-
tion are effective in minimizing RV pacing, espe-
cially in patients with ICDs, who often do not require
rate support, but clinical benefit and long-term re-
sults (including impact on atrial fibrillation) are un-
known at this time.
In this respect, Medtronic’s Managed Ventricular
PacingTM (MVP) has no AV interval (ending in VS),
so that no ventricular pacing will occur after a long
PR (AS–VS or AP–VS) interval. Sustained marked
first-degree AV block may be hemodynamically im-
portant and symptomatic, like retrograde VA con-
duction.
Effect of drugs and electrolyte
imbalance
The class IA agents procainamide and disopyra-
mide increase the pacing threshold only in toxic
or supratherapeutic doses. Class IB drugs are safe.
Class IC agents (flecainide and propafenone) can
cause a marked increase in the pacing threshold in
therapeutic doses. Beta-blockers generally do not
increase the threshold. Despite the claim that so-
talol can increase the threshold, the drug appears
safe clinically. There is no convincing evidence that
amiodarone increases the pacing threshold. Corti-
costeroids, epinephrine, and isoproterenol decrease
the pacing threshold.
Hyperkalemia
In patients with pacemakers, hyperkalemia causes
two important clinical abnormalities:
1. Widening of the paced QRS complex (and paced
P wave) on the basis of delayed myocardial con-
duction. Other common causes of a wide paced
QRS complex include amiodarone therapy and
severe myocardial disease.
2. Increased atrial and ventricular pacing thresh-
olds.
Pacing threshold
The level of hyperkalemia causing changes in the
pacing threshold varies from patient to patient.
When serum K > 7.0 mEq/L, there will almost
always be an increase in the pacing threshold. A
modest elevation of the K level (e.g., 6.5 mEq/L)
may cause failure of atrial and/or ventricular
capture, suggesting that other metabolic variables
may influence the sensitivity of cardiac tissue
to hyperkalemia. These include other types of
electrolyte imbalance, acid–base abnormalities,
oxygen saturation, the rate of change of plasma K
level, the intracellular–extracellular gradient, and
the etiology and severity of heart disease. For this
reason, the cardiac manifestations of hyperkalemia
in the clinical setting tend to occur at much lower K
levels than those measured during an experimental
infusion of potassium.
Latency
Hyperkalemia can cause prolonged latency, a condi-
tion also known as first-degree pacemaker exit block.
Latency describes the delay from the pacing stim-
ulus to the electrocardiographic onset of atrial or
ventricular depolarization. The normal value for the
RV is < 40 ms. First-degree ventricular pacemaker
exit block can progress to second-degree Wencke-
bach (type I) exit block, characterized by gradual
prolongation of the pacemaker stimulus to the on-
set of the paced QRS complex, ultimately resulting
in an ineffectual stimulus. The pacing disturbance
may then progress to 2 : 1, 3 : 1 exit block, etc., and
eventually to complete exit block with total lack of
capture. Total unresponsiveness to ventricular stim-
ulation has been reported with a K level of only
6.6 mEq/L.
Hyperkalemia-induced ventricular pacemaker
exit block (not uncommonly associated with drug
toxicity, especially type 1A antiarrhythmic agents)
is potentially reversible, unlike other causes of
increased RV latency, which occur predominantly in
severe or terminal myocardial disease. Wenckebach
exit block can be produced experimentally in the
laboratory by perfusion of cardiac tissue with a
large concentration of antiarrhythmic agents and
potassium, an effect that is often reversible. This
phenomenon is rate- and output-dependent. Con-
sequently, with first-degree exit block or prolonged
latency, an increase in the pacing rate leads to
prolongation of the latency interval. An increase
in the amplitude of the stimulus may shorten the
latency interval and convert type I second-degree
to first-degree exit block.
Differential effect on atrial versus
ventricular myocardium
In a dual chamber device, hyperkalemia may cause
failure of atrial capture associated with preservation
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of ventricular pacing. This differential effect on atrial
and ventricular excitability (pacing) correlates with
the well-known clinical and experimental observa-
tions that the atrial myocardium is more sensitive
to hyperkalemia than the ventricular myocardium.
This situation should always be suspected in hospi-
talized patients who have severe heart failure with
relatively sudden decompensation with hypoten-
sion and a wider paced QRS complex compared to
previous recordings. In this situation, loss of atrial
capture causing decompensation should be demon-
strated at the maximum programmable AV delay to
rule out increased latency, and at double ECG stan-
dardization to confirm the loss of atrial activity.
Magnet application
Magnet application is being used less and less
nowadays, because telemetry offers more sensitive
parameters of battery status. Magnet application
is important in the evaluation of oversensing by
eliminating the sensing function of pacemakers,
and for assessing the presence of capture in the
presence of a spontaneous rhythm faster than the
lower rate of the pacemaker (Table 19).
Reminder: A magnet over an ICD eliminates its anti-
tachycardia function but does not convert it to asyn-
chronous pacing.
Table 19. Pacemaker magnet
application.
1. Conversion to the asynchronous mode: VOO
or DOO modes assess capture when the
spontaneous rhythm is faster than the lower
rate of the pacemaker
2. Assess capture during asynchronous pacing
3. Elective replacement indicator
4. Provides reed-switch activation as required
for some programmers to function
5. Eliminates sensing: useful during
electrocautery; provides diagnosis of
oversensing
6. Patient can trigger electrogram storage
during symptomatic episode
7. Termination of endless loop tachycardia
8. Competitive underdrive pacing for the
termination of some reentrant tachycardias
9. May help identification of device, as some
have typical magnet response
Capture verification algorithms
The longevity of an implantable pacemaker is deter-
mined by the capacity of the battery, its chemistry,
and the current drain. Automatic capture verifica-
tion aims at reducing the latter while maintaining
safety. The pacing threshold may change according
to physiologic conditions, disease conditions, and
maturation of the lead–tissue interface. This has re-
sulted in the traditional practice of programming
pacing output voltages to at least twice as great as
the measured pacing threshold (the so-called safety
margin) to ensure consistent capture. This relatively
high output voltage represents potential wastage of
battery capacity.
The detection and evaluation of the cardiac de-
polarization (or evoked response, ER) of the pacing
pulse is a reliable surrogate for myocardial systole.
ER must be differentiated from polarization, which
is the residual charge at the electrode–tissue inter-
face that follows the output pulse. This voltage is
normally blinded by the standard blanking period
initiated upon delivery of the output pulse. The pres-
ence of a blanking period after the ventricular output
therefore requires a special detection circuit for ER
detection. As a rule, a large variety of capture verifi-
cation systems work in > 90% of patients (Table 20).
St. Jude systems
The “traditional” St. Jude Ventricular AutoCap-
tureTM feature or DMax is strictly dependent on
lead type (low polarization) and configuration.
It is mandatory to elicit ventricular stimulation
tip to can, and to achieve ER detection tip to ring
(bipolar leads are needed). Consequently, the pacing
configuration has to be programmed to unipolar to
use the original method.
The new Enhanced Ventricular AutoCaptureTM
system (PDI) from St. Jude can be used with either
a unipolar or a bipolar lead, and, when a bipolar
lead is implanted, the device can be programmed
to either unipolar or bipolar ventricular pacing con-
figuration. The original AutoCapture and the new
enhanced AutoCapture feature are both predicated
on analysis of the ER, but the methods of evaluat-
ing the ER are somewhat different. The availability
of the two different analysis methods explains why
the ventricular Enhanced AutoCapture feature can
be used with leads and programmed configurations
that the original method could not use. Although
PDI should replace DMax, and this will probably
happen in the future, it would be wise to keep
DMax available until there is extensive experience
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Manufacturer
Beat-to-beat ER
detection
Dedicated lead
for ER detection
Configuration for
ER detection
Fusion
management
Right ventricle
St. Jude DMaxa Yes Low polarization Bipolar Yes
St. Jude PDI
(Zephyr)b
Yes No Any Yes
Boston Scientific Yes No Any Yes
Medtronic No No Any No
Atrium
Medtronicc No No N/A No
St. Jude No Low polarization Bipolar No
a Traditional Autocapture system designated DMax.
bThe Zephyr pacemaker permits the selection of either DMax or the new system (designated PDI) for
Autocapture.
cThe only system where ER detection is not involved. All the other listed systems use ER detection either
on a beat-to-beat basis or strictly only at the time of periodic threshold determination.
with PDI. Both systems perform periodic threshold
searches. Both versions of ventricular AutoCapture
maintain a pacing output voltage of 0.25 V above the
threshold determined by the system. In addition, a
threshold search is triggered whenever the system
detects a loss of capture as determined by the beat-
to-beat capture verification analysis. Backup pacing
pulses are delivered whenever the device detects a
loss of capture with the primary ventricular pacing
pulse.
Medtronic’s Capture Management and Boston
Scientific’s Automatic Capture algorithms are the
default algorithms in their respective devices: no
special set-up is required, and they are on imme-
diately upon implantation of the pulse generator.
In contrast, St. Jude does not allow the autocapture
algorithm to be the default setting in the pacemaker.
The St. Jude system must be intentionally evaluated
and then enabled. It is only in the post-implant
phase that the patient can be evaluated to determine
whether AutoCapture using either DMax or PDI
can be utilized. For the ventricular Enhanced Auto-
Capture feature, the system automatically chooses
between two evaluation methods based on the type
of lead and programmed pacing configuration.
With either the original or the new AutoCapture
system, the AutoCapture Setup Test must be run,
which automatically determines whether the ratio
of evoked response to polarization is adequate to
recommend activation of the AutoCapture feature.
Consequently, the ability to use AutoCapture is
assessed on a patient-by-patient basis, not on the
type of lead per se. While setting up AutoCapture
requires a few more steps, called the AutoCapture
Setup Test, these initial steps will tell if the ER
signal amplitude and polarization signal ampli-
tudes are appropriate to allow AutoCapture to be
enabled.
St. Jude automatic atrial capture
verification
An atrial capture verification algorithm (Atrial
Autocap) was recently introduced in the St. Jude
Zephyr series of pacemakers. It requires a low po-
larization bipolar lead. The system works by detect-
ing the atrial evoked response but does not function
on a beat-to-beat basis like its ventricular counter-
part. The atrial threshold is measured every 8–24
hours. The system can adjust the output, but with a
larger margin than the 0.25 V working margin that
is associated with the true AutoCapture algorithm,
because between evaluations it does not monitor
capture and cannot provide a higher-output backup
pulse, which is only possible during the periodic
evaluations. During threshold testing, the device
emits a backup pulse only when there is loss of atrial
capture. The safety margin cannot be programmed.
After threshold determination the device incre-
ments the output voltage by a value according to a
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published table. The final atrial output voltage cor-
responds to a safety margin of approximately 1.7 : 1.
Keeping good records
Good records are essential, and they should include
representative printouts of data and rhythm strips
and stored electrograms. They should include a 12-
lead ECG (Table 21).
Factors influencing pacemaker
longevity
Battery current drain (expressed in A) is the most
important determinant of battery longevity. Pacing
requires more current than sensing (Table 22).
Pacemaker longevity can be enhanced by careful
programming, and by selecting steroid-eluting leads
with a small-radius tip electrode (small surface area
for stimulation), which provide low thresholds and
Table 21. Data required in pacemaker chart or computerized file.
Patient data Name, age, address, phone number, etc.
Pacemaker data Date of implantation
Model and serial number of leads
Model and serial number of pulse generator
Data from
implantation
Pacing threshold(s)
Sensing threshold(s)
Intracardiac electrograms
Lead impedance(s)
Status of retrograde VA conduction
Presence of diaphragmatic or accessory muscle stimulation with 5 and 10 V output
Technical
specifications
Pacemaker behavior in the magnet mode
Record of elective replacement indicator: magnet and/or free-running rate, mode
change, telemetered battery data (impedance and voltage)
Data from
pacemaker clinic
Programmed parameters from time of implantation and most recent changes
12-lead ECG and long rhythm strips showing pacing and inhibition of pacing to
evaluate underlying rhythm
12-lead ECG upon application of the magnet
Electronic rate intervals and pulse duration measured with a special monitor
Interrogation and printout of telemetric data (always print a copy of the initial
interrogation and measured data)
Systematic
evaluation of
pacing system
Atrial and ventricular pacing and sensing thresholds
Retrograde VA conduction and propensity to endless loop tachycardia
Evaluation of crosstalk
Myopotential interference (record best way of reproducing abnormality)
Special features: automatic mode switching parameters, ventricular safety pacing,
non-competitive atrial pacing, etc.
Evaluation of sensor function with exercise protocols, histograms, and other data to
demonstrate heart rate response in the rate-adaptive mode
Final telemetry printout at end of evaluation and date: check that any changes in
parameters are intentional by comparing the final parameters with those obtained at
the time of initial pacemaker interrogation; any discrepancy must be justified in the
record
Ancillary data Symptoms and potential pacemaker problems
ECGs with event markers and electrograms mounted in the chart
Intolerance of VOO pacing upon application of the magnet
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current drain.
1. The greater the percent pacing, the shorter
the longevity
2. Increase in the pacing rate (cycle length)
3. Increase in output voltage
4. Increase in pulse duration
5. Change from single chamber to dual
chamber mode
6. Use of rate-adaptive function with non-atrial
sensor
7. Decrease in lead impedance (impedance,
while not programmable, can be controlled
by selecting a high-impedance lead at the
time of implantation)
8. Programming, telemetering, storage of
diagnostics
efficient high impedance (over 1000 ). The high
impedance is at the electrode–tissue level, where the
maximum voltage is available at the electrode tip
for stimulation. The high impedance reduces cur-
rent drain from the battery by Ohm’s law. Thus, ide-
ally one should implant small-surface-area, steroid-
eluting, and porous electrodes. The porosity creates
a complex surface structure which increases the ef-
fective surface area for sensing and improves the
efficiency of sensing.
Caveat: Do not confuse battery current drain with
current output (mA) at the electrode–myocardial in-
terface with delivery of the pacemaker pulse. When
trying to conserve battery life, monitor the battery
current drain as you program various parameters.
Elective replacement indicator (ERI) versus
reset situation: differential diagnosis when
the mode of operation is identical
The reset mode, usually VVI or VOO, represents a
normal protective response to high-intensity elec-
tromagnetic interference. A reset pacemaker does
not represent malfunction, and it can easily be re-
programmed to its previous mode. The backup pac-
ing circuit of certain DDD pacemakers can produce
a similar situation when activated by low battery
voltage as a mechanism to reduce the current re-
quirement from the battery.
1. In ERI (or recommended replacement time,
RRT), the battery voltage is low and the bat-
tery impedance is high. The ERI point is
manufacturer-defined. Note that when the bat-
tery voltage of a dual chamber pacemaker reaches
ERI, switching to the VVI mode automatically in-
creases the battery voltage to a higher level than
the specified ERI point. In reset, the battery volt-
age is high and the battery impedance has not yet
reached the ERI points.
2. Battery stress test: program the pacemaker to
dual chamber mode at a relatively fast rate and
high output and watch for a while. If the pace-
maker continues to function normally the diag-
nosis was reset (from EMI). If it switches back to
VVI the diagnosis was ERI.
Caveat: From the ERI point, a pacemaker will reach
end-of-life (EOL) or end-of-service (EOS) in about
3 months. At EOL, pacing becomes erratic and
unreliable, with the possibility of total system
failure.
Pacemaker follow-up
The frequency and type of follow-up depend on the
projected battery life, type, mode, and programming
of pacemakers, the stability of pacing and sensing,
the need for programming change, the underlying
rhythm (pacemaker dependency), travel logistics,
type of third-party insurance, and alternative meth-
ods of follow-up such as remote monitoring via the
Internet. Most centers follow the Medicare guide-
lines for pacemaker follow-up (for single chamber
pacemakers, twice in the first 6 months after implant
and then once every 12 months; for dual chamber
pacemakers, twice in the first 6 months after implant
and then once every 6 months).
Remote monitoring
Remote monitoring is recommended as part of a
comprehensive and cost-effective pacemaker pa-
tient management program. Patients should be told
of the availability of remote monitoring. Failure to
inform patients may eventually cause medicolegal
problems in the case of late discovery of an ICD
problem. Furthermore, patient consent is advised
as the data passes through a third party. Today, re-
mote follow-up systems allow clinicians to monitor
their pacemaker patients away from the device clinic
or hospital. Follow-up done remotely uses specific
equipment to interrogate and upload data to a se-
cure web site via the patient’s telephone line. These
systems transmit device diagnostic data (from inter-
rogation), stored electrograms, and the presenting
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rhythm. In this way, they provide the same informa-
tion obtained at an office visit. Remote interrogations
complement, and in some cases may even replace,
in-clinic pacemaker follow-up visits. Remote follow-
up is designed to supplement periodic visits to the
pacemaker center, and should not replace compre-
hensive follow-up. Yet some workers use remote
monitoring instead of visits on alternate follow-up
sessions.
Remote monitoring may discover undocumented
and asymptomatic arrhythmias, intermittent lead
problems, and data helpful in optimizing device pa-
rameters and medical therapy. Remote monitoring
should be considered as a form of intensified follow-
up, especially in cases where an advisory mandates
careful follow-up. Remote reprogramming of a pace-
maker is not available. Medicare guidelines have
also been published for this form of follow-up.
General approach
There is usually more than one correct way to evalu-
ate and program a pacemaker for each patient. Using
a systematic approach assures that no step is for-
gotten and no test unwittingly omitted. At the first
visit, one examines the pacemaker and lead inser-
tion sites for hematoma, seroma, increased warmth,
or erythema for possible early infection.
In patients with recently or chronically implanted
devices, arm swelling on the site of insertion or the
presence of excessive superficial venous collaterals
may indicate large vein thrombosis and the possible
need for anticoagulation or thrombolytic therapy.
The minimum evaluation includes measurement
of battery voltage, pacing threshold, impedance, and
sensing functions. The degree of pacemaker depen-
dence should be estimated. The session starts with
device interrogation with a programmer wand or by
wireless. Measured and diagnostic data are then ex-
amined. These capabilities include such features as
real-time pacing, lead impedance, battery-life indi-
cators, amplitudes of the atrial and ventricular sig-
nals, and real-time and stored ventricular EGMs.
Lead dislodgment usually occurs in the first days
after implantation, and may occur up to 3 months
after initial implantation. RV lead dislodgment oc-
curs in 1–2% of cases. Lead displacement may be
due to improper initial lead positioning, poor lead
fixation, or excessive arm–shoulder motions soon
after surgery. Dislodgment of the lead may cause
loss of capture and undersensing. The diagnosis is
confirmed by device interrogation showing changes
in the sensing and pacing thresholds compared to
implantation data, and the relatively long record of
periodic automatic threshold measurements by the
device itself. A chest x-ray confirms the diagnosis.
Immediate lead repositioning is mandatory.
Real-time EGMs are recorded simultaneously
with the surface ECGs, and annotated markers pro-
vide valuable information. The marker channel de-
picts how the device actually interprets cardiac
activity. Annotations used by the marker channel
vary according to the manufacturer, but there usu-
ally exists a legend key or description on the pro-
grammer screen or in the accompanying product
manual.
Stored EGMs are recordings frozen in time and
stored in the device memory for subsequent retrieval
and analysis. The pacemaker records these electro-
grams automatically after a specific triggered event,
typically arrhythmia detection, diagnosis, and out-
come of therapy. A programmable pre-trigger in-
terval immediately precedes the trigger; the longer
the pre-trigger interval, the greater the likelihood of
recording the initiating event of the tachyarrhyth-
mia. The “pre-trigger” interval is programmable.
Pacemakers possess a limited storage capacity, and
a strategy of overwriting the oldest information
means that only the most recent data may be re-
trievable (first in, first out). Obviously, with a finite
memory capacity, single-channel EGM recording
can store more episodes than dual-channel record-
ings that consume more memory. Representative
strips of important stored electrograms should be
printed and inserted into the patient’s chart or elec-
tronic record.
Follow-up of lead impedance
The leads are the weakest part of the pacemaker
system, and the mechanical stresses are responsible
for fracture and insulation problems. The major lead
complications include (in decreasing frequency) in-
sulation defects, lead fractures, loss of ventricular
capture, abnormal lead impedance, and sensing fail-
ure.
Lead impedance tends to fall in the first 2 weeks
after implantation but then reaches a plateau and re-
mains relatively stable at approximately 15% higher
than the implantation value. Pacemakers automat-
ically track the impedance over time by making
periodic measurements. The trend data can be re-
trieved by standard pacemaker interrogation. How-
ever, such a change in an asymptomatic patient war-
rants closer follow-up.
The ventricular lead is evaluated for pacing
impedance, R-wave amplitude, and pacing thresh-
old, together with real-time recordings of the ven-
tricular EGMs. The measured pacing impedance is
compared to the chronic baseline value. Decreases of
30% or more or pacing impedances below 200–250 
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may be indicative of insulation failure. Sudden and
significant increases in pacing impedance may be
indicative of conductor fracture. The atrial lead is
evaluated in the same way.
Always print out the diagnostic data before pro-
gramming. The therapy summary outlines the ar-
rhythmic episodes since the last visit, and how the
pacemaker interpreted them. These counters should
be cleared after each visit to avoid confusion in the
future. Diagnostic data offer invaluable information
regarding the functional status of the device and
leads. The device itself determines atrial and ventric-
ular sensing data and lead impedances at regular in-
tervals. The programmer measures the amplitude of
the atrial and ventricular EGMs (as seen by the pace-
maker) periodically and stores the values obtained
automatically. Alternatively, one can determine the
signals directly from the telemetered EGM by mea-
suring from the upper peak to the lower peak. Signif-
icantly abnormal measurements of predetermined
ranges, or deviations from previous measurements,
are usually highlighted on the programmer upon
interrogation of the device
Event counters
A heart-rate histogram shows the distribution of all
recorded paced and sensed events by rate and other
rate-related information recorded since the last pa-
tient session. Each bar represents the percentage of
time the intrinsic or paced rate fell within a spe-
cific rate range. Each bar is divided into segments,
which indicate the portion that was paced or sensed.
Histograms are useful to evaluate the programmed
sensor response by examining the breakdown of the
heart rates into ranges. Careful analysis should en-
able an assessment of the appropriateness of the
current rate sensor settings. If the sensor parame-
ter is programmed “on” or “passive,” a bar graph
displays the percentage of paced events that would
result if the rate were determined exclusively by re-
sponse to the activity sensor (100% paced). Inter-
mittent atrial fibrillation should be suspected if the
atrial histogram shows a high rate event. If the spon-
taneous heart rate exceeds the sensor-indicated rate
with inhibition of the pacemaker, the histogram will
underestimate the actual heart rate.
Counter information will also indicate the
number of atrial and ventricular extrasystoles,
atrial/ventricular tachycardias, and will also indi-
cate and display the number of times certain algo-
rithms are activated – for example, mode switch, rate
drop response, etc.
Like the rate histogram, the AV conduction his-
togram indicates the percentage of the total number
of heart beats counted since the last patient session.
It can also be displayed in rate groups. The AV con-
duction sequence categories are as follows:
AS − VS : atrial sense − ventricular sense
AS − VP : atrial sense − ventricular pace
AP − VS : atrial pace − ventricular sense
AP − VP : atrial pace − ventricular pace
The interpretation of many events requires knowl-
edge of the integrity of pacing and sensing within
the system. Many systems also report the number
of ventricular premature complexes. Not all VPCs
indicated by the pacemaker represent true VPCs,
because a pacemaker-defined VPC is a sensed ven-
tricular event that is not preceded by a detected
atrial event. Atrial undersensing may falsely indi-
cate a high percentage of VPCs. Loss of atrial or
ventricular pacing cannot be determined by these
recorded events. Histograms may enhance the pro-
grammability of the AV interval. The degree of
ventricular pacing has become important to pre-
vent LV dysfunction. It is estimated from the event
histograms that record the cardiac activity. The
data may lead to reprogramming to minimize RV
pacing.
The pacemaker as an implantable
Holter system: electrogram storage
It is questionable whether marker annotations alone
stored in pacemaker memory are useful in assessing
the number and duration of arrhythmic episodes.
The development of electrogram storage and re-
trieval by pacemakers has added a new dimension
to the diagnosis of spontaneous arrhythmias and
device malfunction. Pacemakers store the data ei-
ther automatically according to a detection algo-
rithm or by a patient-activated system whenever a
symptomatic patient applies a magnet or a special
activator over the device. Annotated high-quality
EGMs allow reliable assessment of stored episodes
by visual inspection in practically 100% of cases. The
final diagnosis of the retrieved data scrutinized by
the physician may, of course, differ from the auto-
matic interpretation by the detection algorithm of
the device.
The EGM must be sampled at twice the minimal
frequency component to register all the information
contained in it. Sampling at 256 samples/second
allows good reproduction, and a minimum rate of
128 samples/second is necessary to achieve a suffi-
ciently diagnostic EGM quality. One byte of memory
is generally required for each sample. Assuming a
pacemaker with 8 kB of memory dedicated to EGM
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Function Purpose Details
Noncompetitive atrial
pacing (NCAP)
(Medtronic)
Intended to prevent
initiation of atrial
tachyarrhythmias by atrial
stimulation in the relative
refractory period of the
atrial myocardium
An atrial event sensed in the unblanked
PVARP starts a 300 ms NCAP interval, at
the end of which the pacemaker emits an
atrial stimulus. The resultant timing
intervals may be altered
Autointrinsic
conduction search (St.
Jude); AV search
hysteresis (Boston
Scientific); search
AV+ (Medtronic)
Determines the time the
device periodically extends
the paced/sensed AV delay
to search for intrinsic
conduction
The algorithm extends the paced/sensed
AV delay periodically
Ventricular intrinsic
preference (VIP) (St.
Jude)
Upgraded autointrinsic
conduction search, as
above
As above
Sleep function Intended to slow the
pacing rate during sleep
Manual programming of sleep times or
automatic detection of sleep by sensor
activity
Rate smoothing
(Boston Scientific)
Programmable feature
designed to prevent
sudden large changes in
pacing cycle-to-cycle
intervals
Prevents the pacing rate from changing
by more than a programmable
percentage from one cycle to the next.
The pacemaker stores in memory the
most recent R–R interval, either intrinsic
or paced. Based on this R–R interval, and
the rate smoothing value or percentage,
the device determines the duration of the
next pacing cycle involving atrium and
ventricle
Ventricular rate
stabilization (VRS)
(Medtronic)
When VRS is enabled, it
acts as a constant
rate-smoothing algorithm.
The VRS operates when the
rate that corresponds to the
R–R median interval (of the
last 12 measured
ventricular intervals) is less
than or equal to a fixed rate
of 85 bpm. It is intended as
a response to VPCs
On each ventricular event, the device
calculates a new ventricular interval as
the sum of the previous ventricular
interval plus the programmed interval
increment value for VRS (or a
predetermined minimum interval, if it is
larger than this sum). This minimum
interval is determined from the
programmed maximum rate for VRS
Rate drop hysteresis
(Medtronic); sudden
Brady response
(Boston Scientific)
Treatment of vasovagal
syncope. Response to
sudden decrease in
intrinsic atrial rate by
applying dual chamber
pacing at an elevated rate
A programmable feature of some
dual-pacemaker generators. Automatic
acceleration of dual chamber pacing rate
(e.g., to 100 ppm) for up to several
minutes after detection of a sudden fall in
intrinsic heart rate
continued
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Function Purpose Details
Algorithms to prevent
atrial fibrillation
Algorithms incorporated in
antibradycardia
pacemakers to control the
atrial pacing rate or
duration of atrial pacing
cycles
Dynamic atrial overdrive pacing at a rate
slightly faster than basic sinus rhythm,
which results in an increase in pacing
time and creates a consistent atrial
activation sequence in the presence of an
“irritable” atrium. Response to atrial
premature complex (APC): (1) post-APC
response to prevent short–long
sequences (a form of rate smoothing); (2)
APC suppression by increasing the basal
pacing rate to suppress APCs.
Post-exercise rate control to prevent
abrupt drop in rate after exercise.
Transient overdrive pacing after a
mode-switch episode
Sinus preference
(Medtronic)
Search function whereby
the pacemaker looks for a
sinus rate slightly below
the sensor-indicated rate
Promotes sinus tracking (AV
synchronization with an intrinsic P
wave) within a programmable rate zone
below the sensor-indicated rate
Sensing assurance
(Medtronic);
autosense (Boston
Scientific)
Automatically adjusts atrial
and ventricular sensitivities
within defined limits
The pacemaker monitors the peak
amplitude of sensed signals. The
pacemaker automatically increases or
decreases sensitivity to maintain an
adequate sensing margin with respect to
the patient’s sensed P and R waves.
Conducted AF
response (Medtronic);
ventricular rate
regularization (Boston
Scientific)
Ventricular response
pacing is designed to
regularize the ventricular
rate in patients with an
irregular ventricular
response during AF. A
variant of rate-smoothing.
The pacing rate is modified on a
beat-to-beat basis to pace at or just above
the mean intrinsic ventricular rate. Long
pauses and shorter cycles are suppressed,
thereby reducing the ventricular rate
irregularity
Sudden Brady
response (Boston
Scientific)
Designed to respond to
sudden decreases in
intrinsic atrial rates by
applying dual chamber
pacing at an elevated
pacing rate
Sensing integrity
counter (Medtronic)
Diagnostic counter that
stores the number of short
unphysiologic ventricular
intervals recorded between
patient sessions
A large number of short intervals may
indicate that the ventricular sensing lead
is damaged and creates false signals. It
may also indicate oversensing, a loose
set-screw or VPCs
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Function Purpose Details
Safety switch
automatic lead
configuration (Boston
Scientific); lead
monitor (Medtronic)
The safety switch feature
allows the pacemaker to
monitor lead integrity and
to switch the pacing and
sensing configuration from
bipolar to unipolar if the
impedance criteria indicate
unacceptably high or low
lead impedances. If very
high-impedance leads are
being used, this function
should be turned off
The pacemaker monitors lead impedance
during paced events. If the measured
impedance falls outside a certain range
(such as 200–2500 ) for any daily
measurement, both pacing and sensing
bipolar configurations will automatically
be switched permanently to unipolar for
that chamber
MRI-safe pacemaker Specially designed for
protection against MRI.
About 50% of pacemaker
patients eventually need an
MRI
A number of circumstances must be
addressed before programming the
MRI-safe function
recording, and a sampling rate of 128 samples/
second, the duration of (uncompressed) single-
channel EGM recording is 8 kB × 1024 bytes/kB
divided by 128 bytes/second, which is equal to
64 seconds. Compression algorithms can increase
this duration further, because repeated sequences
such as the baseline can be stored using far less
memory. Thus the 64 seconds in the previous
example can be expanded to 320 seconds with 5 : 1
average compression, yielding 320 seconds of EGM
storage.
Pacemaker technology can now store electro-
grams with the following features:
1. Separate channels for atrial and ventricular
EGMs of sufficient resolution and duration.
2. Onset and termination data: a programmable
number of cardiac cycles before arrhythmia on-
set (“pre-trigger EGM”) and some cycles after ar-
rhythmia termination.
3. Simultaneous annotated markers are essential.
Marker annotations and intervals may facilitate
understanding of why and how the pacemaker
detected and classified an event. An additional
marker annotation (e.g., arrow, line) should indi-
cate the exact moment when arrhythmia detec-
tion criteria are fulfilled.
The memory capability improves our understand-
ing of a variety of electrophysiologic mecha-
nisms that will enhance the diagnosis and treat-
ment of atrial and ventricular tachyarrhythmias.
The memory function will be especially useful
to optimize programming of increasingly complex
devices.
Most pacemakers can be programmed to record
certain events such as high-rate atrial and ven-
tricular events with stored electrograms, and to
store other situations provided the device memory
has not been fully utilized. The occurrence of
abnormalities is recorded for retrieval even in the
absence of electrograms. Stored episodes > 220
complexes per minute and > 5 minutes in duration
have a high correlation with atrial fibrillation (AF)
and flutter. Multiple episodes of AF with prolonged
duration or rapid ventricular response may require
anticoagulation and rate control. There is emerging
evidence that strokes can be prevented by the early
diagnosis and treatment of paroxysmal AF based on
remote pacemaker monitoring. Atrial tachyarrhyth-
mias (AT) are common in the general pacemaker
population. Patients with prior history of AT show
a higher arrhythmia burden, but the subsequent
incidence is quite considerable even in those
patients without any history of atrial arrhythmias.
The majority of ATs in this patient population are
asymptomatic, and symptoms do not correspond
to an actual arrhythmic episode in most patients.
Episodes of possible ventricular tachycardia can
also be documented. Stored electrograms can reveal
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sensing problems, and other situations according
to the manufacturer. These data contribute to
optimal device programming and patient man-
agement. Triggers that activate the recording of
representative electrograms include automatic
mode switching, high atrial rates, high ventricular
rates, ventricular premature beats under certain
circumstances, pacemaker-mediated tachycardia,
and magnet placement. Finally, stored electrograms
may also help in defining whether the symptoms
experienced by pacemaker patients are due to
arrhythmias.
Special functions of pacemakers
Contemporary pacemakers are sophisticated de-
vices with a multiplicity of functions, many of which
are manufacturer-specific (Table 23). One must be-
come familiar with these device refinements and ap-
ply them cautiously to pacemaker patients, and one
must understand their behavior for troubleshooting
what appears to be erratic pacemaker behavior or
malfunction in the setting of manifestations accord-
ing to pacemaker design.
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Cardiac resynchronization
hemodynamics
Dual-site or biventricular (RV and LV) pacing has
emerged as an effective therapy for patients with
dilated cardiomyopathy (severe systolic left ven-
tricular dysfunction on the basis of ischemic or
non-ischemic etiology) and congestive heart failure
(CHF) associated with NYHA class III or IV symp-
toms and major left-sided intraventricular conduc-
tion delay such as left bundle branch block. The
intraventricular conduction disorder causes an inef-
ficient dyssynchronous or uncoordinated pattern of
LV activation with segments contracting at different
times. The erratic LV contraction causes a shorter di-
astole and/or overlapping systole/diastole with ag-
gravation of functional mitral regurgitation. Biven-
tricular pacing works by reducing the degree of
electromechanical disparity. LV dyssynchrony typ-
ically arises from electrical delay resulting in me-
chanical delay between the septal and lateral walls.
Thus the improved sequence of electrical activation
(a process known as resynchronization) translates
into beneficial acute and long-term hemodynamic
effects by virtue of a more coordinated and effi-
cient LV contraction associated with a reduction of
functional mitral regurgitation. The target sites for
LV pacing consist of the lateral and posterolateral
coronary veins. There are virtually no data about
the role of right ventricular outflow tract pacing as
opposed to RV apical pacing during cardiac resyn-
chronization therapy (CRT). The hemodynamic ben-
efit of CRT occurs virtually with an on/off effect
(with additional long-term reverse remodeling of
the LV) and stems primarily from ventricular re-
coordination rather than optimization of the AV
delay.
Patients for CRT are selected primarily on electro-
cardiographic criteria. However, the severity of LV
mechanical systolic dyssynchrony is a much better
predictor of a CRT response. Echocardiography has
provided direct evidence of wall motion resynchro-
nization in patients receiving CRT. In many stud-
ies the presence of ventricular dyssynchrony de-
fined by various echocardiographic measurements
appears to predict response to CRT, with the extent
of improvement in the systolic function related to
the degree of ventricular dyssynchrony. Although
many workers have searched for the best echocar-
diographic index to identify LV dyssynchrony so as
to predict responders to CRT before device implan-
tation, this issue is still debatable. For this reason the
American and European guidelines for CRT do not
require echocardiographic proof of mechanical LV
dyssynchrony.
Enrollment in most of the major CRT trials in-
cluded: (1) CHF in NYHA functional class III or IV
despite optimal pharmacologic therapy, (2) LVEF <
35%, (3) LV end-diastolic diameter > 55 mm, and (4)
QRS duration >120 or specifically < 150 ms. Many of
the trials have shown benefit in patients with a QRS
≥ 120 ms. The American guidelines for biventricu-
lar pacing include medically refractory symptomatic
NYHA class III or IV patients with idiopathic dilated
or ischemic cardiomyopathy. The European guide-
lines are similar except that they require evidence
of LV dilatation. Many CRT patients (almost all in
the United States) also receive an ICD (CRT-D) de-
vice. The European guidelines (2007) recommend
that the use of CRT without an ICD should be based
on (1) the patient’s expectation of survival less than
1 year, and (2) healthcare logistical constraints and
cost considerations.
CRT with only left ventricular pacing
Initial investigations with monochamber LV pacing
revealed similar hemodynamic benefit using either
LV or biventricular pacing during acute CRT stud-
ies, and in some instances LV stimulation had even
a greater positive hemodynamic effect than biven-
tricular pacing. A prospective, multicenter, random-
ized, single-blind, parallel, controlled trial compar-
ing biventricular versus monochamber LV pacing
demonstrated that LV pacing alone resulted in a sig-
nificant improvement of LV ejection fraction (LVEF),
which was comparable in magnitude to the im-
provement in the biventricular group. Mortality
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and morbidity were also comparable in the two
groups.
Indications for CRT with only left
ventricular pacing
Proponents of single-lead LV pacing for CRT argue
that the implantation technique is less challenging
and less costly. In this respect the expanding use of
the ICD in CRT patients for primary prevention of
sudden death limits the applicability of monocham-
ber LV pacing. Possible areas of clinical applicability
might include CHF patients with important comor-
bidities associated with a dismal long-term prog-
nosis. Thus the role for single-lead LV pacing is
presently quite small. Single-lead LV pacing with-
out an ICD may become important in the future if it
is shown that primary prevention of LV dysfunction
or heart failure with CRT is worthwhile in selected
patients with LVEF > 35%.
Advantages of a right ventricular lead
for CRT
Although RV pacing is not required for hemody-
namic benefit in most CRT patients, the addition of
an RV lead offers important advantages:
1. Many patients (almost all in the United States)
receive an CRT-D device.
2. Programmability of the interventricular (V–V) in-
terval between LV and RV stimulation may im-
prove hemodynamics.
3. Sensing from only an LV lead runs the risk of left
atrial sensing in case of lead displacement toward
the left atrium. This may cause ventricular inhi-
bition or inappropriate ICD discharge if there is
an ICD in place.
4. Antitachycardia pacing (ATP) may be more effec-
tive with RV + LV ATP (with ICD) than physician-
supervised LV ATP (with no ICD), because ven-
tricular arrhythmias in patients with ischemic
cardiomyopathy tend to originate from the sep-
tum.
5. Patients requiring antibradycardia pacing are
best served with a biventricular system, because
the dislodgment rate of LV leads is much higher
than those of RV leads.
6. Theoretically, biventricular pacing may be less
proarrhythmic than LV pacing alone, because it
is associated with less temporal dispersion of re-
polarization. Finally, it is important to remember
that turning off RV pacing may help a few pa-
tients refractory to biventricular pacing and those
with marked latency of LV stimulation where
V–V programmability cannot advance the LV
output sufficiently ahead of the RV output.
NYHA class I and II patients with
LBBB and depressed LV function
Recent studies in NYHA class I and II patients with
QRS ≥ 120 ms and LVEF ≤ 35% have shown that
CRT produces definite long-term improvement of
LV function in the setting of minimal or no symp-
tomatic changes. The REVERSE (Resynchronization
Reverses Remodeling in Systolic Left Ventricular
Dysfunction) trial involved asymptomatic or mildly
symptomatic patients with QRS ≥ 120 ms and LVEF
≤ 40% for 24 months. Mean baseline LVEF was
28.0%. After 24 months of CRT, and compared with
those of control subjects, clinical outcomes and LV
function were improved and LV dimensions were
decreased in this patient population. These obser-
vations suggest that CRT prevents the progression
of disease in patients with asymptomatic or mildly
symptomatic LV dysfunction. The MADIT III study
involved patients with LVEF ≤ 30%, QRS ≥130 ms,
and NYHA class I or II symptoms, but there was no
change in mortality. CRT was associated with a sig-
nificant reduction in LV volumes and improvement
in the LVEF. CRT combined with ICD decreased
the risk of heart-failure events. These findings may
eventually find their way into the official guide-
lines.
Right bundle branch block
The incidence of LV dyssynchrony is much less in
patients with RBBB than in those with an LBBB
type of conduction disorder. CRT in patients with
RBBB has generally been disappointing, although
a few patients may improve. Some experts be-
lieve that CRT should not be used in patients with
RBBB. If CRT is being considered in RBBB, signif-
icant LV dyssynchrony must be established before
proceeding.
CRT in patients with a narrow
QRS complex
Small non-controlled studies have demonstrated
that heart-failure patients with a narrow QRS
(< 120 ms) and evidence of LV dyssynchrony may
benefit from CRT. Yet a recent trial showed no bene-
fit. Despite the growing body of evidence suggesting
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that echocardiographic criteria may be reliable for
the evaluation of mechanical LV dyssynchrony, CRT
remains controversial in patients with a narrow QRS
complex and is generally not recommended.
Impact of CRT
The improved sequence of electrical activation with
CRT, which has no positive inotropic effect as such,
improves cardiac efficiency by restoring the near-
normal LV contraction pattern. This translates into
beneficial acute and long-term hemodynamic effects
by virtue of a more coordinated and efficient LV
contraction and function. Long-term hemodynamic
improvement by reverse LV remodeling causes an
increase in LVEF (usually up to 6% in randomized
trials) and a decrease in LV systolic and diastolic vol-
umes. These changes occur progressively and may
take 3–6 months or longer (> 1 year) to become es-
tablished. CRT also reduces functional mitral regur-
gitation, with both an acute effect and further im-
provement on a long-term basis by superimposed
LV reverse remodeling. Cardiac output increases,
while LV filling pressure decreases without increas-
ing myocardial oxygen consumption.
CRT improves NYHA functional class (0.5–0.8 in
randomized trials), exercise tolerance (20% mean
increase in distance walked in 6 minutes in ran-
domized trials), quality of life, and morbidity. Long-
term reverse remodeling of the failing LV results
in reductions in CHF hospitalizations and mortal-
ity, independent of defibrillator therapy, when com-
bined with optimal pharmacotherapy. There is also
a reduction of sympathetic/parasympathetic imbal-
ance, attenuating the chronic sympathetic activation
of heart failure and of neurohumoral activation due
to increased systolic blood pressure and improved
LV filling time. The benefits of CRT are similar in
magnitude to those of ACE inhibitors and beta-
blockers, and are superimposed on the benefits of
medical therapy. Despite the presence of LV reverse
remodeling, interruption of CRT results in worsen-
ing of LV function and desynchronization.
Upgrading to a biventricular system in patients
with advanced heart failure and continuous RV pac-
ing results in significant reverse LV remodeling in
the long-term follow-up, and improvement in over-
all synchronicity of LV function. The long-term risk
of mortality and morbidity is similar to that in pa-
tients undergoing de novo CRT. Symptomatic im-
provements and degree of reverse remodeling are
also comparable.
Percentage of biventricular pacing
One must ensure that biventricular pacing takes
place 100% of the time. The percentage of biventricu-
lar pacing and ventricular sensing must be carefully
checked in the stored memorized data retrieved
from the device. Remote home monitoring is par-
ticularly helpful for this assessment. Devices must
be programmed carefully to prevent “electrical”
desynchronization. Troubleshooting loss of resyn-
chronization may be difficult, and requires a thor-
ough knowledge of biventricular pacemaker func-
tion, timing cycles, and complex algorithms.
Failure of CRT benefit
The transvenous implantation success rate is about
90–95%. About 30% of patients do not respond to
CRT. A number of factors may be responsible for
this failure. The two major causes are placement
of LV lead at a suboptimal location and the lim-
itation of ECG-based patient selection criteria. In
about one-third of heart-failure patients with LBBB
or left-sided intraventricular conduction delay, ECG
patterns are not associated with significant LV me-
chanical dyssynchrony. This observation correlates
with the incidence of the non-responder rate in clin-
ical trials of CRT. Since retiming to recoordinate LV
contraction is the primary goal of CRT, it is therefore
unlikely, but not impossible, that CRT will benefit
patients with wide QRS complexes in the absence of
mechanical dyssynchrony. Echocardiography with
tissue Doppler imaging (TDI) can detect the direc-
tion and velocity of the contracting or relaxing my-
ocardium. TDI is a reproducible technique to detect
regional myocardial function and timing of events
by measuring the time to peak systolic velocity dur-
ing ejection phase in several myocardial segments.
TDI is emerging as a useful tool to improve the se-
lection of patients for CRT.
Recent investigations (contrary to popular belief)
suggest that in some patients an LV lead positioned
in an anterior rather than a lateral or posterior LV
location may not necessarily produce harmful or no
effect. Hemodynamic measurement would be in or-
der before considering lead revision.
Scar burden
Lack of adequate capture threshold and failure of
response to CRT (in the presence of LV dyssyn-
chrony) may be related to the presence of extensive
scar tissue in the target region for LV pacing. There-
fore, in patients with ischemic cardiomyopathy and
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history of previous infarction, the extent of scar tis-
sue should be assessed before CRT implantation.
Alternative routes to left ventricular
pacing
Constraints of coronary venous anatomy, diaphrag-
matic stimulation, and late LV lead dislodgements
require alternative routes for LV pacing. Surgical
techniques include minimally invasive surgical ap-
proaches (minithoracotomy, video-assisted thoraco-
scopic surgery, and robotically assisted placement of
LV leads), and minimally invasive subxiphoid epi-
cardial approach.
Only a few patients have received an endocar-
dial LV lead for CRT implanted via a transseptal ap-
proach. LV endocardial pacing in a biventricular sys-
tem provides more homogeneous intraventricular
resynchronization and better hemodynamic perfor-
mance than epicardial biventricular pacing (through
the coronary venous system). The risks and bene-
fits of this approach are unclear in view of insuf-
ficient experience. Major concerns include throm-
boembolism and mitral valve disruption.
Bifocal RV pacing consists of implantation of two
RV leads: one placed at the RV apex, and the other
in the RV outflow tract. This approach has been
used when LV implantation is unsuccessful. It pro-
duces CRT of a lesser degree than biventricular pac-
ing. Bifocal RV pacing must not be the first line of
therapy, and should not be a substitute for cardiac
surgery when LV pacing cannot be accomplished for
technical reasons, except in patients who might not
tolerate, or who refuse, a thoracotomy for LV lead
placement.
Triventricular pacing (two leads in the RV and one
in the LV) may produce important hemodynamic
improvement in initial responders to biventricular
pacing who eventually develop heart failure on a
long-term basis. The question arises as to whether
triangular ventricular pacing (a combination of bi-
focal RV pacing with LV pacing) might eventually
prove more useful than regular biventricular pacing
for primary CRT, rather than being presently consid-
ered a bail-out procedure. In contrast, systems with
two LV leads and one RV lead do not appear useful.
What is a CRT responder?
There is no standardized definition of when a patient
should be considered a non-responder. There is no
consensus on whether indices of LV reverse remod-
eling or clinical status should be used as end points
for assessing CRT response. This is compounded by
the observations that CRT recipients may have clin-
ical improvement without echocardiographic im-
provement and vice versa. Improvement in NYHA
functional class or increased distance walked in
6 minutes, or improved heart-failure-related qual-
ity of life is considered by some workers as an ad-
equate response, but these parameters may be in-
fluenced by spontaneous changes and/or a placebo
effect. Others would consider an adequate response
in terms of changes in oxygen uptake at anaerobic
threshold during exercise or reduction of LV systolic
and diastolic volumes along with improvement in
NYHA functional class. Improved systolic function
is assessed by the LVEF and LV end-systolic volume
(LVESV), which are commonly used parameters of
LV reverse remodeling. A change in LVESV (reduc-
tion of LVESV > 15%) after 6 months is the single best
predictor of a good long-term prognosis, with lower
long-term mortality and heart-failure events, and it
is theoretically less subject to placebo effect. Some
patients who have no or minimal acute changes in
any assessment modality may show gradual and
delayed improvement after a few months. As a rule,
patients without reverse remodeling are more symp-
tomatic, and there is clear evidence that reverse
remodeling translates into reduced morbidity and
mortality.
Complications of CRT implantation
Left ventricular lead dislodgment. The dislodg-
ment rate for LV leads is higher (2–5%) than that
for atrial or RV leads, and it tends to occur soon
after implantation. Micro-dislodgment may cause
a high pacing threshold.
Coronary venous lead complications. The inci-
dence of short-term complications (displacement,
high threshold, phrenic nerve stimulation) is
about 5%. At 1 year another 5% of leads malfunc-
tion. Lead failure after 1 year is rare. The pacing
threshold, R-wave amplitude from LV lead, and
impedance do not change significantly on a long-
term basis to produce a clinical problem.
Infection. The infection rate with a primary implan-
tation should be 0.5–1%, but a long procedure for
CRT increases the risk.
Coronary sinus dissection and perforation. Coro-
nary sinus (CS) dissection may be caused by too
vigorous advancement of the guiding catheter or
by injection of the contrast medium through an
angiography catheter with its tip pressed against
the vessel wall. The incidence of coronary sinus
dissection is 2–5%. CS dissection usually heals
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well, and CS perforation is rare. Some workers
believe that lead placement should be abandoned
if the dissection is distal in the coronary sinus,
and implantation of the LV lead performed several
weeks later. A lead can usually be passed through
a proximal coronary sinus dissection by finding
the true lumen of the coronary sinus for satisfac-
tory passage of the LV lead. With a dissection, an
echocardiogram should be performed to rule out
a pericardial effusion.
Phrenic nerve stimulation and diaphragmatic pa-
cing. Phrenic nerve stimulation is a common prob-
lem, and can be difficult to demonstrate during
implantation in the sedated and supine patient.
It may become evident only when the patient
becomes active and changes body position. This
complication is related to the anatomic vicinity of
the left phrenic nerve to the LV pacing site, espe-
cially when the LV lead is implanted into a pos-
terior or posterolateral coronary vein. It may also
be related to LV lead dislodgment. Occasionally,
after implantation, phrenic nerve stimulation can
be controlled by lowering the LV voltage (main-
taining capture), provided the capture threshold
for phrenic nerve stimulation is much higher than
that of LV capture. Special programmable options
with bipolar LV leads allow programming of func-
tion in terms of true bipolar LV pacing as well as
using the RV ring as an anode and the LV tip
or ring as the cathode. The latter arrangement is
available if there is an associated ICD. In the ab-
sence of an ICD, true unipolar pacing can also be
performed from one or the other LV electrode to
the device can as the anode. These manipulations
alter the pacing vector non-invasively (electronic
repositioning). This function enables more flexi-
bility to overcome problems with high LV pacing
thresholds and phrenic nerve stimulation.
Impact of comorbidities
After CRT, chronic renal failure, diabetes mellitus,
and a history of atrial fibrillation are strong inde-
pendent predictors of death.
Programming of CRT devices
Some of the CRT failures in randomized trials can be
attributed to improper patient selection, suboptimal
LV lead placement, inadequate medical therapy, and
inappropriate device programming.
General considerations
The 12-lead ECG should be studied before any pro-
gramming activity. The goal of CRT programming
is to ensure ventricular resynchronization virtually
100% of the time and to optimize AV and inter-
ventricular (V–V) timing. As heart-failure patients
represent a heterogeneous group, optimal CRT de-
vice performance can only be achieved by tailored
programming on an individual basis(Table 24). It
is important to evaluate the patient as well as the
device. One should assess the patient’s NYHA func-
tional class, physical activity, current medications,
heart-rate histograms, the percentage of atrial and
ventricular pacing. and special problems such as
phrenic nerve stimulation and any underlying atrial
and ventricular rhythm abnormalities. Testing also
includes evaluation of intrathoracic impedance data
about pulmonary fluid status (in patients with a
CRT-D device), and exercise testing in selected pa-
tients to look for abnormalities such as atrial un-
dersensing or threshold problem not apparent at
rest. CRT programming requires careful attention
to the patient’s hemodynamic problem, knowledge
of CRT device technology, and the electrocardio-
graphic manifestations of normal and abnormal de-
vice function.
Twelve-lead electrocardiography
Basic electrocardiography
A 12-lead ECG is essential for CRT evaluation. A
single-channel rhythm strip from a pacemaker pro-
grammer is inappropriate. During evaluation of
CRT devices the 12-lead ECG yields important in-
formation about the presence or absence of fusion
with the intrinsic conducted QRS complex, the bal-
ance between RV and LV activation, and the pres-
ence of RV anodal capture in patients with unipolar
LV leads. Complete assessment requires comparison
of the QRS morphology during native conduction,
single chamber RV, single chamber LV, and biven-
tricular pacing.
QRS morphology during right ventricular
apical pacing
Pacing from the RV, regardless of site, virtually al-
ways produces a left bundle branch block (LBBB)
pattern in the precordial leads. RV apical pacing
produces negative paced QRS complexes in the in-
ferior leads (II, III, and aVF), because depolarization
begins in the inferior part of the heart and travels
superiorly away from the inferior leads. The mean
paced QRS frontal-plane axis is always superior,
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AV delay 1. A long AV delay should not be used
2. Optimize the AS–VP delay and avoid ventricular fusion with the spontaneous
conducted QRS complex. Promote atrial sensing (VDD mode) because atrial
pacing produces less favorable hemodynamics
3. Consider promoting fusion of LV pacing with RBB activation (short AV delay) on a
trial basis only if the absence of fusion yields suboptimal CRT
4. Program rate-adaptive (dynamic) AV delay off during temporary pacing for
testing (with VDD mode slower than sinus rate to sense atrial activity)
5. Programming rate-adaptive AV delay for long-term pacing is controversial
V–V delay Programming the interventricular delay may be important in patients with a
suboptimal CRT response
Atrial sensing and
PVARP
1. Short PVARP (aim for 250 ms); may have to use algorithms for the automatic
termination of endless loop tachycardia.
2. Program off the post-VPC PVARP extension and the pacemaker-mediated
tachycardia termination algorithm based on one cycle of PVARP extension
3. Automatic mode switching off in devices using a relatively long PVARP mandated
by the mode-switching algorithm
4. Program the PVAB to eliminate far-field R-wave sensing by the atrial channel
Upper rate Relatively fast upper rate so the patient does not have “break- through” ventricular
sensing within their exercise zone. Initial upper rate of 140 ppm or faster is often
appropriate in the absence of myocardial ischemia during pacing at this rate
AV conduction 1. Use drugs that impair AV delay
2. Consider ablation of the AV junction in patients with a long PR interval or intra- or
interatrial conduction in case of difficult management
usually in the left, or less commonly in the right su-
perior quadrant. Pacing from the RV outflow tract
or septum shifts the frontal-plane paced QRS axis
to the inferior quadrant. The inferior leads become
positive.
QRS morphology during left ventricular
pacing from the coronary venous system
Single-site LV pacing from the posterior or postero-
lateral coronary vein (the traditional sites for CRT)
results in a right bundle branch block (RBBB) pat-
tern (dominant R wave) in a correctly positioned
lead V1. Leads V2 and V3 may or may not be posi-
tive. With apical lead position, ECG leads V4–V6 are
typically negative. With basal lead position, ECG
leads V4–V6 are usually positive, as with the concor-
dant positive R waves during overt pre-excitation
in left-sided accessory pathway conduction in the
Wolff–Parkinson–White syndrome. Pacing from the
middle or the great (anterior) cardiac vein (unsatis-
factory sites for CRT) produces an LBBB pattern of
depolarization.
Thus, when lead V1 during LV pacing shows a
negative QRS complex during LV pacing, one should
consider incorrect ECG lead placement, lead loca-
tion in the middle or great (anterior) cardiac vein,
or rarely an undefined mechanism involving a se-
vere intra-myocardial conduction abnormality re-
lated to substantial scarring. The frontal-plane axis
during LV pacing from the lateral and inferolateral
wall often points to the right inferior quadrant (right
axis deviation), less commonly to the right superior
quadrant, and only occasionally the axis may point
to the left inferior or left superior quadrant.
QRS morphology during biventricular pacing
Biventricular pacing with the RV lead located at the
apex. Biventricular pacing often shifts the frontal-
plane vector to the right superior quadrant in
an anticlockwise fashion (as if starting with RV
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apical right ventricular lead.
 Normal situation
 Right ventricular outflow tract and LV pacing
 Incorrect placement of lead V1 (too high on the chest)
 Lack of LV capture
 LV lead displacement
 Marked LV latency (exit block, delay from the LV stimulation site with or without myocardial scar)
 Ventricular fusion with conducted QRS complex
 Pacing via the middle cardiac vein or anterior interventricular vein
 Unintended placement of two leads in the RV
 Reversal of RV and LV connections
pacing), although the frontal-plane axis may oc-
casionally reside in the left superior quadrant dur-
ing uncomplicated biventricular pacing. The QRS
is often positive in lead V1 during biventricular
pacing when the RV is paced from the apex. A
negative QRS complex in lead V1 may occur dur-
ing uncomplicated biventricular pacing with RV
apical pacing, but its presence mandates a thor-
ough investigation to rule out the following situ-
ations: incorrect placement of lead V1 (too high
on the chest), lack of LV capture, LV lead dis-
placement, marked LV latency (exit block), major
conduction delay from a scarred LV stimulation
site, ventricular fusion with the conducted QRS
complex, coronary venous pacing via the middle
cardiac vein (also the anterior cardiac vein), or
even unintended placement of two leads in the
RV (Table 25). A negative QRS complex in lead
V1 during uncomplicated biventricular pacing
probably reflects different activation of a hetero-
geneous biventricular substrate (ischemia, scar,
His–Purkinje participation in view of the varying
patterns of LV activation in spontaneous LBBB,
etc.) and does not necessarily indicate a poor (elec-
trical or mechanical) contribution from LV stimu-
lation.
Biventricular pacing with the RV lead in the out-
flow tract. During biventricular pacing with the
RV lead in the outflow tract, the paced QRS in
lead V1 is often negative, and the frontal-plane
paced QRS axis is often directed to the right infe-
rior quadrant (right axis deviation).
QRS duration
Measurement of QRS duration during follow-up is
helpful in the analysis of appropriate biventricular
capture and the presence of fusion with intrinsic
conduction. Chronic studies have shown that the
degree of narrowing of the paced QRS duration is
a poor predictor of the mechanical CRT response.
In this context, it is interesting that monocham-
ber LV pacing with a paced QRS complex wider
than that of biventricular pacing can produce CRT
virtually as effective as that of biventricular pa-
cing. Loss of capture in one ventricle will cause a
change in the paced QRS morphology and dura-
tion in the 12-lead ECG similar to that of either sin-
gle chamber RV or LV pacing. As the paced QRS
during biventricular pacing is often narrower than
that of monochamber RV or LV pacing, widening
of the paced QRS complex may reflect loss of cap-
ture in one chamber with effectual capture in the
other.
Paced QRS duration and status of mechanical
ventricular resynchronization
The paced QRS during biventricular pacing is of-
ten narrower than that of monochamber RV or LV
pacing. Thus, measurement of QRS duration during
follow-up is helpful in the analysis of appropriate
biventricular capture and fusion with the sponta-
neous QRS. If the biventricular ECG is similar to that
recorded with RV or LV pacing alone and no cause is
found, one should not automatically conclude that
one of the leads does not contribute to biventricular
depolarization without a detailed evaluation of the
pacing system.
Chronic studies have shown that the degree of
narrowing of the paced QRS duration is a poor
predictor of the mechanical cardiac resynchroniza-
tion response. In other words, the degree of QRS
narrowing or its absence does not correlate with
the long-term hemodynamic benefit of biventricu-
lar pacing, because the paced QRS does not reflect
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the underlying level of mechanical dyssynchrony.
In this respect some patients with monochamber
LV pacing exhibit an equal or superior degree of
mechanical resynchronization compared to biven-
tricular pacing despite a very wide paced QRS
complex.
Long-term ECG changes
Many studies have shown that the paced QRS du-
ration does not vary over time as long as the LV
pacing lead does not move from its initial site. Yet
surface ECGs should be performed periodically, be-
cause the LV lead may become displaced into a
collateral branch of the coronary sinus. Dislodge-
ment of the LV lead may result in loss of LV cap-
ture, with the ECG showing an RV-pacing QRS pat-
tern with an increased QRS duration and superior
axis deviation. Variation of QRS duration over time
may play a determinant role if correlated with re-
modeling of the ventricles by echocardiography. Fi-
nally, the underlying spontaneous ECG should be
exposed periodically to confirm the presence of an
LBBB type of intraventricular conduction abnormal-
ity. In this respect, turning off the pacemaker could
potentially improve LV function and heart failure in
patients who have lost their intraventricular conduc-
tion delay or block through ventricular remodeling.
In other words, a spontaneous narrow QRS is better
than biventricular pacing.
Q, q, and QS configuration in lead I
A q wave in lead I is common during uncomplicated
biventricular pacing. A q wave in lead I during un-
complicated RV apical pacing is rare. Loss of the q
wave in lead I during biventricular pacing is 100%
predictive of loss of LV capture. It therefore appears
that analysis of the Q/q wave or a QS complex in
lead I may be a reliable way to assess LV capture
during biventricular pacing.
Ventricular fusion with native conduction
Ventricular fusion with the intrinsic conducted QRS
complex may decrease the effectiveness of CRT in
some patients, while others with a short PR interval
may actually benefit from it. The clinical and hemo-
dynamic impact of fusion in the individual patient
can only be determined by trial and error. The pres-
ence of ventricular fusion should be suspected in
the presence of marked QRS narrowing, especially
in patients with a short spontaneous PR interval. It
should be ruled out by observing the paced QRS
morphology during progressive shortening of the
AS–VP (atrial sensing – ventricular pacing) interval
in the VDD mode or the AP–VP (atrial pacing – ven-
tricular pacing) interval in the DDD mode.
In patients with sinus rhythm and a relatively
short PR interval, ventricular fusion with compet-
ing native conduction during biventricular pacing
may cause misinterpretation of the ECG, and this is
a common pitfall in device follow-up. The AS–VP
interval should be programmed (with rate-adaptive
function) to ensure pure biventricular pacing under
circumstances that might shorten the PR interval,
such as increased circulating catecholamines. It is
important to remember that a very narrow paced
QRS complex may represent ventricular fusion (as-
sociated with a suboptimal hemodynamic response)
with the conducted QRS complex rather than near-
perfect electrical ventricular resynchronization. In
this respect, remarkable narrowing of the paced QRS
complex occurs with triventricular pacing (two RV
sites + LV), as advocated for heart-failure patients
who have become refractory to conventional biven-
tricular pacing.
Upper rate response
Upper rate behavior of CRT devices differs from that
of conventional pacemakers, because the majority
of CRT patients have relatively normal sinus node
function and AV conduction. When the atrial rate
exceeds the programmed upper rate, biventricular
pacemakers exhibit two forms of upper rate behav-
ior according to the location of the P wave in the
pacemaker cycle.
1. Pre-empted Wenckebach upper rate response.
In the setting of a relatively short postventricular
atrial refractory period (PVARP), when the spon-
taneous ventricular cycle shortens beyond the
programmed upper rate interval, the AV inter-
val of each pacemaker cycle becomes partially or
incompletely extended (> programmed AS–VP
interval), creating an attempted Wenckebach type
upper rate response. There are no pacemaker
stimuli because the P wave and the spontaneous
QRS complex are both sensed by the device. This
form of upper rate response, based on a sinus rate
faster than the programmed (atrial-driven) up-
per rate, tends to occur in patients with relatively
normal AV conduction, a short programmed AV
delay, a short PVARP, and a relatively slow pro-
grammed (atrial-driven) upper rate.
2. Upper rate limitation with P wave in the
PVARP. When the P–P interval during biventric-
ular pacing becomes shorter than the total atrial
refractory period (TARP) (in the setting of rela-
tively normal sinus node function), spontaneous
P waves fall into the PVARP, where they can-
not be tracked. The conducted QRS complex (VS)
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linked to the preceding P wave (in the PVARP)
initiates a PVARP that will contain the succeed-
ing P wave. This sequence ensures the perpetu-
ation of functional atrial undersensing with loss
of biventricular pacing. The prevailing AV de-
lay (or the spontaneous PR interval or AR–VS)
is longer than the programmed AS–VP. There are
no pauses and no pacemaker stimuli. This form of
upper response is therefore quite different from
2 : 1 fixed-ratio block produced by conventional
pacemakers, because all the P waves remain in
the PVARP.
Programming the upper rate
Because patients with heart failure are susceptible to
sinus tachycardia (particularly during heart-failure
exacerbation with elevated sympathetic tone), it is
important to program a relatively fast upper rate
to avoid an upper rate response manifested by the
emergence of spontaneous conducted QRS com-
plexes. In patients with normal sinus and AV nodal
function, the risk of tracking rapid atrial rates with a
biventricular device is not an important issue. There-
fore, it is appropriate to program the upper rate to
≥ 140 bpm. If necessary the tendency towards si-
nus tachycardia may be attenuated by larger doses
of beta-blockers, an important consideration in pa-
tients with an ICD and slow ventricular tachycardia
(VT), where the VT detection rate must be faster then
the programmed upper rate.
Loss of resynchronization below the
programmed upper rate, and optimal
programming of PVARP
Desynchronized fast AR–VS sequences containing
trapped or locked P waves within the PVARP can
occur in an upper rate response, but also in some
circumstances below the programmed upper rate.
There are numerous causes of electrical desynchro-
nization at rates slower than the programmed up-
per rate, especially in association with a relatively
long PVARP (Table 26). For example, during sinus
Table 26. Loss of cardiac resynchronization during DDD or DDDR pacing in the
presence of preserved biventricular pacing.
(A) Intrinsic 1. Atrial undersensing from low-amplitude atrial potentials
2. T-wave oversensing and other types of ventricular oversensing, such as
diaphragmatic potentials.
3. Long PR interval
4. Circumstances that push the P wave into the PVARP, such as a junctional or
idioventricular rhythm.
5. New arrhythmia, such as atrial fibrillation with a fast ventricular rate
6. Short runs of unsustained, often relatively slow, ventricular tachycardia; such
arrhythmias are common and often asymptomatic
7. First-generation devices with a common sensing channel: ventricular double
counting and sensing of far-field atrial activity
(B) Extrinsic 1. Inappropriate programming of the AV delay or any function that prolongs the AV
delay, such as rate smoothing, AV search hysteresis, etc.
2. Low maximum tracking rate
3. Slowing of the atrial rate upon exit from upper rate behavior
4. Functional atrial undersensing below the programmed upper rate: (a) precipitated
by an atrial premature beat or ventricular premature beat; (b) long PVARP
including automatic PVARP extension after a VPC and single beat PVARP
extension, related to algorithms for automatic termination of endless loop
tachycardia
5. Inappropriately slow programmed lower rate permitting junctional escape (cycle
length < lower rate interval) in patients with periodic sinus arrest
6. Intra-atrial conduction delay where sensing of AS is delayed in the right atrial
appendage: a short AS–VP interval may not be able to achieve biventricular pacing
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rhythm (below the upper rate), a sensed ventricular
premature complex (or an oversensed T wave) ini-
tiates a regular PVARP. This event shifts pacemaker
timing so that the succeeding undisturbed sinus P
wave now falls into the PVARP. This refractory-
sensed P wave inside the PVARP conducts to the
ventricle, producing a spontaneous QRS complex
sensed by the device. The sinus P waves will re-
main trapped in the PVARP as long as the P–P in-
terval is shorter than the prevailing TARP (equal
to (AR–VS) + PVARP). Hence, biventricular pacing
will remain inhibited until either the occurrence of
a non-refractory sensed atrial depolarization (when
the P–P intervals becomes longer than the prevailing
TARP) or delivery of an atrial pacing pulse outside
the TARP.
Similarly, when a fast atrial rate (above the pro-
grammed upper rate) gradually drops below the
programmed upper rate, biventricular pacing will
remain inhibited for some time according to the
above prevailing TARP formula. Based on these con-
siderations, one should program a short PVARP of
250 ms or less. The PVARP extension after a ven-
tricular premature complex should be turned off,
as well as the pacemaker-mediated tachycardia ter-
mination algorithm based on PVARP prolongation
for one cycle. A short PVARP is safe because end-
less loop tachycardia is rare in CRT patients without
conduction system disease, apart from LBBB or its
equivalent.
Some devices provide a programmable option to
record ventricular sensing episodes. Such record-
ings are useful in reprogramming CRT devices.
Many such episodes are due to AF or unsustained
slow VT. The latter is very common and often of
no important clinical significance. These ventricu-
lar sensing recordings may provide a clue to the
mechanism of electrical desynchronization, such as
an unsuspected upper rate response requiring re-
programming of the upper rate to a faster value.
Programming automatic unlocking of P waves
from the PVARP
Locking of the P wave in the PVARP is facilitated by
a long spontaneous PR interval, a long PVARP, and
a relatively slow programmed upper rate. Special
algorithms can be programmed to restore 1 : 1 atrial
tracking when P waves are locked in the PVARP
at rates slower than the programmed upper rate. A
device can detect AR–VS sequences, a situation in-
terpreted as electrical ventricular desynchronization
whereupon temporary PVARP abbreviation (for one
cycle) permits the device to sense a sinus P wave be-
yond the PVARP. This promotes atrial tracking and
ventricular resynchronization. These algorithms do
not function when the atrial rate is faster than the
programmed upper rate, or during automatic mode
switching. These algorithms are particularly useful
in patients with sinus tachycardia and first-degree
AV block, in whom prolonged locking of P waves
inside the PVARP can be an important problem.
Programming the lower rate
The optimal lower rate in CRT patients is unknown
and may exhibit great variability according to the
presence and severity of heart failure. One should
always aim for atrial sensing, which is hemody-
namically more favorable than atrial pacing. There
is evidence that atrial pacing may increase the risk
of AF. Thus, the lower rate should be programmed
to maintain sinus rhythm. In the occasional patient
an accelerated idioventricular or junctional rhythm
will compete with biventricular pacing, requiring
an increase in the lower rate limit to overdrive and
suppress the interfering rhythm.
Far-field R-wave oversensing
Far-field R-wave oversensing on the atrial channel
impairs dual chamber SVT/VT discrimination but
it does not cause inappropriate detection of VT (by
an ICD) when the ventricular rate remains in the
sinus zone. It may also cause inappropriate mode
switching and loss of electrical desynchronization
in the DDI mode. Far-field R-wave oversensing of-
ten shows a pattern of alternating short and long
atrial cycle lengths, because the marker depicting the
oversensed R wave remains close to the ventricular
electrogram. Control of far-field R-wave sensing
can be achieved by programmability in several
ways:
1. Prolongation of the postventricular atrial blank-
ing period, which carries the risk of undersensing
AF.
2. Decrease of atrial sensitivity, which can also jeo-
pardize sensing of AF.
3. Algorithmic rejection by identifying a spe-
cific pattern of atrial and ventricular events
(Medtronic PR Logic).
4. Programmable automatic decrease of atrial sen-
sitivity after ventricular events. This function is
similar to the dynamic ventricular sensitivity in
ICD devices.
Programming of left ventricular pacing
output
Traditionally a safety margin of twice the voltage
threshold is recommended for LV capture. Battery
longevity is an important consideration in CRT
P1: SFK/UKS P2: SFK
part-III BLBK303-Barold May 17, 2010 10:52 Trim: 276mm×219mm Printer Name: Yet to Come
415
devices, where two ventricles are being paced con-
tinuously and LV pacing may require a high output,
as the pacing threshold is generally twice that of RV
pacing. Thus, an LV safety margin of 1.5 × voltage
threshold may be reasonable without increasing the
risk of asystole. Such a lower safety margin must be
individualized. Battery longevity may be enhanced
by algorithms that automatically measure the LV
threshold and may help maintain LV capture while
reducing output.
Left ventricular automatic capture
verification
Loss of LV capture and phrenic nerve stimulation
(requiring a lower LV output for elimination) are
two important causes of CRT interruption. To main-
tain effective LV capture with a minimal output, au-
tomatic algorithms for capture verification may be
helpful. As an example, the Left Ventricular Cap-
ture Management (LVCM) algorithm of Medtronic
measures the time from an atrial stimulus to the
RV sensed event in one test cycle as the intrinsic
AV interval (e.g. 200 ms). Thereafter, it measures
the interval from LV pacing to the RV sensed event
in another test cycle. Only if this V–V interval is
significantly (at least 80 ms) shorter than the in-
trinsic AV interval, the algorithm assumes capture.
Using this algorithm, LV output can be pro-
grammed (at a voltage safety margin < 2 : 1)
to reduce battery current drain, improve resyn-
chronization success, and decrease phrenic nerve
stimulation
Anodal stimulation in biventricular
pacemakers
Although anodal capture may occur with high-
output traditional bipolar RV pacing, this phe-
nomenon is almost always not discernible electro-
cardiographically. Biventricular pacing systems that
utilize a unipolar lead for LV pacing via a coro-
nary vein may create RV anodal pacing. The tip
electrode of the LV lead is the cathode, and the
proximal electrode of the bipolar RV lead often
provides the anode for LV pacing. This arrange-
ment creates a common anode for RV and LV pac-
ing. A high current density (from two sources)
at the common anode during biventricular pacing
may cause anodal capture, manifested as a paced
QRS complex with a somewhat different configura-
tion from that derived from standard biventricular
pacing.
A different form of anodal capture involving the
proximal electrode of the bipolar RV lead can also
occur with contemporary biventricular pacemakers
with separately programmable ventricular outputs.
During monochamber LV pacing at a relatively high
output, RV anodal capture produces a paced QRS
complex identical to that registered with biventric-
ular pacing. Occasionally this type of anodal cap-
ture prevents electrocardiographic documentation
of pure LV pacing if the LV pacing threshold is
higher than that of RV anodal stimulation. Such an-
odal stimulation may complicate threshold testing
and should not be misinterpreted as pacemaker mal-
function. Furthermore, if the LV threshold is not too
high, appropriate programming of the LV output
should eliminate anodal stimulation in most cases.
It is important to understand that in the presence
of anodal capture it is impossible to advance LV ac-
tivation by V–V interval programming because the
effective V–V interval remains at zero. The use of
true bipolar LV leads eliminates all forms of RV an-
odal stimulation.
Triggered ventricular pacing
The triggered ventricular pacing mode, available
in some devices, is a programmable option that
attempts resynchronization by triggering a biven-
tricular output immediately when the CRT device
senses a spontaneous QRS complex within the pro-
grammed AV delay, or when it senses a pacemaker-
defined ventricular premature complex. Because
ventricular sensing in modern CRT devices is lim-
ited to the RV channel, only rhythms arising from the
RV will be sensed early enough to possibly allow
resynchronization by triggered LV pacing. Ectopic
rhythms arising remotely from the RV lead will be
sensed relatively late and, therefore, the delivered
triggered stimulus may occur too late for effective
electrical resynchronization. There are little hemo-
dynamic data about the efficacy of triggered biven-
tricular pacing. Preliminary evidence suggests that
this process may be helpful in some patients with
improvement of the aortic VTI.
Programming verification by exercise
testing
Exercise testing in CRT patients is now technically
less difficult, with the advent of wireless device
telemetry. Exercise testing is helpful in the overall
evaluation of CRT, particularly in patients with a
suboptimal CRT response where no obvious cause is
found at rest. An exercise test may reveal loss of cap-
ture, atrial undersensing, various arrhythmias, and
the development of spontaneous AV conduction be-
cause of PR shortening or upper rate limitation. In
the latter, the upper rate should be reprogrammed to
ensure consistent biventricular capture with effort.
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Exercise testing is vital in CRT patients with per-
manent atrial fibrillation who have not undergone
ablation of the AV junction.
In CRT patients with severe chronotropic incom-
petence (defined by the failure to achieve 85% of
the age-predicted heart rate, determined as 220 mi-
nus the patient’s age in years) rate-adaptive pacing
DDDR may provide incremental benefit on exercise
capacity. An exercise test facilitates programming
the rate-adaptive mode and its related parameters.
Effect of interventricular timing on the
electrocardiogram of biventricular
pacemakers
Contemporary biventricular devices permit some
degree of hemodynamic adjustment by program-
ming the interventricular interval, usually in vari-
ous steps from LV ahead of RV or RV ahead of LV.
In the absence of anodal stimulation, increasing the
V–V interval gradually from 0 to 80 ms (LV first)
will progressively increase the duration of the paced
QRS complex and alter its morphology, with a larger
R wave in lead V1 indicating more dominant LV de-
polarization. The varying QRS configuration in lead
V1 with different V–V intervals may correlate with
the hemodynamic response, but this has not been
established.
RV anodal stimulation during biventricular pac-
ing interferes with a programmed interventricular
(V–V) delay aimed at optimizing cardiac resynchro-
nization (often programmed with the LV preced-
ing the RV), because RV anodal capture causes si-
multaneous RV and LV activation (the V–V interval
becomes zero). In the presence of anodal stimula-
tion, the ECG morphology and its duration will not
change if the device is programmed with V–V inter-
vals of 80, 60, and 40 ms (LV before RV). The delayed
RV cathodal output (80, 60, 40 ms) then falls in the
myocardial refractory period initiated by the preced-
ing anodal stimulation. At V–V intervals ≤ 20 ms,
the paced QRS may change because the short LV–RV
interval prevents propagation of activation from the
site of RV anodal capture in time to render the catho-
dal site refractory. Thus, the cathode also captures
the RV and contributes to RV depolarization, which
then takes place from two sites: RV anode and RV
cathode.
Programming the optimal AV delay
The atrioventricular (AV) interval during AV se-
quential pacing influences LV systolic performance
by modulating preload. The influence of the AV de-
lay appears to be less important than the proper
choice of LV pacing site. The majority of the acute
and long-term benefit from CRT is independent of
the programmed AV interval. Nevertheless, pro-
gramming of the left-sided AV delay is important in
CRT patients. Appropriate AV interval timing can
maximize CRT benefit, and if programmed poorly
it has the potential to curtail the beneficial effects.
Optimization will not convert a non-responder (ac-
cording to strict definitions) to a responder, but may
convert an under-responder to improved status.
The optimal AV delay in CRT patients exhibits
great variability from patient to patient. This sug-
gests that an empirically programmed AV delay in-
terval is suboptimal in many patients. Thus, empiric
programming of the AV delay is generally not rec-
ommended. One should always aim for atrial sens-
ing, which is, as a rule, hemodynamically more fa-
vorable than atrial pacing. Thus the lower rate is
often programmed to a relatively slow value. Opti-
mized AV synchrony is achieved by the AV delay set-
ting that provides the best left atrial contribution to
LV filling, the maximum stroke volume, shortening
of the isovolemic contraction time, and the longest
diastolic filling time in the absence of diastolic mitral
regurgitation (in patients with a long PR interval).
In clinical practice there are many techniques for
optimizing the AV delay, as well as great variabil-
ity in their use. The techniques include invasive
(LV or aortic dP/dt max) and non-invasive tech-
niques (largely echocardiography). AV optimiza-
tion in DDD(R) pacemakers has traditionally been
achieved using non-invasive Doppler echocardio-
graphy, which still remains widely used in CRT
patients for acute and long-term hemodynamic
assessment. However, Doppler echocardiographic
methods for AV optimization in CRT patients
vary substantially in performance. They include
analysis of mitral, LV outflow tract, and aortic
blood flow velocity profiles using conventional
pulsed and continuous-wave Doppler techniques,
and determination of dP/dt as derived from the
continuous-wave Doppler profile of mitral regur-
gitation. Non-echocardiographic techniques include
radionuclide angiography, impedance cardiogra-
phy, plethysmography, and data from a peak endo-
cardial acceleration sensor incorporated into a pac-
ing lead.
Echocardiographic techniques for AV (and V–V)
optimization require experienced personnel and are
time-consuming. Furthermore, CRT optimization by
echocardiography is sensitive to intra- and inter-
observer variability. The best method of measuring
or assessing the effects of AV interval programming
in terms of accuracy, cost, rapidity, ease, and per-
haps full automaticity, remains to be defined, but
a recently developed semi-automatic method holds
great promise (discussed later).
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Long-term evaluation of the AV delay
The optimal follow-up and long-term programming
of the AV delay is uncertain. There is evidence
suggesting that the optimal AV and V–V inter-
vals change with time in patients undergoing CRT.
Biventricular stimulation will result in LV reverse
remodeling, with changes in LV end-diastolic and
end-systolic volumes and pressures over time. This
dynamic process also includes autonomic changes,
and it may take several months before a new steady
state of maximum improvement in LV function is
reached. The status of AV interval optimization
should therefore be assessed periodically. Further
studies are needed to determine how often the AV
interval needs to be optimized.
Intra- and interatrial conduction delay
Intra- and interatrial conduction delay are now
being recognized as important abnormalities in
patients with heart failure who are candidates for
CRT. These abnormalities of conduction should be
suspected in patients with extensive atrial myocar-
dial disease, absent atrial electrical activity or low
electrogram amplitudes, and in patients who un-
derwent surgical procedures such as mitral valve
replacement and a maze procedure.
Interatrial conduction delay
Interatrial conduction delay is characterized by a
wide and notched P wave (> 120 ms), tradition-
ally in ECG lead II, associated with a wide terminal
negative deflection in lead V1. The latter is com-
monly labeled left atrial enlargement, though it re-
flects left atrial conduction disease. Interatrial con-
duction time is also measured as the activation time
from the high right atrium or onset of the P wave to
the distal coronary sinus (60–85 ms). In the presence
of interatrial conduction delay with late left atrial ac-
tivation, left atrial contraction occurs late, and even
during LV systole. Consequently, the need to pro-
gram a long AV delay to adjust for delayed left atrial
contraction can preclude ventricular resynchroniza-
tion because of the emergence of competing spon-
taneous AV conduction. The incidence of interatrial
conduction delay in patients who are candidates for
CRT is unknown. When the ECG suggests interatrial
conduction delay, it would be wise to look for de-
layed left atrial activation at the time of CRT implan-
tation by showing that the conduction time from the
right atrium to the left atrium is longer than the con-
duction time from the right atrium to the ventricles
(onset of the QRS complex).
In the presence of interatrial conduction delay,
one should consider placing the atrial lead in the
high septum (Brachmann’s bundle) or low inter-
atrial septum or proximal coronary sinus where
pacing produces a more simultaneous activation of
both atria and abbreviates total atrial activation time
judged by a decrease in P wave duration. In the
presence of established CRT with an atrial lead in
the right atrial appendage, restoration of mechani-
cal left-sided AV synchrony requires simultaneous
bi-atrial pacing performed by the implantation of a
second atrial lead, either in the proximal coronary
sinus or low atrium near the coronary sinus to pre-
empt left atrial systole. Ablation of the AV junction
permits control of the AV delay to promote mechan-
ical left-sided AV synchrony.
Intra-atrial conduction delay (late atrial
sensing)
In some patients with right intra-atrial conduction
delay, conduction from the sinus node to the right
atrial appendage (site of atrial sensing) is delayed in
the absence of significant conduction delay from the
sinus node to the AV junction or to the left atrium.
The clinical incidence of this entity and its associa-
tion with interatrial conduction delay are unknown.
In this situation, left atrial activation may take place
or may even be complete by the time the device
senses the right atrial electrogram. The AS–VS in-
terval (AS = atrial sensed event, VS = ventricu-
lar sensed event) becomes quite short because AS
is delayed but VS is not. Thus, in CRT patients, it
may be impossible to program an optimal AV delay
without interference from a comparatively early VS
event, because of the emergence of competing spon-
taneous conduction. In such a cases VS produces
potentially harmful ventricular fusion or incomplete
cardiac resynchronization. Thus, one is often forced
to program unphysiologically short sensed AV de-
lays, and possibly long paced AV delays, to adjust
for the delay associated with first-degree pacemaker
exit block. In a difficult situation, ablation of the fast
pathway of the AV node or complete AV junctional
ablation can be performed with satisfactory result.
This approach is similar to the use of pacing in
patients with hypertrophic obstructive cardiomy-
opathy and a short PR interval, where AV junc-
tional ablation is the only way to ensure complete
pacemaker-induced ventricular depolarization.
Fusion with the spontaneously conducted
QRS complex: does it matter?
One study demonstrated that LV dP/dt max was
higher with LV than with biventricular pacing,
provided that LV pacing was associated with
ventricular fusion caused by intrinsic activation via
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the right bundle branch. The clinical implications
of this study are unclear. It is currently impossible
to obtain sustained LV stimulation with a stable
degree of fusion, because of perturbation of intrinsic
conduction related to autonomic factors. As present,
it is best to program the AV delay to minimize
ventricular fusion with spontaneous ventricular
activity until more data are available, and a reliable
way is found to synchronize right bundle branch
activity or unpaced RV sensed events with LV
stimulation. The hemodynamic impact of fusion
cannot as yet be predicted. It may be beneficial
and inevitable in some patients with a short PR
interval, but it may also carry the risk of incomplete
resynchronization. Indeed, in some patients the
elimination of fusion may be hemodynamically
beneficial. In patients with a short PR interval,
optimization of the AV interval may be suboptimal
or impossible at short AV delays without fusion.
Therefore, a relatively longer (possibly hemody-
namically more favorable) AV interval associated
with fusion may be programmed on a trial basis in
a patient with a suboptimal CRT response.
Programming the interventricular (V–V)
interval
The usefulness of programming the V–V interval is
controversial, in view of two recent trials showing no
benefit. Despite the negative results in these recent
trials, V–V interval optimization may prove benefi-
cial in some heart-failure patients with a suboptimal
CRT response. In most patients, V–V interval opti-
mization produces a rather limited improvement in
LV function and/or stroke volume, but in individual
patients it may lead to significant benefit. V–V inter-
val optimization should decrease LV dyssynchrony,
provide more simultaneous LV activation with faster
LV emptying and longer diastolic filling, possibly
increase LV ejection fraction, and reduce mitral re-
gurgitation in some patients. V–V programmability
may also partially compensate for less than opti-
mal LV lead position by tailoring ventricular tim-
ing, and it may correct for individual heterogeneous
ventricular activation patterns commonly found in
patients with LV dysfunction and heart failure. V–V
interval optimization can be viewed as the indi-
vidual adjustment of left and right ventricular AV
intervals, and its benefit is additive to AV interval
optimization.
Programming of the V–V interval is guided by
the same techniques as AV delay optimization. De-
termination of the extent of residual LV dyssyn-
chrony after V–V programming requires more so-
phisticated echocardiographic techniques such as
tissue Doppler imaging. Contemporary biventri-
cular ICD devices permit programming of the V–V
interval usually in steps from 0 to +80 ms (LV first)
and from 0 to +80 ms (RV first), to optimize LV
hemodynamics. The V–V interval is zero for simul-
taneous LV and RV pacing. Programmability of the
V–V interval is based on evidence that CRT with se-
quential rather than simultaneous pacing of the two
ventricles yields the best mechanical efficiency.
Optimized V–V intervals show great patient-to-
patient variability and usually cannot be identified
clinically in the majority of patients. Consequently,
adjustment of the V–V interval, like the AV in-
terval, must be individualized. The range of opti-
mal V–V intervals is relatively narrow, most com-
monly involving LV pre-excitation by 20 ms. RV
pre-excitation should be used cautiously, because
advancing RV activation may cause a decline of LV
function. Consequently, RV pre-excitation should be
reserved for patients with LV dyssynchrony in the
septal and inferior segments provided there is hemo-
dynamic proof of benefit. Patients with ischemic car-
diomyopathy (with slower conducting scars) may
require more pre-excitation than those with idio-
pathic dilated cardiomyopathy. V–V programming
is of particular benefit in patients with a previous
myocardial infarction.
Prior to performing V–V interval optimization,
consideration should be given to pacing lead config-
uration, the presence of anodal capture (which forces
the V–V interval to 0), and manufacturer-related dif-
ferences of V–V timing. Further, careful analysis of
the 12-lead ECG during RV, LV, and biventricular
pacing is crucial.
Impact of V–V interval programming on the
effective AV delay: differences between
device manufacturers
V–V interval programming allows separate pro-
gramming of the RV and LV AV delays. In most
devices (all American manufacturers except Boston
Scientific/Guidant) the ventricular channel ad-
vanced by V–V interval programming will be paced
at the programmed AS/AP delay. In Boston Scien-
tific (Guidant) devices AS/AP timing seen on the
programmer applies to the RV channel, and if LV ac-
tivation is advanced by V–V interval programming,
the LV/AV delay can be calculated by subtracting
the V–V interval from the AS/AP delay.
Latency and delayed intra- and
interventricular conduction
In some CRT patients, lack of hemodynamic im-
provement may be due to imbalance between RV
and LV electrical activation related to variations of
electrical excitability and impulse propagation such
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as electrical latency, slow impulse propagation in
proximity of the lead (due to scar), or more globally
delayed intra- and interventricular conduction.
The interval from the pacemaker stimulus to the
onset of the earliest paced QRS complex on the 12-
lead ECG is called latency, and during RV pacing
this interval normally measures < 40 ms.
Prolonged LV latency intervals during stimula-
tion from within epicardial cardiac veins may be
due to interposed venous tissue and epicardial fat
preventing direct contact between electrode and
LV myocardium, and/or an overlying scar. Infero-
lateral akinesis or severe hypokinesis may be as-
sociated with prolonged LV latency intervals in-
volving the area of the LV lead implantation site.
This is concordant with recent reports about low
response rates to CRT in patients with LV dyssyn-
chrony and posterolateral scar, as demonstrated by
echocardiography and contrast-enhanced magnetic
resonance imaging. Delayed LV depolarization re-
lated to latency during simultaneous biventricular
pacing (V–V = 0 ms) generates an ECG pattern dom-
inated by RV stimulation. Advancing LV stimula-
tion via a programmable interventricular (V–V) de-
lay, or programming the device to monochamber LV
pacing, can result in immediate hemodynamic and
symptomatic improvement. Increasing the LV ven-
tricular stimulus output decreases inter-ventricular
conduction time in patients with biventricular pa-
cing systems. Increasing output strength in all likeli-
hood depolarizes larger volumes of myocardium by
creating a larger virtual electrode, and this may be
of particular importance during pacing of diseased
myocardium.
Optimization of V–V timing using the
electrocardiogram
RV and LV latency intervals on the ECG are mea-
sured at a speed of 50–100 mm/s and use the dif-
ference between LV and RV latency intervals as the
value to program the V–V interval. In patients with
long LV latency intervals, programming of incre-
mental left-to-right ventricular (V–V) delays can un-
mask a dominant R wave in lead V1 during biven-
tricular pacing and may guide the selection of a V–V
delay that yields balanced left and right ventricular
depolarization. The accuracy and validity of these
electrocardiographic methods for V–V interval opti-
mization requires further investigation.
A simple ECG method was recently published
which compares the time difference of the interval
from the pacing spike to the beginning of the fast
deflection of the QRS complex in leads V1, V2 dur-
ing pacing from the LV (T1), and from the RV (T2).
The T2–T1 interval was considered as a surrogate
measurement of interventricular delay and defined
as the best V–V, and this was compared to three
echocardiographic measurements of LV synchrony
at V–V interval setting of –30, 0, and +30 ms. Echo re-
sults had an 83% coincidence with the ECG method
(r = 0.81, P < 0.001). The investigators concluded
that the time difference in the fast ventricular depo-
larization observed between RV and LV stimulation
on the surface ECG shows a good correlation with
echocardiographic V–V optimization.
Semi-automatic optimization of AV and
V–V intervals
QuickOpt Timing Cycle Optimization (St. Jude) runs
an automatic sequence of intracardiac EGM mea-
surements and displays on the programmer the op-
timal AV and V–V intervals in 90 seconds. The sys-
tem uses an exclusive algorithm to calculate the
optimal timing values. These values are then pro-
grammed manually into the CRT device. Quick-
Opt optimization was found to be consistently com-
parable to a traditional echocardiographic proce-
dure for determining optimal AV and V–V delays.
Another system (SmartAVDelayTM), recently intro-
duced by Boston Scientific (Guidant), also permits
rapid programmer-based determination of the AV
delay. The algorithm also uses a formula based on in-
tracardiac electrograms that accurately predicts the
AV delay associated with the maximum LV dP/dt.
The device measures the sensed and paced AV de-
lays (AS–VS and AP–VS). It also measures the in-
terventricular conduction interval between the RV
and LV electrograms in the case of a bipolar LV lead,
whereupon the system provides the optimal AV de-
lay automatically. The duration of the surface QRS
complex is used in the semi-automatic function if the
LV lead is unipolar. A further programming adjust-
ment is required if the LV lead is not in the correct
site. This system does not evaluate the V–V delay,
which has to be programmed before determining the
optimal AV delay. The sensed and paced AV delays
are individually determined, in contrast to the St.
Jude system, which calculates the paced AV delay
by adding 50 ms to the optimal sensed AV delay.
Most CRT patients do not undergo AV and
V–V optimization by traditional methods because
echocardiographic optimization typically takes a
long time and is expensive. These new systems
based on intracardiac electrograms allow efficient
and frequent optimization of AV and V–V inter-
vals and can even be used when the device is be-
ing programmed before leaving the surgical suite.
Although preliminary data are encouraging fur-
ther study of these automatic or semi-automatic AV
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and V–V optimization based on intracardiac electro-
grams is needed.
Atrial fibrillation and atrial
tachyarrhythmia
Many patients undergoing CRT have a history of
paroxysmal atrial tachyarrhythmias, often associ-
ated with a rapid ventricular response that inhibits
CRT delivery. Heart rate may be controlled at rest but
not during exercise, and even if the mean heart rate is
pharmacologically controlled, pronounced RR vari-
ability of conducted beats may decrease the number
of resynchronized beats. Atrial fibrillation and atrial
tachyarrhythmias should be aggressively treated,
and if long-term sinus rhythm cannot be achieved,
AV junctional ablation should be performed. In this
respect, one should not be misled by what appears
to be a satisfactory percentage of stored paced beats,
because many could be fusion and/or pseudofu-
sion beats unrelated to effective electrical resyn-
chronization. Heart-failure patients with permanent
AF treated with CRT show sustained long-term im-
provements of LV function and functional capacity
similar to patients in sinus rhythm, but only if AV
junctional ablation is performed.
Some devices have programmable algorithms that
increase the percentage of biventricular pacing dur-
ing AF so as to promote some degree of rate reg-
ularization and CRT (without an overall increase
in the ventricular rate), by dynamic matching with
the patient’s own ventricular responses (up to the
programmed maximum tracking rate). Activation of
this algorithm does not result in ventricular rate con-
trol, and should not be a substitute for AV junctional
ablation. Automatic mode switching should be acti-
vated, and is particularly important in patients with
relatively slow conduction to the ventricle. Some de-
vices have a lower rate interval that may be set sep-
arately during mode switching with the intention of
increasing the percentage of biventricular pacing by
virtue of a relatively fast pacing rate during the DDI
mode. There is no need to program mode switching
in patients without a history of atrial tachyarrhyth-
mias, because possible far-field R-wave sensing may
cause repeated automatic mode switching and elec-
trical desynchronization in some devices when the
base rate in the DDI mode is not particularly fast.
Congestive heart failure after CRT
Reduction of diuretics is important after CRT in pa-
tients with near-optimal LV filling pressures and
Table 27. Poor response to CRT.
 LV lead dislodgment or high threshold
 LV lead in the anterior cardiac vein
 LV lead on non-viable myocardium
 No LV dyssynchrony despite wide QRS
 Irreversible mitral regurgitation
 Long AV delay
 Suboptimal AV delay and/or V–V delay
 Atrial tachyarrhythmias with fast
ventricular rate
 Frequent VPCs
 Severely impaired myocardial function
 Comorbidities
 Too strict a definition of positive
response
an adequate diuresis to prevent prerenal azotemia,
which may mask or delay the benefit of CRT. The
dose of beta-blockers can be increased after CRT, and
this may be successful in patients with previous in-
tolerance. Few, if any, patients respond to CRT alone,
and thus CRT cannot substitute for medical manage-
ment. The combination of device therapy and opti-
mal medical therapy provides synergistic effects to
enhance reverse LV remodeling and long-term sur-
vival. The occurrence of CHF after CRT requires a
comprehensive investigation (Table 27).
Investigation of recurrent heart failure
1. A CRT non-responder should initially be evalu-
ated for the development of atrial fibrillation, or
cardiac ischemia, with a view to consider revascu-
larization. Rate control, including AV node abla-
tion or electrical cardioversion to restore normal
sinus rhythm, is essential in patients who develop
atrial fibrillation.
2. Evaluate LV lead for loss of capture.
3. Evaluate the percentage of biventricular paced
beats from device memory.
4. Optimization of AV and V–V intervals may pro-
vide some improvement within a short period of
time.
5. Echocardiographic evaluation of LV dyssyn-
chrony. If significant intraventricular dyssyn-
chrony is still present, then lead repositioning
should be considered, using epicardial placement
if necessary.
6. Persistent symptoms despite correction of LV
dyssynchrony require evaluation for severe mi-
tral regurgitation. Mitral valve surgery offers
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symptomatic improvement to patients even with
poor LV function, and should be considered in se-
lected patients with persistent significant mitral
regurgitation.
CRT device monitoring of heart failure
A variety of measurements by an ICD can be very
useful in the management of CHF patients. It is be-
lieved that early diagnosis and treatment of impend-
ing CHF may reduce progression of LV dysfunction
and mortality. Hence the importance of periodic re-
mote monitoring. In this respect, it is interesting that
patients may experience rather subtle symptoms
7–21 days before the clinical development of CHF.
During this period, remote monitoring a number of
parameters permits early diagnosis before clinical
manifestations. One manufacturer provides the ca-
pability of remote transmission of blood pressure
and weight.
Intrathoracic impedance
This function (not yet available in pacemakers) is
pertinent to CRT patients, who often receive an ICD
as part of a CRT system (CRT-D). Fluids conduct
electricity more easily than solids. Fluid accumu-
lation in the lungs leads to decreased intrathoracic
impedance and increased conductivity. A Medtronic
device can track thoracic fluid status by the emis-
sion of low-amplitude electrical pulses to measure
transthoracic impedance between the coil of the RV
lead and the can of a CRT device or ICD (OptiVolTM).
This measurement is made multiple times each day.
The OptiVol fluid status monitoring system collects
impedance signals between 12 pm and 6 pm, as this
time period was shown earlier to best reflect fluid ac-
cumulation. Measures of LV end-diastolic pressure
correlate inversely with impedance values.
This impedance level is averaged once a day to cre-
ate a reference range, known as the OptiVol Fluid In-
dexTM, which is a surrogate of impedance. The fluid
index represents the accumulation of consecutive
day-to-day differences between daily and reference
impedance. The physician can select a threshold for
notification of decreased impedance for each patient,
based on stored values. The fluid index rises as the
impedance level drops from increased fluid in the
lungs. An audible alert is available when the fluid
index reaches a certain threshold. Abnormal values
can occur 2 weeks before clinical deterioration. The
cause of the abnormal findings must be investigated,
as it may be due to recent-onset atrial fibrillation. Re-
mote monitoring with the OptiVol feature can result
in early treatment during the pre-clinical stage of
heart-failure decompensation, and can lead to a sig-
nificant reduction of hospital admissions for heart
failure. The ICD provides a heart-failure manage-
ment report with 14-month trends of AT/AF burden,
ventricular rate during AF, heart-rate variability, pa-
tient activity, and night/day heart rates.
Heart-rate variability
Heart rate varies from heartbeat to heartbeat. Heart-
rate variability (HRV) is the beat-to-beat variation
in heart rate (between successive heartbeats, i.e., RR
intervals), and provides an indirect indicator of au-
tonomic status and neurohormonal activation, an
important pathophysiologic factor in a number of
cardiovascular disease states and heart failure. HRV
of a well-conditioned heart is generally large at rest.
During exercise, HRV decreases as the heart rate
and exercise intensity increase. A reduction in HRV
is a marker for reduced vagal activity. HRV reduc-
tion implies enhanced sympathetic activity, and it is
lower in patients with high mortality and hospital-
ization risk. HRV software, which can record daily
measures of HRV, is incorporated into many of the
newer CRT devices. In a dual chamber device HRV
is calculated from atrial sensed activity, while in a
single chamber ICD it is derived from the RR in-
tervals. As the neurohormonal system responds to
detected changes in LV function before the patient
experiences symptoms, HRV data may be useful
for predicting a worsening condition and possibly
preventing a hospital admission. Device-measured
HRV parameters and patient outcomes improve sig-
nificantly after CRT. Lack of HRV improvement 4
weeks after CRT identifies patients at higher risk for
major cardiovascular events. One must remember
that new AF can also cause abnormal HRV. At this
time, HRV is not much used in the real world.
Activity
An activity sensor (piezoelectric or accelerometer)
detects body movement and reflects patient daily
physical activity. The data can be registered even if
the rate-adaptive pacing mode is not programmed.
The accuracy of using activity data to predict heart
failure is dependent on the patient, and partly on
the type of activities. The level of activity may not
decrease early enough before the onset of decom-
pensation, especially in patients with severe heart
failure, who are mostly sedentary. In CRT patients,
an increase in recorded activity represents a good
symptomatic response and CRT efficiency, associ-
ated with a parallel improvement in the quality of
life and NYHA class. Activity data may be impor-
tant when deciding whether a patient can go back
to work.
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Nocturnal heart rate
Nocturnal heart rate is important in patients with
CHF. An increase in nocturnal heart rate may be a
sign of impeding decompensation. If the sinus rate
is higher than expected (e.g., 90 bpm), a CHF patient
requires more beta-blocker therapy. Nocturnal rate
monitoring may also pick up unsuspected episodes
of atrial fibrillation.
Arrhythmias after CRT
Atrial arrhythmias
A history of AF before CRT is associated with a
higher risk of death. Spontaneous conversion of AF
to sinus rhythm occurs in a minority of patients with
permanent AF. CRT appears to reduce AF in pa-
tients with a prior AF history. This may be related
to the significant improvement in LV systolic func-
tion and reduction in mitral regurgitation. In this
respect, improvement in left atrial size and function
after CRT is associated with a lower incidence of new
AF. When compared to the patients who maintain si-
nus rhythm, patients with new-onset AF after CRT
show less reverse remodeling, less improvement in
LV function, more hospitalizations for heart failure,
and increased mortality. Cardioversion of perma-
nent AF should be done only 3–6 months after the
initiation of CRT, when remodeling has stabilized.
Cardioversion may be preceded by therapy with
amiodarone or dofetilide.
Implantation of an atrial lead may be considered
despite the presence of permanent AF for the fol-
lowing reasons: (1) it provides atrial monitoring ca-
pability, especially useful in patients with an ICD;
(2) although CRT rarely induces spontaneous con-
version of atrial fibrillation, electrical cardioversion
may become an option after the establishment of sig-
nificant LV and left atrial reverse remodeling. Lack
of AV synchrony with the return of sinus rhythm
carries the risk of pacemaker syndrome.
Ventricular arrhythmias
Ventricular proarrhythmia after CRT may present
either as sustained monomorphic VT or rarely as
polymorphic VT (torsades de pointes), precipitated
mainly by epicardial (in the coronary venous sys-
tem) LV and to a lesser degree by biventricular pac-
ing. VT induced by LV pacing alone can be elim-
inated by turning off LV pacing, and some cases
of LV-induced VT may sometimes be suppressed
during biventricular pacing. In some patients, the
induction of monomorphic VT by LV or biventric-
ular pacing represents an exacerbation of a previ-
ously controlled arrhythmia, but in others it ap-
pears de novo. In contrast, torsades de pointes are
caused by a different mechanism related to am-
plified transmural dispersion of repolarization as-
sociated with QT prolongation. This is due to en-
hanced transmural dispersion of repolarization (as
in the long QT syndrome) induced by LV epicar-
dial pacing. Fortunately, torsades de pointes are
rare.
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423Appendix: guidelines
American guidelines for pacemaker
implantation
Epstein AE, DiMarco JP, Ellenbogen KA, et al.
ACC/AHA/HRS 2008 guidelines for device-
based therapy of cardiac rhythm abnormalities:
a report of the American College of Cardiol-
ogy/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise
the ACC/AHA/NASPE 2002 Guideline Update for
Implantation of Cardiac Pacemakers and Antiar-
rhythmia Devices) developed in collaboration with
the American Association for Thoracic Surgery and
Society of Thoracic Surgeons. J Am Coll Cardiol 2008;
51: e1–62.
The text that follows is an extract from the pub-
lished guideline, reproduced with the permission
of the American Heart Association. The full guide-
line, regularly updated, is available online at http://
content.onlinejacc.org/cgi/content/full/51/21/e1.
Levels of evidence
Level A Data derived from multiple randomized
clinical trials or meta-analyses
Classification of recommendations
Class I Class IIa Class IIb Class III
Benefit >>> Risk Benefit >> Risk
Additional studies with
focused objectives
needed
Benefit ≥ Risk
Additional studies with
broad objectives needed;
Additional registry data
would be helpful
Risk ≥ Benefit
No additional studies
needed
Procedure/ treatment
SHOULD be
performed/
administered
IT IS REASONABLE to
perform
procedure/administer
treatment
Procedure/treatment
MAY BE CONSIDERED
Procedure/treatment
should NOT be
performed/
administered SINCE IT
IS NOT HELPFUL AND
MAY BE HARMFUL
Multiple populations evaluated
Level B Data derived from a single randomized
trial or non-randomized studies
Limited populations evaluated
Level C Only consensus opinion of experts, case
studies, or standard of care
Very limited populations evaluated
Recommendations for permanent pacing
in sinus node dysfunction
CLASS I
1. Permanent pacemaker implantation is indicated
for sinus node dysfunction (SND) with doc-
umented symptomatic bradycardia, including
frequent sinus pauses that produce symptoms.
(Level of evidence: C)
2. Permanent pacemaker implantation is indicated
for symptomatic chronotropic incompetence.
(Level of evidence: C)
3. Permanent pacemaker implantation is indicated
for symptomatic sinus bradycardia that results
from required drug therapy for medical condi-
tions. (Level of evidence: C)
Cardiac Pacemakers and Resynchronization Step-by-Step: An Illustrated Guide, Second Edition
S. Serge Barold, Roland X. Stroobandt and Alfons F. Sinnaeve
© 2010 S. Serge Barold, Roland X. Stroobandt, and Alfons F. Sinnaeve. ISBN: 978-1-405-18636-0
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CLASS IIa
1. Permanent pacemaker implantation is reasonable
for SND with heart rate less than 40 bpm when
a clear association between significant symptoms
consistent with bradycardia and the actual pres-
ence of bradycardia has not been documented.
(Level of evidence: C)
2. Permanent pacemaker implantation is reasonable
for syncope of unexplained origin when clinically
significant abnormalities of sinus node function
are discovered or provoked in electrophysiologi-
cal studies. (Level of evidence: C)
CLASS IIb
1. Permanent pacemaker implantation may be con-
sidered in minimally symptomatic patients with
chronic heart rate less than 40 bpm while awake.
(Level of evidence: C)
CLASS III
1. Permanent pacemaker implantation is not indi-
cated for SND in asymptomatic patients. (Level of
evidence: C)
2. Permanent pacemaker implantation is not indi-
cated for SND in patients for whom the symp-
toms suggestive of bradycardia have been clearly
documented to occur in the absence of bradycar-
dia. (Level of evidence: C)
3. Permanent pacemaker implantation is not in-
dicated for SND with symptomatic bradycar-
dia due to nonessential drug therapy. (Level of
evidence: C)
Recommendations for acquired
atrioventricular block in adults
CLASS I
1. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree
AV block at any anatomic level associated with
bradycardia with symptoms (including heart fail-
ure) or ventricular arrhythmias presumed to be
due to AV block. (Level of evidence: C)
2. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree AV
block at any anatomic level associated with ar-
rhythmias and other medical conditions that re-
quire drug therapy that results in symptomatic
bradycardia. (Level of evidence: C)
3. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree AV
block at any anatomic level in awake, symptom-
free patients in sinus rhythm, with documented
periods of asystole greater than or equal to 3.0
seconds or any escape rate less than 40 bpm, or
with an escape rhythm that is below the AV node.
(Level of evidence: C)
4. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree AV
block at any anatomic level in awake, symptom-
free patients with AF and bradycardia with one
or more pauses of at least 5 seconds or longer.
(Level of evidence: C)
5. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree AV
block at any anatomic level after catheter ablation
of the AV junction. (Level of evidence: C)
6. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree AV
block at any anatomic level associated with post-
operative AV block that is not expected to resolve
after cardiac surgery. (Level of evidence: C)
7. Permanent pacemaker implantation is indicated
for third-degree and advanced second-degree
AV block at any anatomic level associated with
neuromuscular diseases with AV block, such as
myotonic muscular dystrophy, Kearns–Sayre
syndrome, Erb dystrophy (limb-girdle muscular
dystrophy), and peroneal muscular atrophy, with
or without symptoms. (Level of evidence: B)
8. Permanent pacemaker implantation is indicated
for second-degree AV block with associated
symptomatic bradycardia regardless of type or
site of block. (Level of evidence: B)
9. Permanent pacemaker implantation is indicated
for asymptomatic persistent third-degree AV
block at any anatomic site with average awake
ventricular rates of 40 bpm or faster if car-
diomegaly or LV dysfunction is present or if
the site of block is below the AV node. (Level of
evidence: B)
10. Permanent pacemaker implantation is indicated
for second- or third-degree AV block during exer-
cise in the absence of myocardial ischemia. (Level
of evidence: C)
CLASS IIa
1. Permanent pacemaker implantation is reasonable
for persistent third-degree AV block with an es-
cape rate greater than 40 bpm in asymptomatic
adult patients without cardiomegaly. (Level of ev-
idence: C)
2. Permanent pacemaker implantation is reason-
able for asymptomatic second-degree AV block
at intra- or infra-His levels found at electrophys-
iological study. (Level of evidence: B)
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3. Permanent pacemaker implantation is reason-
able for first- or second-degree AV block with
symptoms similar to those of pacemaker syn-
drome or hemodynamic compromise. (Level of ev-
idence: B)
4. Permanent pacemaker implantation is reasonable
for asymptomatic type II second-degree AV block
with a narrow QRS. When type II second-degree
AV block occurs with a wide QRS, including iso-
lated right bundle-branch block, pacing becomes
a Class I recommendation. (Level of evidence: B)
CLASS IIb
1. Permanent pacemaker implantation may be con-
sidered for neuromuscular diseases such as
myotonic muscular dystrophy, Erb dystrophy
(limb-girdle muscular dystrophy), and peroneal
muscular atrophy with any degree of AV block
(including first-degree AV block), with or without
symptoms, because there may be unpredictable
progression of AV conduction disease. (Level of
evidence: B)
2. Permanent pacemaker implantation may be con-
sidered for AV block in the setting of drug use
and/or drug toxicity when the block is expected
to recur even after the drug is withdrawn. (Level
of evidence: B)
CLASS III
1. Permanent pacemaker implantation is not indi-
cated for asymptomatic first-degree AV block.
(Level of evidence: B) (See section on Chronic Bi-
fascicular Block.)
2. Permanent pacemaker implantation is not indi-
cated for asymptomatic type I second-degree AV
block at the supra-His (AV node) level or that
which is not known to be intra- or infra-Hisian.
(Level of evidence: C)
3. Permanent pacemaker implantation is not indi-
cated for AV block that is expected to resolve and
is unlikely to recur (e.g., drug toxicity, Lyme dis-
ease, or transient increases in vagal tone or during
hypoxia in sleep apnea syndrome in the absence
of symptoms). (Level of evidence: B)
Recommendations for permanent pacing
in chronic bifascicular block
CLASS I
1. Permanent pacemaker implantation is indi-
cated for advanced second-degree AV block or
intermittent third-degree AV block. (Level of
evidence: B)
2. Permanent pacemaker implantation is indicated
for type II second-degree AV block. (Level of
evidence: B)
3. Permanent pacemaker implantation is indicated
for alternating bundle-branch block. (Level of
evidence: C)
CLASS IIa
1. Permanent pacemaker implantation is reasonable
for syncope not demonstrated to be due to AV
block when other likely causes have been ex-
cluded, specifically ventricular tachycardia (VT).
(Level of evidence: B)
2. Permanent pacemaker implantation is reason-
able for an incidental finding at electrophys-
iological study of a markedly prolonged HV
interval (greater than or equal to 100 mil-
liseconds) in asymptomatic patients. (Level of
evidence: B)
3. Permanent pacemaker implantation is reasonable
for an incidental finding at electrophysiological
study of pacing-induced infra- His block that is
not physiological. (Level of evidence: B)
CLASS IIb
1. Permanent pacemaker implantation may be con-
sidered in the setting of neuromuscular dis-
eases such as myotonic muscular dystrophy,
Erb dystrophy (limb-girdle muscular dystrophy),
and peroneal muscular atrophy with bifascicular
block or any fascicular block, with or without
symptoms. (Level of evidence: C)
CLASS III
1. Permanent pacemaker implantation is not indi-
cated for fascicular block without AV block or
symptoms. (Level of evidence: B)
2. Permanent pacemaker implantation is not indi-
cated for fascicular block with first-degree AV
block without symptoms. (Level of evidence: B)
Acute phase of myocardial infarction
CLASS I
1. Permanent ventricular pacing is indicated for
persistent second-degree AV block in the
His–Purkinje system with alternating bundle-
branch block or third-degree AV block within or
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below the His–Purkinje system after ST-segment
elevation MI. (Level of evidence: B)
2. Permanent ventricular pacing is indicated for
transient advanced second- or third-degree
infranodal AV block and associated bundle-
branch block. If the site of block is uncertain,
an electrophysiological study may be necessary.
(Level of evidence: B)
3. Permanent ventricular pacing is indicated for
persistent and symptomatic second- or third-
degree AV block. (Level of evidence: C)
CLASS IIb
1. Permanent ventricular pacing may be considered
for persistent second- or third-degree AV block at
the AV node level, even in the absence of symp-
toms. (Level of evidence: B)
CLASS III
1. Permanent ventricular pacing is not indicated
for transient AV block in the absence of
intraventricular conduction defects. (Level of
evidence: B)
2. Permanent ventricular pacing is not indicated
for transient AV block in the presence of iso-
lated left anterior fascicular block. (Level of
evidence: B)
3. Permanent ventricular pacing is not indicated
for new bundle-branch block or fascicular
block in the absence of AV block. (Level of
evidence: B)
4. Permanent ventricular pacing is not indicated for
persistent asymptomatic first-degree AV block in
the presence of bundle-branch or fascicular block.
(Level of evidence: B)
Recommendations for permanent pacing
in hypersensitive carotid sinus syndrome
and neurocardiogenic syncope
CLASS I
1. Permanent pacing is indicated for recurrent syn-
cope caused by spontaneously occurring carotid
sinus stimulation and carotid sinus pressure that
induces ventricular asystole of more than 3 sec-
onds. (Level of evidence: C)
CLASS IIa
1. Permanent pacing is reasonable for syncope with-
out clear, provocative events and with a hyper-
sensitive cardioinhibitory response of 3 seconds
or longer. (Level of evidence: C)
CLASS IIb
1. Permanent pacing may be considered for signif-
icantly symptomatic neurocardiogenic syncope
associated with bradycardia documented spon-
taneously or at the time of tilt-table testing. (Level
of evidence: B)
CLASS III
1. Permanent pacing is not indicated for a hyper-
sensitive cardioinhibitory response to carotid si-
nus stimulation without symptoms or with vague
symptoms. (Level of evidence: C)
2. Permanent pacing is not indicated for situa-
tional vasovagal syncope in which avoidance
behavior is effective and preferred. (Level of
evidence: C)
Recommendations for pacing after
cardiac transplantation
CLASS I
1. Permanent pacing is indicated for persistent in-
appropriate or symptomatic bradycardia not ex-
pected to resolve and for other Class I indications
for permanent pacing. (Level of evidence: C)
CLASS IIb
1. Permanent pacing may be considered when rela-
tive bradycardia is prolonged or recurrent, which
limits rehabilitation or discharge after postopera-
tive recovery from cardiac transplantation. (Level
of evidence: C)
2. Permanent pacing may be considered for syncope
after cardiac transplantation even when brad-
yarrhythmia has not been documented. (Level of
evidence: C)
Recommendations for pacing to prevent
tachycardia
CLASS I
1. Permanent pacing is indicated for sustained
pause-dependent VT, with or without QT pro-
longation. (Level of evidence: C)
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CLASS IIa
1. Permanent pacing is reasonable for high-risk pa-
tients with congenital long QT syndrome. (Level
of evidence: C)
CLASS IIb
1. Permanent pacing may be considered for preven-
tion of symptomatic, drug-refractory, recurrent
AF in patients with coexisting SND. (Level of evi-
dence: B)
CLASS III
1. Permanent pacing is not indicated for frequent
or complex ventricular ectopic activity without
sustained VT in the absence of the long-QT syn-
drome. (Level of evidence: C)
2. Permanent pacing is not indicated for torsade de
pointes VT due to reversible causes. (Level of evi-
dence: A)
Recommendation for pacing to prevent
atrial fibrillation
CLASS III
1. Permanent pacing is not indicated for the pre-
vention of AF in patients without any other indi-
cation for pacemaker implantation. (Level of evi-
dence: B)
Recommendations for pacing in patients
with hypertrophic cardiomyopathy
CLASS I
1. Permanent pacing is indicated for SND or AV
block in patients with HCM. (Level of evidence: C)
CLASS IIb
1. Permanent pacing may be considered in medi-
cally refractory symptomatic patients with HCM
and significant resting or provoked LV outflow
tract obstruction. (Level of evidence: A) As for
Class I indications, when risk factors for SCD are
present, consider a DDD ICD.
CLASS III
1. Permanent pacemaker implantation is not in-
dicated for patients who are asymptomatic or
whose symptoms are medically controlled. (Level
of evidence: C)
2. Permanent pacemaker implantation is not indica-
ted for symptomatic patients without evi-
dence of LV outflow tract obstruction. (Level of
evidence: C)
Recommendations for permanent pacing
in children, adolescents, and patients
with congenital heart disease
CLASS I
1. Permanent pacemaker implantation is indicated
for advanced second- or third-degree AV block
associated with symptomatic bradycardia, ven-
tricular dysfunction, or low cardiac output. (Level
of evidence: C)
2. Permanent pacemaker implantation is indicated
for SND with correlation of symptoms during
age-inappropriate bradycardia. The definition of
bradycardia varies with the patient’s age and ex-
pected heart rate. (Level of evidence: B)
3. Permanent pacemaker implantation is indicated
for postoperative advanced second- or third-
degree AV block that is not expected to resolve or
that persists at least 7 days after cardiac surgery.
(Level of evidence: B)
4. Permanent pacemaker implantation is indicated
for congenital third-degree AV block with a
wide QRS escape rhythm, complex ventricu-
lar ectopy, or ventricular dysfunction. (Level of
evidence: B)
5. Permanent pacemaker implantation is indicated
for congenital third-degree AV block in the infant
with a ventricular rate less than 55 bpm or with
congenital heart disease and a ventricular rate
less than 70 bpm. (Level of evidence: C)
CLASS IIa
1. Permanent pacemaker implantation is reason-
able for patients with congenital heart disease
and sinus bradycardia for the prevention
of recurrent episodes of intra-atrial reentrant
tachycardia; SND may be intrinsic or sec-
ondary to antiarrhythmic treatment. (Level of
evidence: C)
2. Permanent pacemaker implantation is reason-
able for congenital third-degree AV block be-
yond the first year of life with an average
heart rate less than 50 bpm, abrupt pauses
in ventricular rate that are 2 or 3 times the
basic cycle length, or associated with symp-
toms due to chronotropic incompetence. (Level of
evidence: B)
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3. Permanent pacemaker implantation is reasonable
for sinus bradycardia with complex congenital
heart disease with a resting heart rate less than
40 bpm or pauses in ventricular rate longer than
3 seconds. (Level of evidence: C)
4. Permanent pacemaker implantation is reasonable
for patients with congenital heart disease and
impaired hemodynamics due to sinus brady-
cardia or loss of AV synchrony. (Level of
evidence: C)
5. Permanent pacemaker implantation is reason-
able for unexplained syncope in the patient
with prior congenital heart surgery complicated
by transient complete heart block with resid-
ual fascicular block after a careful evaluation
to exclude other causes of syncope. (Level of
evidence: B)
CLASS IIb
1. Permanent pacemaker implantation may be con-
sidered for transient postoperative third-degree
AV block that reverts to sinus rhythm with resid-
ual bifascicular block. (Level of evidence: C)
2. Permanent pacemaker implantation may be con-
sidered for congenital third-degree AV block
in asymptomatic children or adolescents with
an acceptable rate, a narrow QRS complex,
and normal ventricular function. (Level of
evidence: B)
3. Permanent pacemaker implantation may be con-
sidered for asymptomatic sinus bradycardia af-
ter biventricular repair of congenital heart dis-
ease with a resting heart rate less than 40 bpm or
pauses in ventricular rate longer than 3 seconds.
(Level of evidence: C)
CLASS III
1. Permanent pacemaker implantation is not in-
dicated for transient postoperative AV block
with return of normal AV conduction in
the otherwise asymptomatic patient. (Level of
evidence: B)
2. Permanent pacemaker implantation is not indi-
cated for asymptomatic bifascicular block with
or without first-degree AV block after surgery
for congenital heart disease in the absence of
prior transient complete AV block. (Level of
evidence: C)
3. Permanent pacemaker implantation is not indi-
cated for asymptomatic type I second-degree AV
block. (Level of evidence: C)
4. Permanent pacemaker implantation is not indi-
cated for asymptomatic sinus bradycardia with
the longest relative risk interval less than 3 sec-
onds and a minimum heart rate more than 40
bpm. (Level of evidence: C)
Recommendations for cardiac
resynchronization therapy in patients with
severe systolic heart failure
CLASS I
1. For patients who have LVEF less than or equal
to 35%, a QRS duration greater than or equal
to 0.12 seconds, and sinus rhythm, CRT with
or without an ICD is indicated for the treat-
ment of NYHA functional Class III or ambula-
tory Class IV heart-failure symptoms with op-
timal recommended medical therapy. (Level of
evidence: A)
CLASS IIa
1. For patients who have LVEF less than or equal to
35%, a QRS duration greater than or equal to 0.12
seconds, and AF, CRT with or without an ICD
is reasonable for the treatment of NYHA func-
tional Class III or ambulatory Class IV heart fail-
ure symptoms on optimal recommended medical
therapy. (Level of evidence: B)
2. For patients with LVEF less than or equal to 35%
with NYHA functional Class III or ambulatory
Class IV symptoms who are receiving optimal
recommended medical therapy and who have
frequent dependence on ventricular pacing, CRT
is reasonable. (Level of evidence: C)
CLASS IIb
1. For patients with LVEF less than or equal to 35%
with NYHA functional Class I or II symptoms
who are receiving optimal recommended medical
therapy and who are undergoing implantation of
a permanent pacemaker and/or ICD with antic-
ipated frequent ventricular pacing, CRT may be
considered. (Level of evidence: C)
CLASS III
1. CRT is not indicated for asymptomatic patients
with reduced LVEF in the absence of other indi-
cations for pacing. (Level of evidence: B)
2. CRT is not indicated for patients whose func-
tional status and life expectancy are limited pre-
dominantly by chronic non-cardiac conditions.
(Level of evidence: C)
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429European guidelines for pacemakerimplantation
Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for
cardiac pacing and cardiac resynchronization ther-
apy. The Task Force for Cardiac Pacing and Cardiac
Recommendations for cardiac pacing in sinus node disease (European)
Clinical indication Class Level of evidence
1. Sinus node disease manifests as symptomatic bradycardia with or
without bradycardia-dependent tachycardia. Symptom–rhythm
correlation must have been:
 spontaneously occurring
 drug induced where alternative drug therapy is lacking
2. Syncope with sinus node disease, either spontaneously occurring
or induced at electrophysiological study
3. Sinus node disease manifests as symptomatic chronotropic
incompetence:
 spontaneously occurring
 drug induced where alternative drug therapy is lacking
Class I C
1. Symptomatic sinus node disease, which is either spontaneous or
induced by a drug for which there is no alternative, but no
symptom rhythm correlation has been documented. Heart rate at
rest should be < 40 bpm
2. Syncope for which no other explanation can be made but there are
abnormal electrophysiological findings (CSNRT > 800 ms)
Class IIa C
1. Minimally symptomatic patients with sinus node disease, resting
heart rate <40 bpm while awake, and no evidence of chronotropic
incompetence
Class IIb C
1. Sinus node disease without symptoms including use of
bradycardia-provoking drugs
2. ECG findings of sinus node dysfunction with symptoms not due
directly or indirectly to bradycardia
3. Symptomatic sinus node dysfunction where symptoms can reliably
be attributed to non-essential medication
Class III C
When sinus node disease is diagnosed, atrial tachyarrhythmias are likely even if not yet recorded, implying that
serious consideration should be given to anticoagulant therapy.
Resynchronization Therapy of the European Society
of Cardiology. Developed in collaboration with the
European Heart Rhythm Association. Eur Heart J
2007; 28: 2256–95.
The information that follows is extracted from the
published guideline, reproduced with the permis-
sion of Oxford University Press.
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Recommendations for cardiac pacing in acquired atrioventricular block (European)
Clinical indication Class Level of evidence
1. Chronic symptomatic third- or second-degree (Mobitz I or II)
atrioventricular block
2. Neuromuscular diseases (e.g. myotonic muscular dystrophy,
Kearns–Sayre syndrome, etc.) with third- or second-degree
atrioventricular block
3. Third- or second-degree (Mobitz I or II) atrioventricular block:
(i) after catheter ablation of the atrioventricular junction; (ii) after
valve surgery when the block is not expected to resolve
Class I C
B
C
1. Asymptomatic third- or second-degree (Mobitz I or II)
atrioventricular block
2. Symptomatic prolonged first-degree atrioventricular block
Class IIa C
C
1. Neuromuscular diseases (e.g. myotonic muscular dystrophy,
Kearns–Sayre syndrome, etc.) with first-degree atrioventricular
block
Class IIb B
1. Asymptomatic first-degree atrioventricular block
2. Asymptomatic second-degree Mobitz I with supra-Hisian
conduction block
3. Atrioventricular block expected to resolve
Class III C
Recommendations for cardiac pacing in chronic bifascicular and trifascicular block
(European)
Clinical indication Class Level of evidence
1. Intermittent third-degree atrioventricular block
2. Second-degree Mobitz II atrioventricular block
3. Alternating bundle branch block
4. Findings on electrophysiological study of markedly prolonged HV
interval (≥ 100 ms) or pacing-induced infra-His block in patients
with symptoms
Class I C
1. Syncope not demonstrated to be due to atrioventricular block when
other likely causes have been excluded, specifically ventricular
tachycardia
2. Neuromuscular diseases (e.g. myotonic muscular dystrophy,
Kearns–Sayre syndrome, etc.) with any degree of fascicular block
3. Incidental findings on electrophysiological study of markedly
prolonged HV interval (≥ 100 ms) or pacing-induced infra-His
block in patients without symptoms
Class IIa B
C
C
None Class IIb
1. Bundle branch block without atrioventricular block or symptoms
2. Bundle branch block with first-degree atrioventricular block
without symptoms
Class III B
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431Recommendations for permanent cardiac pacing in conduction disturbances
related to acute myocardial infarction (European)
Clinical indication Class Level of evidence
1. Persistent third-degree heart block preceded or not by
intraventricular conduction disturbances
2. Persistent Mobitz type II second-degree heart block associated with
bundle branch block, with or without PR prolongation
3. Transient Mobitz type II second- or third-degree heart block
associated with new onset bundle branch block
Class I B
None Class IIa
None Class IIb
1. Transient second- or third-degree heart block without bundle
branch block
2. Left anterior hemiblock newly developed or present on admission
3. Persistent first-degree atrioventricular block
Class III B
Recommendations for cardiac pacing in carotid sinus syndrome (European)
Clinical indication Class Level of evidence
1. Recurrent syncope caused by inadvertent carotid sinus pressure
and reproduced by carotid sinus massage, associated with
ventricular asystole of more than 3 s duration (patient may be
syncopal or pre-syncopal), in the absence of medication known to
depress sinus node activity
Class I C
1. Recurrent unexplained syncope, without clear inadvertent carotid
sinus pressure, but syncope is reproduced by carotid sinus
massage, associated with a ventricular asystole of more than 3 s
duration (patient may be syncopal or pre-syncopal), in the absence
of medication known to depress sinus node activity
Class IIa B
1. First syncope, with or without clear inadvertent carotid sinus
pressure, but syncope (or pre-syncope) is reproduced by carotid
sinus massage, associated with a ventricular asystole of more than
3 s duration, in the absence of medication known to depress sinus
node activity
Class IIb C
1. Hypersensitive carotid sinus reflex without symptoms Class III C
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432 Recommendations for cardiac pacing in vasovagal syncope (European)
Clinical indication Class Level of evidence
None Class I C
1. Patients over 40 years of age with recurrent severe vasovagal
syncope who show prolonged asystole during ECG recording
and/or tilt testing, after failure of other therapeutic options and
being informed of the conflicting results of trials
Class IIa C
1. Patients under 40 years of age with recurrent severe vasovagal
syncope who show prolonged asystole during ECG recording
and/or tilt testing, after failure of other therapeutic options and
being informed of the conflicting results of trials
Class IIb C
1. Patients without demonstrable bradycardia during reflex syncope Class III C
Recommendations for cardiac pacing in hypertrophic cardiomyopathy (European)
Clinical indication Class Level of evidence
None Class I
1. Symptomatic bradycardia due to beta-blockade when alternative
therapies are unacceptable
Class IIa C
1. Patients with drug refractory hypertrophic cardiomyopathy with
significant resting or provoked LVOT gradient and
contraindications for septal ablation or myectomy
Class IIb A
1. Asymptomatic patients
2. Symptomatic patients who do not have left ventricular outflow
tract obstruction
Class III C
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Cardiac resynchronization therapy in
patients with heart failure
Recommendations (European guidelines) for
the use of cardiac resynchronization therapy
by biventricular pacemaker (CRT-P) or
biventricular pacemaker combined with an
implantable cardioverter defibrillator
(CRT-D) in heart-failure patients
Heart failure patients who remain symptomatic in
NYHA classes III–IV despite OPT [optimal phar-
macological treatment], with LVEF ≤ 35%, LV di-
latation [LV dilatation/different criteria have been
used to define LV dilatation in controlled studies on
CRT: LV end-diastolic diameter > 55 mm; LV end-
diastolic diameter > 30 mm/m2; LV end-diastolic di-
ameter > 30 mm/m (height)], normal sinus rhythm
and wide QRS complex (≥ 120 ms).
 Class I: level of evidence A for CRT-P to reduce mor-
bidity and mortality.
 CRT-D is an acceptable option for patients who
have expectancy of survival with a good func-
tional status for more than 1 year. (Class I: level of
evidence B)
Recommendations for the use of biventricular
pacing in heart-failure patients with a
concomitant indication for permanent pacing
Heart failure patients with NYHA classes III–IV
symptoms, low LVEF ≤ 35%, LV dilatation and a
concomitant indication for permanent pacing (first
implant or upgrading of conventional pacemaker).
(Class IIa: level of evidence C)
Recommendations for the use of an
implantable cardioverter defibrillator
combined with biventricular pacemaker
(CRT-D) in heart-failure patients with an
indication for an implantable cardioverter
defibrillator
Heart-failure patients with a Class I indication for an
ICD (first implant or upgrading at device change)
who are symptomatic in NYHA classes III–IV de-
spite OPT, with low LVEF ≤ 35%, LV dilatation, wide
QRS complex (≥ 120 ms). (Class I: level of evidence B)
Recommendations for the use of biventricular
pacing in heart-failure patients with
permanent atrial fibrillation
Heart failure patients who remain symptomatic in
NYHA classes III–IV despite OPT, with low LVEF
≤ 35%, LV dilatation, permanent AF and indication
for AV junction ablation. (Class IIa: level of evidence C)
Commentary
Acquired AV block
There are many causes of atrioventricular (AV)
block, but progressive idiopathic fibrosis of the con-
duction system related to an aging process of the car-
diac skeleton is the most common cause of chronic
acquired AV block. Barring congenital AV block,
Lyme disease is the commonest cause of reversible
third-degree AV block in young individuals, and it
is usually AV nodal. Before implantation of a perma-
nent pacemaker, reversible causes of AV block such
as Lyme disease, hypervagotonia, athletic heart,
sleep apnea, ischemia, and drug, metabolic, or elec-
trolytic imbalance must be excluded. The indications
for permanent pacing in second- or third-degree AV
block unlikely to regress are often straightforward
in symptomatic patients, but they are more difficult
in asymptomatic patients.
Complete AV block
The 2008 ACC/AHA/HRS guidelines (Appendix 1)
designate asymptomatic complete AV block with ven-
tricular escape rates > 40 bpm as a class II indica-
tion for pacing. The rate criterion of > 40 bpm is
arbitrary and unnecessary. It is not the escape rate
that is critical to stability, but rather the site of ori-
gin of the escape rhythm (junctional or ventricular).
Rate instability may not be predictable or obvious.
Irreversible acquired complete AV block should be a
class I indication for pacing. In neuromuscular dis-
ease such as myotonic dystrophy, pacing should be
considered much earlier in the course of the disease
and offered to the asymptomatic patient once any
conduction abnormality is noted and subsequent
follow-up shows progression even when second-
degree AV block has not yet developed. Waiting for
the development of complete AV block may expose
patients to a significant risk of syncope or even sud-
den death.
Second-degree AV block
Type I block and type II second-degree AV block are
electrocardiographic patterns, and as such should
not be automatically equated with the anatomic site
of block.
Type I block (Wenckebach or Mobitz type I)
Type I second-degree AV block is defined as the
occurrence of a single non-conducted sinus P wave
associated with inconstant PR intervals before and
after the blocked impulse, provided there are at
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least two consecutive conducted P waves (i.e., 3 : 2
AV block) to determine behavior of the PR inter-
val. The PR interval after the blocked impulse is
always shorter if conducted to the ventricle. The
term “inconstant” PR or AV intervals is important,
because the majority of type I sequences are atypi-
cal and do not conform to the traditional teaching
about the mathematical behavior of the PR inter-
vals. The description of “progressive” prolongation
of the PR interval is misleading, because PR intervals
may shorten or stabilize and show no discernible or
measurable change anywhere in a type I sequence.
Indeed, atypical type I structures in their terminal
portion can exhibit a number of consecutive PR in-
tervals showing no discernible change before the
single blocked beat. In such an arrangement the
post-block PR interval is always shorter. Slowing or
an increase of the sinus rate does not interfere with
the diagnosis of type I block.
Increments in AV conduction: Increments in AV con-
duction (AH interval) in Type I AV nodal block are
typically large, but they may occasionally be so tiny
that they superficially mimic type II second-degree
AV block. Type I infranodal block typically exhibits
small increments in AV conduction (HV interval)
and large increments in AV conduction occur un-
commonly.
Site of block: In narrow QRS type I block, the block is in
the AV node in almost all the cases. Type I block can
be physiological, especially during sleep in normal
individuals with high vagal tone, and these people
need no treatment. Asymptomatic type I second-
degree AV block present throughout the day is gen-
erally considered benign. However, some workers in
Britain recommend permanent pacing in this setting
for prognostic reasons, based on long-term mortality
data from a single center. We believe that these obser-
vations need to be confirmed before recommending
pacing for this situation.
IntraHisian narrow QRS type I block is rare. In
practice, cases of narrow QRS intraHisian type I
block due to chronic conduction system disease are
not usually found, because virtually all narrow QRS
type I blocks are dismissed as being AV nodal. In-
traHisian block, although rare clinically, may be pro-
voked by exercise, in contrast to type I AV nodal
block, which generally improves with exercise. Im-
provement of AV block with exercise is highly sug-
gestive of AV nodal second-degree AV block. His
bundle recordings are unnecessary in an asymp-
tomatic patient with narrow QRS type I block. How-
ever, if an electrophysiologic study (performed for
other reasons) in such a patient reveals infranodal
block, a pacemaker should be recommended as a
class I indication because diffuse His–Purkinje dis-
ease is likely to be present.
Type I second-degree AV block with bundle
branch block (which is far less common than narrow
QRS type I block) must not be automatically labeled
as AV nodal. Outside of acute myocardial infarction,
type I block and bundle branch block (QRS ≥ 0.12 s)
occurs in the His–Purkinje system in 60–70% of the
cases. In such cases exercise is likely to aggravate the
degree of AV block. Yet many still believe that type
I blocks are all AV nodal and therefore basically be-
nign. It is believed that the prognosis of infranodal
type I block is as serious as that of type II block, and
a permanent pacemaker is generally recommended
in both types regardless of symptoms. On this basis,
patients with type I block and bundle branch block
should undergo an invasive study to determine
the level of second-degree block in the conduction
system.
However, it is unknown whether underlying
right bundle branch block (unifascicular block) is
prognostically different from underlying left bun-
dle branch block (bifascicular block) in the setting
of asymptomatic type I second-degree infranodal
block.
Type II block (Mobitz type II)
The definition of type II second-degree AV block
continues to be problematic in clinical practice. Type
II second-degree AV block is defined as the occur-
rence of a single non-conducted sinus P wave associ-
ated with constant PR intervals before and after the
blocked impulse, provided the sinus rate or the PP
interval is constant and there are at least two con-
secutive conducted P waves (i.e., 3 : 2 AV block) to
determine behavior of the PR interval. The pause en-
compassing the blocked P wave should equal two
(PP) cycles. The PR interval is either normal or pro-
longed but remains constant. Type II block cannot
be diagnosed whenever a single blocked impulse is
followed by a shortened post-block PR interval or
no P wave at all. In this situation it is either a type I
pattern or an unclassifiable sequence. Stability of the
sinus rate is a very important criterion because a va-
gal surge can cause simultaneous sinus slowing and
AV nodal block, generally a benign condition that
can superficially resemble type II second-degree AV
block. In the presence of sinus arrhythmia, the diag-
nosis of type II block may not be possible if there is
sinus slowing, especially if the block occurs in one of
the longer cycles. In contrast, the diagnosis of type
II block is possible with an increasing sinus rate.
The 2002 and 2008 ACC/AHA/HRS guidelines
use a new classification of type II second-degree
AV block: wide QRS type II block (which makes
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up 65–80% of type II blocks) with a class I indica-
tion for pacing, and narrow QRS type II block with
a class II indication for permanent pacing. This dif-
ferentiation is strange, because there is no evidence
that narrow QRS type II block is less serious than
wide QRS type II block. The statement that “type
II block is usually infranodal especially when the
QRS is wide” may be the basis for this potentially
misleading distinction. Type II block according to
the strict definition is always infranodal and should
be a class I indication regardless of QRS duration,
symptoms, or whether it is paroxysmal or chronic.
The literature on the diagnosis of type II block is
replete with errors, because the diagnostic impor-
tance of the rate criterion and need for an unchanged
PR interval after a single blocked impulse are often
ignored. A constant PR after the blocked beat is a
sine qua non of type II block. The diagnosis of type
II cannot be made if the P wave after a blocked
impulse is not conducted with the same PR interval
as all the other conducted P waves. The shorter PR
interval after a single blocked P wave may caused
either by improved conduction (type I block) or
by AV dissociation due to an escape AV junctional
beat that bears no relationship to the preceding P
wave. In other words, type II second-degree AV
block cannot be diagnosed whenever shortened AV
interval occurs after the blocked P wave. In such a
situation the pattern is either type I or unclassifiable.
Type II block is sometimes described as having all
the conducted PR intervals constant. There is an
important loophole in this statement. It could be
interpreted to mean that the behavior of the first P
wave after the blocked impulse can be disregarded
in the diagnosis. If the P wave is absent there is
no opportunity to determine the behavior of the
first PR interval after the blocked impulse, and the
diagnosis of type II block cannot be established.
Site of block: Type II according to the strict definition
occurs in the His–Purkinje system and rarely above
the site of recording of the His bundle potential in the
proximal His bundle or nodo-Hisian junction. Type
II block has not yet been convincingly demonstrated
in the N zone of the AV node. Most if not all the
purported exceptions involve reports where type I
blocks (shorter PR interval after the blocked beat) are
claimed to be type II blocks by using loopholes in
the definitions of second-degree AV block. Because
type II invariably occurs in the His–Purkinje system,
it should be a class I indication for pacing.
Type II second-degree AV block: true or false?
When confronted with a pattern that appears to be
type II with a narrow QRS complex (especially in
Holter recordings), one must consider the possibil-
ity of type I block without discernible or measurable
increments in the PR intervals. Sinus slowing with
AV block rules out type II block. Vagal AV block
(discussed later) rarely involves more than block of
two consecutive P waves. Difficulty arises when the
sinus rate is stable. When a type II-like pattern with
a narrow QRS complex occurs in association with
type I sequences, true type II block can be safely
excluded, because the coexistence of both types of
block in the His bundle is almost unknown. True nar-
row QRS type II block occurs without sinus slowing
and is typically associated with sustained advanced
second-degree AV block far more commonly than
type I block in association with true type II block. In
other words, AV conduction ratios > 2 : 1 (3 : 1, 4 : 1)
are rare in vagal block.
Fixed-ratio AV block
A 2 : 1 AV block can be AV nodal or in the
His–Purkinje system. It cannot be classified as type
I or type II block because there is only one PR in-
terval to examine before the blocked P wave. A 2 : 1
AV block is best labeled simply as 2 : 1 block. For
the purpose of classification according to the World
Health Organization and the ACC, it is considered
as “advanced block,” as are 3 : 1, 4 : 1 and other AV
blocks. Confusion arises when the term “advanced
AV block” (defined in the ACC/AHA/HRS guide-
lines as a form of second-degree AV block of two or
more P waves) is used to describe both second- and
third-degree AV block.
The site of the lesion in 2 : 1 AV block can often
be determined by seeking the company the 2 : 1 AV
block keeps. An association with either type I or
type II second-degree AV block helps localization
of the lesion according to the correlations already
discussed. Outside of acute myocardial infarction,
sustained 2 : 1 and 3 : 1 AV block with a wide QRS
complex occurs in the His–Purkinje system in 80%
of cases, with 20% in the AV node. It is inappropriate
to label AV nodal 2 : 1 or 3 : 1 AV block as type I block
and infranodal 2 : 1 or 3 : 1 AV block as type II block,
because the diagnosis of type I and type II blocks is
based on electrocardiographic patterns and not on
the anatomical site of block.
When stable sinus rhythm and 1 : 1 AV conduc-
tion is followed by sudden AV block of several im-
pulses (> 1), and all the PR intervals before and after
the block remain constant, this strongly suggests in-
franodal block and the need for a pacemaker. This
arrangement is sometimes called type II block, al-
though it does not conform to the accepted contem-
porary definition of type II block. The purist will
insist on calling this pattern (3 : 1, 4 : 1 AV block)
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type II AV block by citing the original description by
Mobitz in 1924, despite the accepted contemporary
definitions that such patterns should not be labeled
type II AV block. When the first PR interval after the
blocked P waves (in 3 : 1, 4 : 1 AV block) is not equal
to previous PR intervals the block can be either in
the AV node or in the His–Purkinje system.
Paroxysmal AV block has been defined as the
abrupt occurrence or repetitive block of the atrial
impulses with a relatively long (approximately 2
seconds or more) ventricular asystole before the re-
turn of conduction or escape of a subsidiary ven-
tricular pacemaker. We believe that this form of AV
block does not represent a separate entity and is
best considered simply as advanced or complete
block.
First-degree AV block
It is now recognized that even an isolated markedly
long PR interval can cause symptoms similar to
the pacemaker syndrome, especially in the pres-
ence of normal left ventricular function. During
markedly prolonged anterograde AV conduction,
the close proximity of atrial systole to the preced-
ing ventricular systole produces the same hemo-
dynamic consequences as continual retrograde ven-
triculoatrial conduction during VVI pacing. This is
why symptomatic marked first-degree AV block has
been called “pacemaker syndrome without a pace-
maker,” but we believe that the term “pacemaker-
like syndrome” is more appropriate. An AV
junctional rhythm with retrograde ventriculoatrial
conduction may also produce the same patho-
physiology. The 2008 ACC/AHA/HRS guidelines
for pacemaker implantation now advocate pac-
ing in acquired marked first-degree AV block (>
0.30 s) as a Class IIa indication. Patients with a
long PR interval may or may not be symptomatic
at rest. They are more likely to become symp-
tomatic with mild or moderate exercise when the
PR interval does not shorten appropriately and
atrial systole shifts progressively closer towards
ventricular systole. The class II recommendation
does not really apply to patients with congestive
heart failure, dilated cardiomyopathy, and marked
first-degree AV block, where biventricular pacing
would be more beneficial than conventional dual
chamber pacing. The clinician must decide in the
individual patient whether there is a net bene-
fit provided by two opposing factors: a positive
effect from AV delay optimization and a nega-
tive impact of reduced LV function from aber-
rant pacemaker-controlled depolarization. A recent
study suggests that improvement with dual cham-
ber pacing becomes evident with a PR interval > 0.28
seconds.
Intraventricular conduction and
provocable AV blocks
Although the meaning of bifascicular block is obvious,
that of trifascicular block is not as simple. The term
trifascicular block is often used rather loosely. Bilat-
eral bundle branch block, despite 1 : 1 AV conduc-
tion, carries a poor prognosis and should be a class
I indication for pacing, even in an asymptomatic
patient.
Exercise: Permanent pacing is recommended as a
class I indication in symptomatic or asymptomatic
patients with exercise-induced AV block (absent
at rest), because the vast majority is due to
tachycardia-dependent block in the His–Purkinje
system and carry a poor prognosis. This form
of AV block is often reproducible in the electro-
physiology laboratory by rapid atrial pacing, be-
cause it is tachycardia-dependent and rarely due
to AV nodal disease. Exercise-induced AV block
secondary to myocardial ischemia is rare and
does not require pacing unless ischemia cannot be
alleviated.
During an electrophysiologic study: When an electro-
physiologic study is performed for the evaluation
of syncope, many workers believe that AV block or
delay in the following circumstances constitutes an
indication for permanent pacing:
(a) A markedly prolonged HV (from His bundle po-
tential to earliest ventricular activation) interval
(≥ 100 ms; normal = 35–55 ms) identifies pa-
tients with a higher risk of developing complete
AV block and need for a pacemaker. A study can
define by a process of exclusion which patients
might benefit from pacing in the presence of HV
prolongation (≥ 70 ms) and no other electro-
physiologic abnormality such as inducible ven-
tricular tachycardia.
(b) The development of second- or third-degree
His–Purkinje block in an electrophysiological
“stress test” performed by gradually increasing
the atrial rate by pacing is an insensitive sign
of conduction system disease but constitutes a
class I indication for pacing because it correlates
with a high incidence of third-degree AV block
or sudden death.
(c) Bradycardia-dependent (phase 4) block (not
bradycardia-associated, as in vagally induced
AV block) is rare and always infranodal. It
can be evaluated with His bundle recordings
by producing bradycardia and pauses by the
P1: SFK/UKS P2: SFK
appendix BLBK303-Barold May 17, 2010 9:8 Trim: 276mm×219mm Printer Name: Yet to Come
437
electrical induction of atrial or ventricular pre-
mature beats.
(d) A drug challenge with procainamide that de-
presses His–Purkinje conduction may be used
to provoke HV interval prolongation or actual
His–Purkinje block (according to published cri-
teria) in susceptible patients and define the need
for a pacemaker.
Permanent pacing for AV block after acute
myocardial infarction
The requirement for temporary pacing in acute my-
ocardial infarction (MI) does not by itself constitute
an indication for permanent pacing. Unlike many
other indications, the need for permanent pacing
after acute MI does not necessarily depend on the
presence of symptoms
Acute inferior myocardial infarction
Permanent pacing is almost never needed in inferior
MI and narrow QRS AV block. Pacemaker implan-
tation should be considered only if second- or third-
degree AV block persists for 14–16 days. The use of
permanent pacing is required in only 1–2% of all the
patients who develop acute second or third-degree
AV block regardless of thrombolytic therapy. Nar-
row QRS type II second-degree AV block has not yet
been reported in acute inferior MI.
Acute anterior myocardial infarction
Patients who develop bundle branch block and tran-
sient second- and third-degree AV block during an-
terior MI have a high in-hospital mortality rate and
are at a high risk of sudden death after hospital dis-
charge. Sudden death usually is due to malignant
ventricular tachyarrhythmias, and less commonly
related to the development of complete AV block
with prolonged ventricular asystole. The use of per-
manent pacing in patients with transient trifascicu-
lar AV block or bilateral (alternating) bundle branch
block is still controversial, but most workers recom-
mend it with the aim of preventing sudden death
from asystole despite the return of 1 : 1 AV conduc-
tion. Permanent pacing is not indicated in patients
with acute anterior MI and residual bundle branch
or bifascicular block without documented transient
second- or third-degree AV block because there is
no appreciable risk of late development of complete
AV block. Measurement of the HV interval does not
predict which patients will develop progressive con-
duction system disease.
Patients with an anterior MI who require perma-
nent pacing often have a low LV ejection fraction that
makes them potential candidates for a prophylac-
tic implantable cardioverter-defibrillator. A recent
study in patients who suffered an acute MI suggests
waiting 3–6 months before implanting a defibrilla-
tor. Despite this recommendation, it makes sense to
implant a cardioverter-defibrillator (which contains
a pacemaker component) in patients who actually
require only a permanent pacemaker at that junc-
ture. Such patients are also at risk for sudden death
from a ventricular tachyarrhythmia. It makes no
sense to wait 3–6 months without permanent protec-
tion for bradycardia until a cardioverter-defibrillator
can be implanted on the basis of a poor LV ejection
fraction according to the recommendations of a re-
cent trial of ICD after MI.
Vagally mediated AV block
Vagally mediated AV block is generally a benign
condition that can superficially resemble type II
block. This phenomenon has been called “apparent
type II block,” because it simulates type II block, but
it is generally considered a type I variant. Vagally
mediated AV block occurs in the AV node and differs
from neurally mediated (malignant vasovagal) syn-
cope where head-up tilt testing causes sinus arrest
and rarely predominant AV block. Vagally induced
AV block can occur in otherwise normal individ-
uals, and also in patients with cough, swallowing,
hiccups, micturition, etc. when vagal discharge is
enhanced. Electrophysiologic studies in vagally me-
diated AV block are basically normal. Vagally medi-
ated AV block is characteristically paroxysmal and
often associated with sinus slowing. As a rule, AV
nodal block is associated with obvious irregular and
longer PP intervals, and is bradycardia-associated
(not bradycardia-dependent), i.e., both AV block and
sinus slowing result from vagal effects.
An acute increase in vagal tone may occasionally
produce AV block without preceding prolongation
of the AH interval (constant PR), giving the superfi-
cial appearance of a type II AV block mechanism, i.e.,
no PR prolongation before the blocked beat. In this
situation, AH prolongation may occur during the
initial several beats when AV conduction resumes.
Vagally induced block is occasionally expressed in
terms of constant PR intervals before and after the
blocked impulse, an arrangement that may lead to
an erroneous diagnosis of the more serious type II
block if sinus slowing is ignored. Sinus slowing can
sometimes be subtle because the P–P interval may
increase by as little as 0.04 s.
AV block in athletes
Severe sinus bradycardia and third-degree AV block
can occur at rest or after exercise in athletes and
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lead to symptoms such as lightheadedness, syn-
cope, or even Stokes–Adams attacks. These changes
are considered secondary to increased parasympa-
thetic (hypervagotonia) and decreased sympathetic
tone on the sinus and AV node related to physical
training. Most patients become asymptomatic after
physical deconditioning. If the latter produces no re-
sponse or the patient refuses to decrease athletic ac-
tivities, a permanent pacemaker becomes indicated.
Some of the so-called “athletic patients” improved
by pacing represent individuals who would other-
wise benefit from pacing, i.e., subjects with sinus
node disease rendered symptomatic by increased
vagal tone related to training or athletes with spon-
taneous or exercise-induced infranodal block.
Atrioventricular block in athletes is most proba-
bly an expression of hypervagotonia. This form of
AV block may or may not be associated with sinus
bradycardia, because the relative effects of sympa-
thetic and parasympathetic systems on the AV and
sinus node may differ. AV block in athletes responds
to exercise or atropine. A number of authors have in-
dicated that Mobitz type II second-degree AV block
(sometimes called Mobitz AV block as opposed to
Wenckebach AV block) can occur in young athletes.
The diagnosis of type II AV block immediately raises
Table 28. Pitfalls in the diagnosis and treatment of AV block.
 Mobitz type I AV block can be physiological in athletes resulting from heavy physical training
 Mobitz type I AV block can be physiological during sleep in individuals with high vagal tone
 Failure to suspect vagally induced AV block, e.g., vomiting
 Failure to recognize reversible causes of AV block:
(1) Lyme disease
(2) Electrolyte abnormalities
(3) Inferior myocardial infarction
(4) Sleep apnea
 Poor correlation between narrow QRS type I block and symptoms
 Beliefs that all type I blocks with a wide QRS complex are AV nodal
 Non-conducted atrial premature beats masquerading as AV block
 What appears to be narrow QRS type II block may be a type I variant
 Atypical type I sequence mistaken for type II block
 Making the diagnosis of type II block without seeing a truly conducted post-block P wave (shortage of
PR intervals)
 A recording that appears to show both types I and II and a narrow QRS complex may in fact represent
only type I block
 Concealed extrasystoles causing pseudo-AV block (look for associated unexpected sudden PR
prolongation, combination of what appears to be type I and type II and isolated retrograde P waves
from retrograde conduction of the concealed extrasystole)
 Relying solely on a computer-rendered ECG diagnosis: computer interpretations are notoriously
error-prone
the question of a permanent pacemaker, especially in
symptomatic patients. We believe that Mobitz type
II second-degree AV block (always infranodal) does
not occur in otherwise healthy athletes. The pur-
ported occurrence of type II AV block in some re-
ports (with ECGs) appears related to failure to ap-
ply the correct definition of type II second-degree
AV block (Table 28).
Hypertrophic cardiomyopathy
The benefits of pacing in hypertrophic cardiomyopa-
thy (HCM) have been the subject of significant and
ongoing debate. Pacing is not primary therapy for
HCM. Dual chamber right ventricular apical (DDD)
pacing is supposed to reduce LV outflow tract gradi-
ents by a form of cardiac desynchronization by alter-
ing the regional pattern of ventricular contraction.
Pacing should only be considered when the rest-
ing left ventricular outflow gradient is greater than
30 mm Hg, or greater than 50 mm Hg when pro-
voked. In uncontrolled and observational studies,
chronic dual chamber pacing was associated with
amelioration of symptoms and reduction of outflow
gradient in many HCM patients. Pacing often re-
duces the gradient by about 50%. However, several
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randomized crossover clinical trials reported that
subjective symptomatic benefit during pacing fre-
quently occurs with little objective evidence of im-
proved exercise capacity, and can be largely ex-
plained as a placebo effect. Symptomatic relief does
not correlate with gradient reduction.
Although it is not a primary treatment, there is
evidence to support utilizing a trial of dual cham-
ber pacing without an ICD in selected patient sub-
groups such as elderly patients (older than 65 years)
with modest hypertrophy and no risk factors, who
may exhibit both subjective and objective symp-
tomatic benefit with pacing. Pacing, in this sub-
group, provides an alternative more desirable than
surgery. Producing and maintaining a reduction in
gradient (and presumably in symptoms) requires
that pre-excitation of the right ventricular apex
and distal septum be established and that there is
complete ventricular capture (at rest and during
exercise) without compromising ventricular filling
and cardiac output. In this respect, it is important
for the right ventricular lead to be positioned way
out at the apex for apical preexcitation. Program-
ming of the AV interval is vital to guarantee com-
plete ventricular capture. This may require slowing
of AV nodal conduction with a beta-blocker or ve-
rapamil, or possibly ablation of the AV node in se-
lected cases. Pacing alone does not reduce the risk of
sudden death. Patients with well-known risk factors
should be considered for an ICD. Even a single risk
marker is often considered an indication for an ICD.
Vasovagal syncope
Vasovagal syncope carries a benign prognosis in
the majority of patients. Pacing is not a first-line
treatment and should really be considered ther-
apy of last resort. Pacing can only treat the conse-
quences of bradycardia; it plays no role in prevent-
ing vasodilatation and hypotension, frequently the
dominant mechanism leading to syncope. Indeed,
a study using implantable loop recorders revealed
that that only half the patients had a recorded asys-
tolic pause at the time of spontaneous vasovagal
syncope. The result of tilt testing is not predictive
of outcome with pacing. Furthermore, the mech-
anism of tilt-induced syncope is frequently differ-
ent from that during spontaneous syncope recorded
with an implantable loop recorder. The effective-
ness of pacing has been studied in five multicenter
randomized controlled trials. Three gave a positive
result and two gave negative results. The decision
to implant a pacemaker must consider the fact that
vasovagal syncope is basically a benign condition
that frequently affects young patients, in whom a
pacemaker means potential complications over sev-
eral decades of pacing.
VVI pacing may aggravate hemodynamics dur-
ing an episode and is contraindicated. Dual cham-
ber pacing should be used with rate hysteresis or
a rate drop algorithm that allows an increased pac-
ing rate when the device detects a decrease in heart
rate. Pacing may have a role for some patients, spe-
cifically those who have little or no prodrome (no
warning symptoms), those in whom other forms of
therapy fail (refractory to at least three medication
attempts), those with unacceptable injuries, those
with potential occupational hazard, and those who
have profound bradycardia or asystole during syn-
cope. The recommendation should favor the elderly.
Patients selected on the basis of asystole and syncope
recorded by an implanted loop recorder are more
likely to benefit from pacing. For such patients, car-
diac pacing may reduce the frequency of syncope
and increase the amount of time from the onset of
symptoms to a loss of consciousness, thereby pro-
viding time for the patient to take evasive action
(i.e., lie down) and avoid injuries.
Atrial fibrillation
Clinical trials have reported that in patients with
conventional pacemaker indications, atrial-based
“physiologic” pacing is associated with a lower in-
cidence of paroxysmal and permanent atrial fibril-
lation (AF) than single chamber ventricular pacing.
This benefit is not particularly striking despite the
maintenance of AV synchrony. This is most likely
due to unnecessary ventricular pacing, which is fre-
quent in dual chamber pacing. At nominal values,
dual chamber devices usually do not permit intrin-
sic AV conduction but promote ventricular pacing.
Whether atrial pacing itself is antiarrhythmic re-
mains uncertain. A pacemaker should never be im-
planted with the sole purpose of treating paroxys-
mal AF in the absence of bradycardia.
Advanced atrial pacing algorithms for AF preven-
tion may be classified as follows:
1. dynamic sinus rhythm overdrive
2. premature atrial beat reaction (short–long cycle
prevention and ectopy overdrive)
3. post-tachycardia overdrive to prevent early re-
currence of atrial fibrillation
4. prevention of inappropriate rate fall after exercise
These algorithms for AF prevention in patients with
indications for device implantation have shown
mixed and inconsistent benefits. These contradic-
tory results and recently demonstrated very lim-
ited benefit were possibly due to different trial
designs, end points and patient populations. These
algorithms are safe and not costly. A trial of these
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algorithms may be warranted in an occasional pa-
tient. Importantly, AF can be prevented or reduced
by minimizing RV pacing.
A number of clinical trials have investigated the
impact of site-specific atrial pacing on secondary
prevention of AF. Multisite pacing (dual-site right
atrial or biatrial pacing) was demonstrated to add
only minimal benefit for AF prevention. By con-
trast, in some studies septal pacing was reported
to reduce AF recurrence in selected patients. Atrial
septal pacing (high atrium, low atrium and proximal
coronary sinus) can produce important beneficial ef-
fects in patients with paroxysmal AF and interatrial
conduction delay.
Atrial antitachycardia pacing (ATP) therapies are
effective in treating organized atrial tachyarrhyth-
mias (which precede AF), mainly when delivered
early after the onset, particularly if the tachycardia
is relatively slow. Despite this capability of termi-
nating atrial tachycardia, devices with atrial ATP
in combination with atrial pace-prevention algo-
rithms do not suppress atrial tachycardia/AF over
long-term follow-up compared with DDD/R pac-
ing. However, there are subsets of patients, e.g.,
those with atrial flutter, who are likely to benefit
from this therapy. However, the treatment of choice
is radiofrequency ablation of the cavotricuspid isth-
mus for isthmus-dependent atrial flutter.
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atrial capture testing 167
atrial lead dislodgement into right ventricle 173
characteristics 375
managed ventricular pacing 316, 317, 318
normal ventricular depolarization 220
reversed connection of atrial/ventricular leads 175
sick sinus syndrome 392
atrial demand pacing, rate-adaptive (AAIR mode) 148,
149
characteristics 375
managed ventricular pacing 316, 317, 318
sick sinus syndrome 392
atrial detection rate interval (ATDI) 187
atrial electrogram (EGM)
stored 298–9
telemetered 170
atrial escape interval (AEI) 92, 94
atrial-based lower rate timing 160
DDD mode 364
DDI mode 144
spike within QRS complex 165
ventricular channel sensing 197
ventricular-based lower rate timing 163
atrial extrasystole, endless loop tachycardia 131
atrial fibrillation 243–4
asymptomatic escaping 295
atrial capture
lack 388
testing 170
atrial undersensing 244
automatic mode switching 182, 244
biventricular pacing 420
cardiac resynchronization therapy 335, 420, 422
cardioversion 422
conducted response 402
DDD pacemakers 243–4
intermittent 400
isthmus ablation for atrial flutter 296
Cardiac Pacemakers and Resynchronization Step-by-Step: An Illustrated Guide, Second Edition
S. Serge Barold, Roland X. Stroobandt and Alfons F. Sinnaeve
© 2010 S. Serge Barold, Roland X. Stroobandt, and Alfons F. Sinnaeve. ISBN: 978-1-405-18636-0
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atrial fibrillation (Cont.)
overdrive pacing 255
pacemaker tachycardia differential diagnosis 249
during pacing 76
prevention 255
algorithms 402
ventricular pacing response 402
atrial flutter
2:1 lock-in response causing automatic mode
switching failure 179
antitachycardia pacing 302
with atrioventricular block 299
dual chamber pacemakers 391–2
isthmus ablation 296
overdrive pacing 253
pacemaker tachycardia differential diagnosis 249
atrial flutter response (AFR) 186
atrial fusion beats, isoelectric 79
atrial lead 1
coronary sinus 195
dislodgement into right ventricle 171–4
dual chamber pacing 194
interatrial conduction delay 338
intra-atrial septal pacing 195
reversed connection with ventricular 175
atrial myocardial refractory period 168
atrial output
circuit for dual chamber pacing 87
endless loop tachycardia 133
inhibition 144
maximal 104
reduction for crosstalk prevention 105
atrial output pulse
duration 105
postatrial ventricular blanking 97, 98
atrial oversensing, endless loop tachycardia 131
atrial paced event, repetitive nonreentrant VA
synchrony 300
atrial pacing
noncompetitive 401
on premature ventricular complex 140
rate 162
site 157
factors in selection 158
atrial premature complexes 118
atrial capture testing 170
automatic mode switching 180
upper rate limitation 119
atrial rate, velocity 125
atrial refractory interval
automatic mode switching 177
DDD mode 365
atrial refractory period
blanked/unblanked parts 177
retriggerable 190, 392
atrial refractory sensed event 120
atrial sensing
bipolar 147
circuit for dual chamber pacing 87
DDI mode 144
intermittent loss 131
late due to right intra-atrial conduction delay 340–2
optimal 267
VDD mode 145
see also atrial undersensing
atrial sensitivity, endless loop tachycardia 133
atrial stimulation, synchronous 251
atrial stimulus
capture in repetitive nonreentrant VA synchrony 136
DDD/DDDR mode 388, 388–9
ineffectual 143
sensing 96
repetitive nonreentrant VA synchrony 135
atrial tachyarrhythmia
annotations 88
automatic mode switching 182
cardiac resynchronization therapy 335, 420
detection 391
recording 403–4
symbols 88
atrial tachycardia
asymptomatic escaping 295
detection 298
device detection 299
overdrive pacing 253
atrial tachycardia response (ATR) 184, 185, 186
atrial tracking
apparent lack 122
pacemaker syndrome 219
recovery 346
VDD mode 145
atrial undersensing
atrial fibrillation 244
dual chamber pacemakers 388–90
functional 121, 388–90
atrial-based lower rate timing 160–2
atrioventricular block
with atrial flutter 299
biventricular pacing 158
first-degree 96, 274
pacemaker syndrome 318
retrograde conduction 266
Wenckebach type I second-degree 274
atrioventricular conduction
histogram 290, 400
loss 318
managed ventricular pacing 316, 317
promotion 375
table 290
atrioventricular crosstalk 96, 98, 367
atrial lead dislodgement into right ventricle 171,
172
intervals 367
manifestations 367
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prevention 101, 105, 367
tachycardia 367
testing for 104
ventricular safety pacing 99
atrioventricular delay 124
atrial-based lower rate timing 162
AV conduction promotion 375
cardiac resynchronization therapy 336
determination 419–20
dynamic 393
endless loop tachycardia 129, 130
hysteresis 127
intra-/inter-atrial 417–18
left ventricular 337
long fixed 392–3
long-term evaluation 417
non-physiologic 100
optimal 126
paced 102
programming optimal 416–18
QRS complex sensing 106
right ventricular 337
VDD timing cycles 146
ventricular channel in DDD mode 365
ventricular depolarization 220
V–V interval programming 419
atrioventricular dissociation 76
atrioventricular interval (AVI) 94, 123–7
abbreviation 367
atrial premature complexes 118
automatic mode switching 177
DDD pacing 364, 368
duration 368
endless loop tachycardia 132
far-field 134
far-field sensing mechanism 189
managed ventricular pacing 318
optimal 126
paced 124, 125
physiologic 125
postatrial ventricular blanking 98
prolonged 51, 96
rate-adaptive 125
repetitive nonreentrant VA synchrony 136
sensed 124, 125
shortening in ventricular safety pacing 100
TARP shortening 116
timing cycles of DDD pacemaker 91, 92
Wenckebach upper rate response 113
atrioventricular junctional ablation 336
atrioventricular nodal reentry, reciprocal beat
266
atrioventricular nodal tachycardia 298
atrioventricular search hysteresis 393
atrioventricular synchrony 374
hemodynamic benefit 216
spontaneous 55
autointrinsic conduction search 393, 401
automatic capture verification 303–6
bipolar/unipolar non-low polarization leads 305–6
automatic gain control (AGC) 82
automatic interval 48
atrial 84
hysteresis effect 55
ventricular fusion beat 77
ventricular pseudofusion beat 78
automatic mode switching (AMS) 176–90, 390–2
4 out of 7 criteria 180
algorithms 390, 391
atrial fibrillation 182, 244
atrial flutter response 186
atrial refractory period blanked/unblanked parts
177
atrial tachyarrhythmia 182
atrial tachycardia response 184, 185, 186
blanked flutter search algorithm 183
Boston Scientific 184–6
data 282
detect duration 180
dual chamber timing cycles 178
failure due to 2:1 lock-in response in atrial flutter
179
far-field oversensing 301
far-field sensing 180
filtered atrial rate interval 187, 188
histograms 297
Medtronic system 180–2
pacemaker memory 295–7
pacing rate 181
parameters 390
postventricular atrial refractory period 182, 183
programmable base rate 187
retriggerable atrial refractory period 190
right ventricular pacing minimizing 393–4
St Jude algorithm 187–8
supraventricular tachycardia detection 390
termination 181, 182
timing cycles 390–1
automatic threshold search 30, 304
Bachmann bundle pacing 157
basic lower rate (BLR) 55, 56
battery 11, 357, 360
anode 357–8
capacity 10, 18, 357, 360
cathode 357–8
circuit arrangement 15
connection to circuit 358
current drain 14, 18, 38, 283, 357, 397, 398
units 18
data 283
depletion 276
elective replacement indicators 276
end-of-life 17, 276, 398
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battery (Cont.)
end-of-service 398
impedance 10
life expectancy 18, 42, 55, 360
longevity 38, 415
pulse output 18
resistance 281
voltage 10
see also lithium–iodine battery
battery 1 10
battery 2 10
battery stress test 398
bicycling, pacing rate 233
Biotronik home monitoring system 312
bipolar electrogram (EGM) 46
variability 47
bipolar pacing 31, 46, 363
bipolar sensing 363
variability 47
bipolar stimuli
lead fractures 208
surface ECG 204
biventricular (BIV) pacing 158, 270, 320–54, 375
advanced heart failure 407
anodal stimulation 415
atrial fibrillation 420
atrial tracking recovery 346
ECG pattern 348
electrical desynchronization 344
frontal plane axis during single chamber pacing 324
with fusion 329
interventricular timing effects 416
lack of dominant R wave in lead VI 328
late atrial sensing due to right intra-atrial
conduction delay 341
leads 322
left ventricular and right ventricular outflow tract
327
left ventricular delayed activation correction 349
left ventricular latency 350
left ventricular slow conduction 350
optimal programming 410
percentage 407
QRS morphology 410–11
resynchronization 375
right ventricular anodal stimulation 330, 416
right ventricular apical stimulation 324
right ventricular lead
located at apex 326, 411, 412
located in outflow tract 411, 412
in right ventricular outflow tract 327
right ventricular outflow tract/septal stimulation
324
sinus rhythm 329
transvenous left ventricular lead 211
triggered 341
upper rate limitation in biventricular pacing 334
ventricular fusion with spontaneous QRS 329
ventricular lead polarity 323
blood pressure 269
body motion sensors 223
Boston Scientific
automatic mode switching 184–6
capture verification algorithm 396
marker channel 89
phrenic nerve stimulation avoidance 351
PMT termination algorithm 139
V-V interval programming 337
brachial artery pressure, pacemaker syndrome 218
brachial plexus injury 382
Brady Basic Event Markers 90
Brady response, sudden 402
bradyarrhythmias
annotations 88
special events markers 90
symbols 88
bradycardia
pacing location 150
right ventricular pacing 158
Cabrera’s sign 74, 378
capture verification algorithms 395–7
cardiac arrhythmias
diagnosis 283
pacemaker memory 295–7
cardiac memory 379–80
cardiac output 215, 216
cardiac pacing, retrograde conduction 266
cardiac perforation 382–3
cardiac remodeling, right ventricular apical pacing 151
cardiac resynchronization therapy (CRT) 320–54,
405–22
12-lead ECG availability 336
anodal stimulation in biventricular pacemakers 415
atrial fibrillation 420, 422
atrial tachyarrhythmia 420
atrioventricular delay 336
atrioventricular interval, semi-automatic
optimization 419–20
battery longevity 415
benefit failure 407
complications 408–9
congestive heart failure 420–2
electrical desynchronization 335
electrical repositioning 335
far-field R-wave oversensing 415
hemodynamics 405
impact 407–8
interatrial conduction delay 338
intra-/inter-atrial conduction delay 417–18
late atrial sensing due to right intra-atrial
conduction delay 340–2
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left ventricular automatic capture verification
415
left ventricular dyssynchrony 321
left ventricular output 335
left ventricular pacing output programming 415
loss 343
lower rate 335
programming 414
narrow QRS complex 406–7
non-responders 420
with only left ventricular pacing 405–6
optimal atrioventricular delay 416–18
patient selection 405
poor clinical response 352, 421
postventricular atrial refractory period 334
lock 343
restoration by abbreviation 347
programmability 347
programming of devices 335–6, 409–20
verification by exercise testing 416
responder 408
resynchronization loss below programmed upper
rate 413–14
right ventricular lead 406
scar burden 407–8
timing cycles of device 344
triangular 323
triggered ventricular pacing 416
upper rate
limitation 333–4
programming 413–14
response 413
ventricular arrhythmias 422
ventricular triggering 341
V–V interval
optimization 336
programming 337, 418–19
semi-automatic optimization 419–20
Wenckebach upper rate response 333, 334
carotid sinus massage/pressure 51
cathode 15, 16
cellular phones, electromagnetic interference 261
chest electrode positions 4
chest X-ray 270
chronotropic incompetence 217
circuit disruption, intermittent 199
computed tomography (CT), multidetector 383
conduction delay, intra-/inter-atrial 417–18
conductor coil, tri-filar 35
congestive heart failure
biventricular pacemakers 375
cardiac resynchronization therapy 420–2
implantable cardioversion defibrillators 421
coronary sinus
atrial lead 195
dissection 408–9
left ventricular pacing 81
perforation 409
coronary vein
cardiac resynchronization therapy complications 408
left ventricular pacing 81
complications 211
corticosteroids 394
coughing, minute ventilation sensor responses 234
crosstalk
reverse 390–1
see also atrioventricular crosstalk
crystals, body motion sensors 223, 224
current (I) 11, 12, 13, 15, 360
drain 360
units 14
DDD mode see dual chamber pacing (DDD mode)
DDDR mode see dual chamber pacing, rate-adaptive
(DDDR mode)
DDI mode 142, 373
atrial fibrillation and automatic mode switching 244
characteristics 375
lower rate timing 164
normal ventricular depolarization 220
pacing rate 420
DDIR mode
automatic mode switching 181
characteristics 375
normal ventricular depolarization 220
defibrillation 257
defibrillation protection circuit 257
defibrillators
rapid ventricular pacing 254
see also implantable cardioversion defibrillators
deltopectoral muscle stimulation 383–4
demand pacemaker
magnet application 52
undersensing 48
ventricular capture 50
depolarization
electrical activity 6
see also ventricular depolarization
detection paced beats 319
diagnostic data 400
diaphragm contraction 383
diaphragmatic pacing 409
diaphragmatic stimulation 211, 383
avoidance 351
digital ECG 32
digital sampling 32
disopyramide 394
diuretic therapy 420
dofetilide 422
DOO mode 142
Doppler echocardiography, atrioventricular delay 126
droop 23
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drop detection, DDD mode 319
drugs 394–5
dual chamber (DDD) pacemaker 86–106, 363–7
atrial capture 388, 389
atrial fibrillation 243–4
atrial flutter 391–2
atrial refractory interval 365
atrial undersensing 388–90
atrioventricular interval 364
duration 368
endless loop tachycardia 130
fifth timing cycle 97, 366
fixed-ratio block 368
four timing cycles 94
intermittent crosstalk 102
lower rate interval 369
lower rate timing 369
minute ventilation sensors 225
paced ventricular rate 368
pacemaker syndrome 219
postventricular atrial refractory period 365
rate smoothing 117
refractory period 366
sensing 365
seventh timing cycle 111, 112
six intervals 365–6
sixth cycle addition 99, 101
spike within QRS complex 165
three-letter pacemaker code 95
timing cycles 91–2
total atrial refractory period 365
types 373–4
upper rate interval 364, 365, 366, 368–9
upper rate response 107–22, 368–9
ventricular channel 363–4
ventricular safety pacing 366
Wenckebach upper rate response 368–9
dual chamber pacing (DDD mode) 87, 141–58, 142
2:1 block upper rate behavior 239
atrial capture testing 169
atrial channel 364–5
atrial escape interval 364
atrial stimulus 388, 388–9
automatic mode switching 181
characteristics 375
decision tree 148
drop detection 319
electrode interactions 200
lead positions 194–5
lower rate timing 164
managed ventricular pacing 318
modes 142–5
nine intervals 367–8
normal ventricular depolarization 220
pacemaker tachycardia differential diagnosis 249–50
postventricular atrial refractory period 267
timing cycles with automatic mode switching 178
triggered mode 275
unipolar 245
ventricular channel 365
ventricular stimulus 388, 388–9
Wenckebach upper rate response 238
dual chamber pacing, rate-adaptive (DDDR mode)
148, 375–6
2:1 block upper rate behavior 239
atrial stimulus 388, 388–9
automatic mode switching 181
characteristics 375
managed ventricular pacing 318
minute ventilation sensors 225
normal ventricular depolarization 220
pacemaker reset 262
pacemaker tachycardia differential diagnosis 249–50
rate-adaptive postventricular atrial refractory
period 240
sensor function programming 368
sensor-driven rate-smoothing 376
ventricular stimulus 388, 388–9
Wenckebach upper rate response 238
dual sensors 235–7
DVI mode 142, 143, 373
asynchronous in atrial channel 190
atrial capture testing 168
atrial refractory period 392
lower rate timing 164
DVIR mode, atrial refractory period 392
echocardiography 270, 405
with tissue Doppler imaging 407
elective replacement indicator (ERI) 276, 398
elective replacement time (ERT) 262, 276
electric arc welding, electromagnetic interference
261
electricity 10–18, 360
electrocardiogram (ECG)
analog recording 31
automatic gain control 82
biventricular pacing 348
digital 32
left ventricular latency 348
left ventricular pacing 348
long-term changes 412
phone transmission 41
right ventricular pacing 72, 348
saturation 82
surface 43
telemetry real-time read-out 279
electrocardiogram (ECG), 12-lead 2
cardiac resynchronization therapy 336
configuration during transvenous pacing 3
before CRT device programming 409–13
frontal plane leads 6
P1: OTE/PGN P2: OTE/PGN QC: OTE/PGN T1: OTE
ind BLBK303-Barold May 17, 2010 15:18 Trim: 276mm×219mm Printer Name: Yet to Come
457
pacemaker follow-up 265, 269
spike 23
electrocautery
minute ventilation sensor responses 234
pacemaker vicinity 257
electrodes
biventricular pacing 322
difference between signals 46, 47
excitable myocardium contact 36
geometrical surface area 38
high impedance 38
interactions 200
low impedance 38
normally placed 39
porous 37
potential difference 43
ventricular capture loss by visible pacemaker
stimuli 203
wave front advance 47
electrode–tissue interface
polarization voltage 23
ventricular capture loss by visible pacemaker
stimuli 203
electrogram (EGM) 46
phase difference 47
pre-/post-trigger storage 298
real-time 399
storage 403–4
stored 300–2, 399
clinical application 298–9
unipolar 46, 47
see also atrial electrogram (EGM)
electrolytes 16
abnormalities in exit block 202
imbalance 394–5
electromagnetic interference 257
inside hospital 260
outside hospital 261
pacemaker reset 262
electronic appliances 261
electronic article surveillance 261
electronic escape interval 42
electrons 15, 16
emergency button 25
endless loop tachycardia (ELT) 129, 266, 371–2, 373
DDD pacemaker 130
diagnosis 371–2
far-field 134
myopotential sensing during DDD pacing 246
orthodromic macro-reentrant pacemaker
tachycardia 251
pacemaker tachycardia differential diagnosis 250
precipitating factors 131
prevention 267, 371–2
retrograde P waves 137
reverse 251
test for propensity 133
upper rate 132
epileptic seizures, pacing rate 233
epinephrine 394
episode trigger event markers 90
escape interval 42, 48, 50
atrial 84
hysteresis 55, 369
ventricular fusion beat 77
ventricular pseudofusion beat 78
VVI mode 358–9, 362
VVT mode 85
escape rate (ESCR) 55, 56
evoked potential, ventricular detection 305
evoked response
detection 304
sensing 303
exercise testing 416
exercise tolerance improvement with CRT 407,
408
exit block 202, 207
external cardioversion 257
extracorporeal shock wave lithotripsy (ESWL)
260
false signals 198, 386
electrode intermittent contact 200
mechanisms 199
filtered atrial rate interval (FARI) 187, 188
first-degree exit block 394
fixed ratio block 2:1 109
avoidance of abrupt block 112
treadmill stress test 110
upper rate limitation 111
Wenckebach upper rate response 113, 114
flecainide 394
frontal plane axis 6
QRS complex 73
quadrants 9
see also mean frontal plane axis
general anesthesia, minute ventilation sensor
responses 234
general surgery, pacemakers 257
Guidant, phrenic nerve stimulation avoidance
351
heart
hemodynamics 215
topographic anatomy 192
heart failure
cardiac resynchronization therapy device
monitoring 421–2
recurrent 420–1
risk with right ventricular apical pacing 152
volume overload 353
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heart rate 215
drop 319
histogram 293, 400
nocturnal 422
open loop rate-adaptive pacing 222
pressure on pacemaker 224
variability 421–2
hemisphere concept of frontal plane leads 6
hemodynamic disadvantage 266
hemoptysis 380
hemothorax 380
His bundle pacing 156
direct 392
His–Purkinje system
activation penetration 150
left ventricular depolarization 156
histograms 289
atrioventricular conduction 290, 400
automatic mode switching 297
heart rate 293, 400
ventricular 290
interpretation 290
P wave amplitude 291
sensor indicated rate 293
Holter monitoring 270
implantable system 400, 403–4
pacemaker recording 285
rhythms 358
triggered mode 275
hyperkalemia 394–5
exit block 202
hypertrophic cardiomyopathy 270
hyperventilation, minute ventilation sensor responses
234
hypothyroidism, exit block 202
hysteresis 55–6, 359
atrioventricular delay 127
atrioventricular search 393
escape interval 369
impedance 10
technology equipment and minute ventilation
sensor responses 234
telemetry measurement 281
implantable cardioversion defibrillators (ICD)
cardiac resynchronization therapy 406
congestive heart failure 421
internet-based remote monitoring 310–12
leads 383
right ventricular pacing avoidance 392
infections
cardiac resynchronization therapy complications
408
pocket 382
insulation defects, lead 13, 199, 205, 207, 387, 388
muscle stimulation 212
interatrial conduction delay (IACD) 157, 338–9
atrial capture testing 170
cardiac resynchronization therapy 338
internet-based remote monitoring of ICDs 310–12
interventricular interval see V–V interval
interventricular septum, plane 192
intra-atrial septal pacing 195
intracardiac electrograms
pacemaker follow-up 265
telemetry 277
real-time read-out 279
intracardiac sensing 42
intrathoracic impedance 421
intravascular pacemaker complications 381
intrinsic rhythm 56
iodine ions 16, 17
isoproterenol 394
isthmus ablation for atrial flutter 296
large vein thrombosis 399
latency
delayed intra-/inter-ventricular conduction 419
hyperkalemia effects 394
lead(s) 13, 33–9
bipolar 363
biventricular pacing 322
damage 382
data 283
displacement 39, 207, 382, 399
dual chamber pacing 194–5
fixation 35
fractures 13, 198, 199, 204, 206, 207, 387
with conversion from bipolar to unipolar mode
208
high-impedance 38
impedance 282
follow-up 399–400
implantable cardioversion defibrillators 383
insulation defects 13, 199, 205, 207, 387, 388
muscle stimulation 212
intermittent circuit disruption 199
loose connections 204
low-impedance 38
malfunction 387, 387–8
malposition 382
monitoring 287
non-low polarization 305–6
normally placed 39
pacemaker complications 381, 382
perforation 193, 212
polarity of ventricular 323
problem analysis 207
resistance 13
steroid-eluting 36, 360, 397–8
twisted 210
unipolar 363
P1: OTE/PGN P2: OTE/PGN QC: OTE/PGN T1: OTE
ind BLBK303-Barold May 17, 2010 15:18 Trim: 276mm×219mm Printer Name: Yet to Come
459
VVI pacing 193
see also atrial lead; ventricular lead
lead aVF 6, 7, 8, 9
lead I 8, 9
Q, q and QS configuration 412
lead II 8, 9
lead III 8, 9
lead VI 22
left bundle branch block (LBBB) 22, 348, 410
AAI pacing 274
ECG 412
interventricular dyssynchrony 321
myocardial infarction 378
NYHA class I and II patients 406
right ventricular outflow tract pacing 155
right ventricular pacing 377
left intercostal muscle stimulation 383
left ventricle
depolarization 150
epicardial stimulation 22
perforation 383
left ventricular automatic capture verification 415
left ventricular capture threshold 351
left ventricular depolarization, His–Purkinje system
156
left ventricular dysfunction
atrial pacing site 158
biventricular pacing 158
long-term risk with right ventricular apical pacing
151
left ventricular dyssynchrony
cardiac resynchronization 321, 406, 407
echocardiographic evaluation 421
interventricular 321
intraventricular 321
mechanical 407
left ventricular endocardial lead misplacement 81
left ventricular end-systolic volume 408
left ventricular function preservation 150
left ventricular leads
bipolar 351
dislodgement 408, 412
endocardial 408
left ventricular output, cardiac resynchronization
therapy 335
left ventricular pacing 81
alternative routes 408
complications 211
from coronary venous system 410
delayed activation correction 349
endocardial 378
epicardial 322, 422
latency 348–9, 350
monochamber 324, 327
with biventricular pacemaker 325
right ventricular anodal capture 331, 332
output programming 415
QRS complex morphology 410
transvenous 322
ventricular tachycardia induction 422
left ventricular remodeling, reverse 407, 420
left ventricular slow conduction 350
level detector 59
limb leads 3
lithium ions 16, 17
lithium–iodine battery 16, 17, 357, 360
load 15
locked-in phenomenon 391
low atrial septum pacing 157
Lower Rate detection 319
lower rate interval (LRI) 55, 358
atrial-based lower rate timing 160
DDD pacemakers 364, 369
DDI mode 144
definition 229
dual chamber pacemakers 369
programmability 369, 370–1
repetitive nonreentrant VA synchrony 136
VDD mode 145
VDD timing cycles 146
ventricular-based lower rate timing 163
lower rate timing 160–5
atrial-based 160–2
pacing mode 164
ventricular-based 163
lung fluid monitoring 353
magnet
application 269, 395
on demand pacemaker 52
in oversensing 198, 200
bipolar function restoration 208
interval 52
mode 376–7
positioned over pacemaker 52, 53
reed switch closing 54
magnetic reed switch 54
magnetic resonance imaging (MRI)
contrast-enhanced 352
electromagnetic interference 260
magnetic resonance imaging (MRI)-safe pacemaker
403
managed ventricular pacing (MVP) 316–18
ventricular back-up 317
markers 44
atrial capture testing 169
Medtronic 88
pacemaker follow-up 265
telemetry 277
ventricular safety pacing 102
maximum sensor driven rate 232
definition 229
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maximum tracking rate 232, 345
mean frontal plane axis 2, 6
determination 7–8
QRS complex 73
Medical Implant Communications System (MICS) 309
Medtronic algorithm
atrial tracking recovery 346
capture verification 396
Left Ventricular Capture Management 415
PMT intervention 138
Medtronic arrhythmia report 297
Medtronic Atrial Capture Management 307
Medtronic automatic mode switching system 180–2
blanked flutter search algorithm 183
Medtronic Capture verification system 305, 306
Medtronic Cardiac Compass 295
Medtronic internet-based remote monitoring 310–11
Medtronic Managed Ventricular PacingTM 394
Medtronic markers 88
memory effect 75
metal detector gates, electromagnetic interference 261
minute ventilation sensors 225–7
circuit 226, 227
unwanted responses 234
mitral regurgitation 420
mode switching algorithms 391
multiprogrammability 370–1
muscle stimulation 212
myocardial cells, conduction in ventricular fusion 77
myocardial infarction (MI)
anterior 378
exit block 202
inferior 378–9
manifestations 378–9
right ventricular pacing for old anterior 74
ventricular pacing 379
myocardial ischemia, right ventricular pacing 379
myocardial refractory period 20
pacemaker stimulus fall 53
repetitive nonreentrant VA synchrony 135
myocardium
echocardiography with tissue Doppler imaging 407
excitable and electrode contact 36
hyperkalemia effects 394–5
myopotential sensing
noise interference mode 245
oversensing 386
pacemaker tachycardia differential diagnosis 249
undersensing secondary to oversensing 246
unipolar DDD pacing 245–6
myopotentials 386
maneuvers to demonstrate 247
myotonic jerks, pacing rate 233
noise interference mode in myopotential sensing 245
noise sampling 257
non-competitive atrial pacing (NCAP) 241, 401
NYHA class I and II patients with LBBB and
depressed LV function 406
NYHA functional class improvement with cardiac
resynchronization therapy 407, 408
Ohm’s law 10, 11, 13, 14, 360
OptiVol Fluid IndexTM 421
output capacitor, recharging 34
output pulse 23
amplitude 23
duration (width) 23
leading edge 23, 34
trailing edge 23, 34
overdrive pacing 253
atrial fibrillation prevention 255
overdrive rate, automatic mode switching 181
overdrive suppression 374
oversensing 48, 49, 196–200, 384, 386
detected by inappropriate mode switching 301
false signals 198, 199, 386
magnet application 198, 200
myopotential 245
pacemaker response to interference 386–7
triggered mode 275
undersensing secondary to 246
ventricular 122, 302
P waves
AAI pacemaker 84
amplitude histogram 291
atrial capture testing 170
atrial pace on premature ventricular complex 140
detection prevention by long PVARP 122
dissociated 134
high atrial pacing threshold 135
hyperkalemia 202
interatrial conduction delay 338, 339
intracardiac amplitude 282
locked-in postventricular atrial refractory period
343, 344
long AV delay programming 167
paced 79, 84
postventricular atrial refractory period
detection prevention 122
programming automatic unlocking 414
upper rate limitation 413
retrograde 74, 266
sensed 137
unsensed 93
ventricular premature complex 300
sensing prevention 122
spontaneous 84
tracking 145
ventricular desynchronization 345
Wenckebach interval 119
paced ventricular event (VP) 358
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pacemaker(s)
activity recording 2–9
care 356
circuit derangement 199
complications 380, 381, 382–4, 384–5, 386–90
electrical 383–4, 384–5, 386–90
generator-related 384
intravascular 381
lead-related 381, 382
pocket-related 381, 382
venous access 380, 381, 382
components 1
data 282, 283
stored 288, 294
definition 1
device information 287
diagnostics 287
sensing thresholds 292
follow-up 398–400
functions 357
general surgery 257
hemodynamics 214–41, 374–5
implantation 264, 357
interference 256–62
interrogation 271, 280
interval 358
longevity 397–8
memory 288
arrhythmias 295–7
automatic mode switching 295–7
stored data 294
output pulse 23
capture verification systems 303
data 283
failure 202
regulation 304
programming 403
rate 358
refractory period 20
special functions 315–19, 401–3
timing cycles 355
unidentified 284
units 14
see also battery; programming, pacemakers
pacemaker alternans 380
pacemaker code, three-letter (ICHD) 45, 95
pacemaker dependency 374, 399
pacemaker electrocardiography, basic 71–82
pacemaker filter 362
pacemaker follow-up 263–307
active phase threshold end determination 273
general approach 269–70
Quick LookTM 287
systematic 265, 271
threshold initial steps automatic determination
272
transtelephonic 268
marker annotations 88
pacemaker monitoring, remote 308–14
benefits 313
internet based 310–12
organizational model 314
quality assurance 314
wireless programming 309
pacemaker radiography 191–5
pacemaker reset 262
pacemaker runaway 213
pacemaker stimulus 376
complications 384, 384–5
constant amplitude 27
digital ECG 32
fall in myocardial refractory period 53
lack of capture 27
large 31
not followed by QRS complex 50
small 31
pacemaker syndrome 218, 266
blood pressure 269
dual chamber pacemakers 219
first-degree atrioventricular block 318
pacemaker tachycardia 233, 242–51
differential diagnosis during DD(R) pacing
249–50
orthodromic 250
macro-reentrant 251
sensor-related 250
pacemaker-mediated tachycardia (PMT) 138, 139
pacing
three-letter pacemaker code 45
see also rate-adaptive pacing
pacing anode 3
pacing cathode 3
pacing cycle length, permitted maximum change 117
pacing impedance 13, 38, 399–400
lead fractures 208
pacing mode
characteristics 375
decision tree 148
lower rate timing 164
selection controversies 149
pacing pulse, leading/trailing edge 23, 34
pacing rate
changes 387
environmental interference 233
pacing states, storage 289
pacing threshold 360–2, 399–400
acute 36
automatic determination 361–2
chronic 36
curve 28
determination 26–7
evolution 36
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pacing impedance (Cont.)
hyperkalemia effects 394
supernormal phase 361
paper speed 5
paraHisian pacing area 153, 156
patent foramen ovale, left ventricular pacing 81
peak systolic velocity 321
phantom programming 369
phrenic nerve stimulation 351, 409
by lead 211
piezoelectric crystals 223, 224
piezoelectric effect 223
pneumothorax 380
pocket erosion 382
pocket hematoma 382
pocket seroma 382
pocket-related complication pacemakers 381, 382
polarity 363
polarization phenomenon 34, 37
polarization voltage 23, 34, 37
Post Mode Switch Overdrive Pacing 181
postatrial ventricular blanking (PAVB) 97, 105, 366
automatic mode switching 390
crosstalk prevention 105, 367
period 98, 99
ventricular safety pacing window 100, 101
post-extrasystolic pauses, prevention 255
postventricular atrial refractory period (PVARP) 92,
93, 94
adaptive 376
atrial flutter detection 391–2
atrial pace on premature ventricular complex 140
atrial premature complexes 119
atrial refractory sensed event 120
atrial tracking recovery 346
atrial undersensing 388–9, 390
automatic extension 121
automatic mode switching 182, 183, 390
cardiac resynchronization therapy 334, 335
DDD pacemakers 365
dual chamber pacing 267
endless loop tachycardia 133
prevention 371–2
functional atrial undersensing 121
lock in cardiac resynchronization therapy 343
management 347
long 122
optimal programming 413–14
P waves
detection prevention 122
locked in 343, 344
programming automatic unlocking 414
upper rate limitation 413
pacemaker-mediated tachycardia 138
PMT termination algorithm 139
programmability 347
QRS complex sensing 106
rate-adaptive 240
repetitive nonreentrant VA synchrony 135
retrograde P wave fall 135, 136
shortening 376
upper rate interval 116
ventriculoatrial crosstalk 390–1
Wenckebach upper rate response 113
potassium balance 394–5
P–P interval
automatic mode switching 188
Wenckebach upper rate response 368
P–R interval 366
length 344
premature ventricular complex see ventricular
premature complex (VPC)
premature ventricular events (PVE) 120
procainamide 394
programmability 57
programmed voltage 29
programmers 270, 357
emergencies 25
pacemaker interrogation 280
unidentified pacemakers 284
programming
cardiac resynchronization therapy devices 335–6,
409–20
pacemakers 24, 358
asystole 25
propafenone 394
pseudofusion beats 78, 275, 366–7
pseudopseudo fusion beat 103
pseudotachycardia 358
pulmonary embolism 382
pulse amplitude 29, 30
pulse current 283
pulse duration
pacing threshold 26, 27
threshold curve 28
voltage relationship 360–1
pulse generator 203
pulse width
constant 26
decreasing 27
pump pressure 12
Purkinje fibers 77
Qr complex 377
qR complex 377
QRS complex
asynchronous pacing 21
conducted
far-field sensing mechanism in atrial channel 189
sensing 96
ventricular channel inhibition 100
correctly sensed 48
duration 411
surface 420
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far-field sensing 106, 134
hyperkalemia 202
intracardiac amplitude 282
isoelectric onset 349
left ventricular pacing latency 349
loss of capture 411
morphology 348
biventricular pacing 410–11
left ventricular pacing from coronary venous
system 410
right ventricular apical pacing 409
narrow
cardiac resynchronization therapy 406–7
with isoelectric fusion beats 79
spontaneous 412
narrowing 411
normally conducted 21
paced 21, 23, 26, 27, 48
anodal stimulation in biventricular pacemakers
415
atrial lead dislodgement into right ventricle
172
broad 31
dominant R wave 377
duration during right ventricular pacing 378
electrical latency 348
frontal-plane axis 412
narrow representing ventricular fusion 412
P waves 76
telemetry real-time read-out 279
ventricular fusion beat 77
ventricular pseudofusion beat 78
VVT mode 85
wide 22, 41, 52
pseudotachycardia 358
sensed 103
ventricular stimulus inhibition 244
sensing of terminal portion 106
spike 165
spontaneous 21, 26, 27, 42, 52
atrial lead dislodgement into right ventricle 172
conducted 85
exit block 202
sensed 42, 85
telemetry real-time read-out 279
unsensed 48
ventricular fusion beat 77, 329
ventricular fusion with 418
ventricular pseudofusion beat 78
supernormal phase 361
unsensed 103
ventricular depolarization by pacing 22
ventricular pseudofusion beats 363
ventricular safety pacing window 367
QRS vector (axis) 6, 7, 8, 9
QS pattern, right ventricular atrial pacing 72
QT interval
sensing 228
sensor responses 234
Quick LookTM follow-up 287
R wave 7, 44
dominant 9
lack in biventricular pacing 328
paced ventricular beats in lead VI 80
right ventricular pacing 377
far-field oversensing 415
far-field sensing 251, 301
left ventricular pacing 81
pseudotachycardia 358
right ventricular atrial pacing 72
sensed 120
tall in left ventricular pacing 81
radiotherapy, electromagnetic interference 260
random access memory (RAM) 286
rate 5
rate drop hysteresis 401
rate drop response (RDR) 319
rate modulation, hemodynamic benefit 216
rate smoothing 117, 401
rate-adaptive pacing 214–41, 375–6
2:1 block upper rate behavior 239
algorithms 230–1
atrial-driven rate 232
chronotropic incompetence 217
deceleration curves 231
definitions 229
indicators 221
open loop 222
pacemaker programming 376
pacing rate 231, 232
range 230
post-exercise recovery 231
sensor threshold 376
sensor-driven rate 231, 232
slope 229, 230
threshold 229
Wenckebach upper rate response 238, 376
rate-adaptive postventricular atrial refractory period
(PVARP) 240
read only memory (ROM) 286
record-keeping 271, 397
reed switch, magnetic 54
refractory period sensing 365
remote monitoring 398–9
repetitive nonreentrant VA synchrony (RNRVAS) 135,
266, 372–3
atrial capture testing 170
prevention 136
retrograde P waves 137
stored electrograms 300
termination 300
treatment 136
ventricular depolarization 220
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repolarization, memory-related abnormalities 379–80
reporting 271
reset mode 398
resistance (R) 11, 12, 13, 360
telemetry measurement 281
units 14
respiratory rate, minute ventilation 225, 226
response mode, three-letter pacemaker code 45
retrograde ventriculoatrial conduction
atrial capture 168
evaluation 133
retrograde ventriculoatrial synchrony in dual chamber
pacemakers 128–40
reverse left ventricular remodeling 407, 420
rheobase 361
right atrial appendage pacing 157
right atrial electrode 1
right atrial pacing site 157
right bundle branch block (RBBB) 22, 348, 410
cardiac resynchronization therapy 406
dominant R wave in lead V1 80
pattern 377, 378
right intra-atrial conduction delay, late atrial sensing
340–2
right ventricle
atrial lead dislodgment into 171–4
endocardial stimulation 22
perforation 383
right ventricular anodal capture 323
monochamber left ventricular pacing 331, 332
right ventricular anodal stimulation 330, 416
right ventricular apex
lead position 39
ventricular electrode 211
right ventricular apical pacing 72, 73, 150
QRS complex morphology 409
risks 151, 152
right ventricular electrode 1, 211
right ventricular lead
perforation 211
position 193
right ventricular outflow tract 327
right ventricular outflow tract
anatomy 153
lead position 39
monochamber pacing 327
pacing 154–5, 377
area 153
leads 154
right ventricular lead 327
right ventricular pacing 316
alternative sites 153
apical 72, 73, 150
QRS complex morphology 409
risks 151, 152
bifocal 408
cardiac memory 380
dominant R wave 377
ECG 72, 348
mean GRS axis in frontal plane 73
minimizing 392–4
algorithms 392–4
monochamber 324
myocardial infarction diagnosis 379
myocardial ischemia diagnosis 379
normal QRS patterns 377–8
old anterior myocardial infarct 74
outflow tract 72, 73
paced QRS duration 378
septal 153, 154–5
site selection 158
small r wave in lead V1 377–8
right ventricular septal pacing 154–5
area 153
R-on-T phenomenon 358
R–R interval 164, 366
runaway protection circuit 213
R-wave amplitude 399–400
S wave 7
Cabrera’s sign 74, 378
safety margin 360–1
safety ratio concept 29
safety switch automatic lead configuration 403
sampling 285
search hysteresis 56
search interval 56
sensed ventricular event (SP) 358
sensing 50, 275, 362–3, 400
advanced concepts 57–70
atrial 145
bipolar 147
atrial stimulus 96, 144
basic concepts 40–57
circuit 59
evoked response 303
myopotential
pacemaker tachycardia differential diagnosis 249
during unipolar DDD pacing 245–6
potential difference between electrodes 43
QT interval 228
slew rate determination 362
stimulus–T interval 228
three-letter pacemaker code 45
thresholds 292
determination 271
triggered impulse 275
ventricular 143, 144, 145
unipolar 147
see also atrial sensing; oversensing; undersensing;
ventricular sensing
sensing amplifier 46
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sensing assurance 402
sensing integrity counter 403
sensitivity 362–3
high/low 59
sensor(s)
blending 235–7
body motion 223
cross-checking 236, 237
dual 235–7
false responses 236
minute ventilation 225
open loop rate-adaptive pacing 222
programming 270
unwanted responses 233–4
sensor indicated rate histogram 293
sensor-driven interval (SDI)
dual sensor pacing 237
rate-adaptive pacing 232, 238
sensor-driven rate (SDR) 232
sensor-driven rate-smoothing 368, 376
sensor-driven upper rate interval (SDURI) 239
sensor-driven ventricular cycle 241
shivering, pacemaker tachycardia 233
sick sinus syndrome
pacing mode 149
retrograde conduction 266
right ventricular pacing 158
single lead VDD contraindication 147
ventricular activation sequence 392
single chamber system 358–60
basic measurements 359
minute ventilation sensors 225
pacemaker events 359
timing cycles 359
sinus interval, oversensing of false signals 198
sinus preference 402
sinus rate, continuous overdrive 255
sinus rhythm
antitachycardia pacing 302
biventricular pacing 329
pacemaker syndrome 218
short sensed atrioventricular delay 342
sinus tachycardia
electrical desynchronization in biventricular
pacemakers 344
pacemaker tachycardia differential diagnosis 249
sleep function 401
slew rate determination 362
spike, ECG 23
spontaneous atrial interval (SAI) 108
atrial premature complexes 118
fixed ratio block 2:1 109, 112
rate-adaptive pacing 232
Wenckebach upper rate response 114, 115
spontaneous atrial rate (SAR) 108, 109
rate-adaptive pacing 232
treadmill stress test 110
Wenckebach upper rate response 114, 115
ST elevation, myocardial infarction diagnosis 379
St Jude
atrial pace on premature ventricular complex 140
automatic atrial capture verification 396–7
automatic mode switching
algorithm 187–8
histograms 297
capture verification algorithms 395–7
medical markers 90
pacemaker in far-field oversensing causing
automatic mode switching 301
PMT termination algorithm 139
St Jude Autocapture 303–4, 305
ST segment, atrial capture testing 168
Staphylococcus aureus 382
Staphylococcus epidermidis 382
steroid-eluting leads 36, 360, 397–8
stimulus–T interval 228, 234
strength–duration curve 28, 361
stroke volume 215
subclavian artery
leads implanted via puncture 209
left ventricular pacing 81
subclavian crush syndrome 209
subclavian vein, pacing through 3
sudden Brady response 402
superior vena cava syndrome 380, 381, 382
supernormal phase 361
supraventricular tachycardia (SVT)
detection with automatic mode switching 390
rate smoothing 117
reentrant 253
symbols 44
synchronous atrial stimulation (SAS) 251
systolic function improvement with cardiac
resynchronization therapy 408
T wave
cardiac memory 379–80
negative 75
sensing 122, 198
resynchronization loss 343
stimulus 41
tachycardia, treatment with pacing 253–4
tachypnea, minute ventilation sensor responses 234
telemetry 24, 57
atrial electrogram 170
concept 277
data 57, 277
impedance measurement 281
marker annotations 88
real-time read-out 279
resistance measurement 281
ventricular electrogram 278
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TENS (transcutaneous electrical nerve stimulation)
261
thoracic impedance 225, 226
lung fluid monitoring 353
measurement 227
threshold search, automatic 304
threshold voltage 29
thrombolytic therapy 399
tidal volume 225, 226
timer action 21, 42
spontaneous ventricular activity 85
timing cycles 359
timing intervals 5
tissue Doppler imaging (TDI) 407
tissue impedance 13
torsades de pointes 422
total atrial refractory period (TARP) 92, 94
DDD pacemakers 365
endless loop tachycardia 130
fixed ratio block 2:1 109
P wave tracking 345
paced ventricular rate 368
retriggerable atrial refractory period
392
upper rate control 267
upper rate interval 111, 116
relationship 112, 114
Wenckebach upper rate response 114, 115,
368
total refractory period, re-initiation 257
tracking 108
fixed ratio block 2:1 109
treadmill stress test 110
transceiver 24
transtelephonic follow-up 268
marker annotations 88
treadmill stress test 110, 270
tri-filar conductor coil 35
triggered pacing mode 275, 298
biventricular pacing 341
triventricular pacing 408
paced QRS complex narrowing 412
troubleshooting 201–13
diaphragmatic stimulation 211
exit block 202, 207
lead fractures 204, 206, 207
with conversion from bipolar to unipolar mode
208
lead insulation defects 205
lead problem analysis 207
missing stimuli during VVI pacing 204
muscle stimulation 212
pacemaker runaway 213
pseudomalfunction 204
subclavian crush syndrome 209
twiddler’s syndrome 210
ventricular capture loss by visible pacemaker
stimuli 203
twiddler’s syndrome 210
undersensing 48, 49, 384, 385, 386
atrial 244
oversensing of false signals 198
unipolar electrogram (EGM) 46, 47
unipolar pacing 31, 46, 363
muscle stimulation 212
sensing 363
unipolar sensing 363
unipolar stimuli, lead fractures 208
univentricular pacing 324
upper rate interval (URI) 111, 115, 367–8
2:1 block 118
atrial premature complexes 119
atrial undersensing 389
atrial-driven 238, 239
control 267
DDD pacemakers/pacing 364, 365, 366, 368–9
endless loop tachycardia 130
far-field 134
limitation 118
cardiac resynchronization 333–4
programmed 130
sensor-driven 239
spontaneous shorter R-R interval 122
Wenckebach upper rate response 112, 113, 114, 116,
368
upper rate limit (URL) 109, 110, 111
atrial premature complexes 119
functional atrial undersensing 121
upper rate response
atrial premature complexes 118
atrial undersensing 389
cardiac resynchronization therapy 413
DDD pacemakers 107–22, 368–9
limitation with P wave in PVARP 413
VDD mode 142, 149, 373–4
lower rate timing 164
single lead 147
VDD timing cycles 146
vegetations 382
venous access, pacemaker complications 380, 381,
382
venous thrombosis 380, 382
ventricles see left ventricle; left ventricular entries;
right ventricle; right ventricular entries
ventricular action potential 20
ventricular activation sequence 374–5
ventricular activity, spontaneous 85
ventricular arrhythmias 422
ventricular asystole 96
ventricular blanking, postatrial 97, 98, 99
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ventricular capture
carotid sinus massage 51
demand pacemaker 50
loss by visible pacemaker stimuli 203
ventricular channel
DDD mode 365
inhibition 245
sensing 197
timing cycles of DDD pacemaker 91
ventricular conduction, atrial capture management
307
ventricular cycle, sensor-driven 241
ventricular demand pacing (VVI mode) 42, 148, 358–9
atrial channel 364
atrial fibrillation and automatic mode switching 244
atrial lead dislodgement into right ventricle 173, 174
characteristics 375
electrode interactions 200
escape interval 358–9, 362
false signals 199
lead position 193
memory 286
missing stimuli 204
pacemaker reset 262, 398
pacemaker syndrome 218
pseudomalfunction 204
reversed connection of atrial/ventricular leads 175
right ventricular outflow tract/septal pacing 155
runaway 213
stimulus-to-stimulus interval 358–9
ventricular pacing rate 217
ventricular pseudofusion beats 363
ventricular demand pacing, rate-adaptive (VVIR
mode) 148, 375
characteristics 375
minute ventilation sensors 225
ventricular pacing rate 217
ventricular depolarization
abnormal in memory effect 75
maintenance of normal 220
normal AV conduction 127
normal paced complexes 79
pacemaker-induced 22, 77
spontaneous 77, 78
ventricular desynchronization, P wave tracking 345
ventricular dyssynchrony 405
ventricular ectopy, T wave detection 234
ventricular electrogram 43
intrinsic deflection and slew rate 60
telemetered 278
ventricular depolarization 220
ventricular extrasystole, endless loop tachycardia 131
ventricular fibrillation 41, 358
ventricular fusion
with native conduction 412
with spontaneous QRS complex 418
ventricular fusion beats 74, 76, 363
isoelectric 79
T wave detection 234
ventricular heart rate histogram 290
ventricular intrinsic preference 401
ventricular lead 1
perforation 270
reversed connection with atrial 175
ventricular myocardial refractory period 20
ventricular output circuit, dual chamber pacing
87
ventricular oversensing 122, 302
ventricular pace 44
ventricular paced event 300
ventricular paced interval (VPI) 108, 109
ventricular paced rate (VPR)
fixed ratio block 2:1 109
tracking 108, 110
treadmill stress test 110
Wenckebach upper rate response 115
ventricular pacemaker exit block 394
ventricular pacing 400
alternative site 392
asynchronous 21, 41
atrial activity patterns 76
managed 316–18
memory effect 75
myocardial infarction diagnosis 379
pacemaker syndrome 218
rate 217
response in atrial fibrillation 402
single chamber 324
single site 330
triggered 416
triple site 330
two site 330
unipolar 147
see also biventricular (BIV) pacing
ventricular premature complex (VPC) 84, 103, 120,
400
atrial pace 140
atrial-based lower rate timing response 161
endless loop tachycardia 371
orthodromic macro-reentrant pacemaker
tachycardia 251
repetitive nonreentrant VA synchrony 135
retrograde P wave 300
telemetry real-time read-out 279
unsensed 48
ventricular pseudofusion beat 78, 275, 363,
366–7
ventricular pseudopseudo fusion beat 103
ventricular pulse inhibition 98
ventricular rate
rapid 245
stabilization 401
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ventricular refractory period (VRP) 94, 358
DDD pacemakers 364
electromagnetic interference 257
QRS complex sensing 106
timing cycles of DDD pacemaker 91
ventricular repolarization, normal paced complexes 79
ventricular resynchronization, mechanical 411
ventricular rhythm, competitive 41
ventricular safety pacing (VSP) 99, 100, 101
atrial lead dislodgement into right ventricle 173, 174
crosstalk prevention 105
DDD pacemakers 366
ECG patterns 102
interference 100
myopotential sensing 246
unsensed f waves 243
ventricular paced event 300
ventricular premature complexes 103
window 367
ventricular sense (Vs)
in refractory period 44
Vs-Vs interval 164
ventricular sensing
DDI mode 144
DVI mode 143
oversensing 122, 302
unipolar 147
VDD mode 145
ventricular safety pacing window 101
ventricular sensing circuit 87
ventricular sensitivity
maximal 104
reduction 105
ventricular stimulation 19–33
ventricular stimuli
atrial event interval 124
atrial lead dislodgement into right ventricle
172
DDD/DDDR mode 388, 388–9
interval 102
QRS complex sensing 106
VDD mode 145
ventricular tachycardia
cardiac resynchronization therapy 422
detection of inappropriate due to ventricular
oversensing 302
left ventricular pacing 422
rapid 299
ventricular vulnerable period 41
ventricular-based lower rate timing 163
ventriculoatrial conduction 129, 266
endless loop tachycardia 132
retrograde 76
sustained 266
ventriculoatrial crosstalk 390–1
ventriculoatrial interval, PMT termination algorithm
139
ventriculoatrial synchrony 372
sustained pacemaker mediated rhythms 137
see also repetitive nonreentrant VA synchrony
(RNRVAS)
voltage (U) 11, 13, 360
pacemaker sensing 43, 47
pacing threshold 26
permanent pacemaker 23
pulse duration 360–1
safety margin 360
transients 386
units 14
volume overload 353
VOO mode 21, 358
pacemaker reset 398
V–V interval
cardiac resynchronization therapy
optimization 336
programming 337, 418–19
semi-automatic optimization 419–20
delayed conduction 419
latency 419
programming 337, 349
cardiac resynchronization therapy 337, 418–19
impact on atrioventricular delay 419
VVI see ventricular demand pacing (VVI mode)
VVIR see ventricular demand pacing, rate-adaptive
(VVIR mode)
VVT mode 85, 359
triggered mode 275
walking test 270
walking upstairs/downstairs, pacing rate 233
wall motion resynchronization 405
water equivalent 10, 12
water flow 12
Wenckebach interval (WI) 119
Wenckebach type I second-degree AV block 274
Wenckebach upper rate response 111, 112, 113, 114,
115
2:1 block 116
atrial premature complexes 118
cardiac resynchronization 333, 334
DDD pacemakers 368–9
pre-empted 389, 413
rate smoothing 117
rate-adaptive pacing 238, 376
retrograde VA conduction during VVI pacing
266
total atrial refractory period 368
upper rate interval 368
wireless programming 24, 57, 309
Wolff–Parkinson–White syndrome 410
